BioMedLib Search Engine
[ goto HOMEPAGE ]
Locate the most relevant articles, quickly.
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
adult leukemia acute myelogenous in remission 2005:2010[pubdate] *count=100
184 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
adult leukemia acute myelogenous in remission
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 184
1.
Callera F, Mulin CC, Rosa ES, Melo DB, Melo CM:
High prevalence of morphological subtype FAB M1 in adults with de novo acute myeloid leukemia in São José dos Campos, São Paulo.
Sao Paulo Med J
; 2006 Jan 5;124(1):45-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High prevalence of morphological subtype FAB M1 in adults with de novo
acute
myeloid
leukemia in
São José dos Campos, São Paulo.
CONTEXT AND OBJECTIVE: Geographical variations have been described
in acute myelogenous leukemia
(
AML
).
The aim of this study was to demonstrate the high prevalence of French-American-British (FAB) M1 subtype in adults with de novo
AML
in São José dos Campos, State of São Paulo, Brazil.
DESIGN AND SETTING: Retrospective analysis, at Hospital Pio XII in São José dos Campos, a public
non
-teaching institution.
METHODS: Records from 39 consecutive
adult
patients with de novo
AML
referred to Hospital Pio XII between January 2002 and September 2004 were reviewed.
The rates of
remission
, relapse, mortality according treatment phase, survival and
leukemia
-free survival were calculated.
The
remission
and the relapse rates were 82% and 41% respectively.
The mortality rate was 69% (induction of
remission
: 7/39, 17.9%; post induction: 10/32, 31.2%; and relapse: 10/16, 62.5%).
The survival rate was 30% and
leukemia
-free survival was 33%.
CONCLUSIONS: The study demonstrated a high prevalence of FAB M1 subtype in adults with de novo
AML
in São José dos Campos.
Our data suggest the occurrence of different regional prevalences of FAB
AML
categories in Brazil.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ pathology
[MeSH-minor]
Adult
. Age Distribution. Brazil / epidemiology. Female. Genetic Heterogeneity. Humans. Male. Middle Aged. Prevalence. Retrospective Studies. Sex Distribution. Survival Rate
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16612463.001).
[ISSN]
1516-3180
[Journal-full-title]
São Paulo medical journal = Revista paulista de medicina
[ISO-abbreviation]
Sao Paulo Med J
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Brazil
2.
Sharma S, Pati HP:
Erythrocyte enzyme abnormalities in leukemias.
J Assoc Physicians India
; 2006 Jun;54:453-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Red cell enzymes were assayed in a total of 67 patient including 24 patients with
AML
(19 relapse, 5
remission
), 16 patients with ALL (10 relapse, 6
remission
), 22 patients with CML and 5 patients with blastic CML.
Diagnosis of
leukemia
was based on clinical presentation, peripheral blood smear and bone marrow examination (as per FAB classification).
Red cell HK was high in all
leukemia
subtypes.
Notably there was no PK deficiency in
AML
or G6PD deficiency in ALL.
Activities of G6PD and PK could be correlated in cases of CML,
AML
, (p<0.05) and ALL (p<0.01) i.e. when there was increased activity of G6PD, PK activity also tended to be higher.
HK activity showed a positive correlation with PK and G6PD activity in cases of CML (p<0.05), however
in acute leukemia
there was no such correlation.
Alteration of enzyme activities among red cells
in leukemia
occurred only during relapse.
At the time of
remission
there has been no significant alteration in any of the enzyme activities.
It would therefore, appear that enzyme alterations seen
in leukemia
patients is due to abnormal pluripotent stem cell that has given to a
leukemia
cell.
With the recovery of normal stem cells function during
remission
, enzyme abnormalities tend to become normal.
[MeSH-major]
Erythrocytes, Abnormal / metabolism.
Leukemia
/ enzymology
[MeSH-minor]
Adolescent.
Adult
. Aged. Female. Humans.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / enzymology.
Leukemia
,
Myeloid
,
Acute
/ metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / enzymology.
Remission
Induction. Risk Factors
MedlinePlus Health Information.
consumer health - Childhood Leukemia
.
MedlinePlus Health Information.
consumer health - Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16909693.001).
[ISSN]
0004-5772
[Journal-full-title]
The Journal of the Association of Physicians of India
[ISO-abbreviation]
J Assoc Physicians India
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
India
3.
Piccaluga PP, Martinelli G, Rondoni M, Visani G, Baccarani M:
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia.
Expert Opin Biol Ther
; 2006 Oct;6(10):1011-22
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Advances and potential treatment for Philadelphia chromosome-positive
adult acute
lymphoid leukaemia.
Philadelphia chromosome-positive (Ph+)
acute
lymphoblastic
leukaemia (ALL) is the most common subtype of ALL in adults.
Therefore, allogeneic stem cell transplantation performed during the first
remission
is the recommended therapy.
[MeSH-major]
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / genetics.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / therapy. Philadelphia Chromosome
[MeSH-minor]
Adult
. Animals. Humans. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / drug therapy. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / genetics. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / therapy. Randomized Controlled Trials as Topic / trends. Stem Cell Transplantation / methods. Stem Cell Transplantation / trends
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16989583.001).
[ISSN]
1744-7682
[Journal-full-title]
Expert opinion on biological therapy
[ISO-abbreviation]
Expert Opin Biol Ther
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
England
[Number-of-references]
61
Advertisement
4.
Fujiwara M, Satou N, Izumi N, Shibasaki Y, Higashimura M, Tsukada N, Koike T:
[A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
Gan To Kagaku Ryoho
; 2007 Nov;34(11):1793-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[A short duration treatment with intensive consolidation therapy for patients with
acute myelogenous leukemia
--13 year experience in a single institute].
Fifty-seven patients with
acute myelogenous leukemia
(
AML
) received the following treatment in our hospital between May 1992 and April 2005.
Group A: combination of enocitabine, daunorubicin, 6-mercaptopurine riboside and prednisolone (BHAC-DMP) for
remission
induction, BHAC-DMP or idarubicin (IDR)+cytarabine (Ara-C) for first consolidation, combination of prednisolone, Ara-C, mitoxantrone and etoposide (PAME) for second consolidation, and PAME for late intensification; Group B: IDR+Ara-C for
remission
induction, PAME for first consolidation, and high-dose Ara-C+mitoxantrone for second consolidation; Group C (
acute
promyelocytic
leukemia
, APL) : all-trans retinoic acid (ATRA) for
remission
induction, BHAC-DMP or IDR+Ara-C for first consolidation, and PAME for second consolidation.
The complete
remission
(CR) rate was 77% in Group A, 76% in Group B, and 71% in Group C.
A short duration treatment with intensive consolidation therapy was effective for patients with
AML
and improved their quality of life (QOL).
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Leukemia
,
Myeloid
,
Acute
/ drug therapy
[MeSH-minor]
6-Mercaptopurine / administration & dosage.
Adult
. Aged. Cytarabine / administration & dosage. Cytarabine / analogs & derivatives. Daunorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Evidence-Based Medicine. Female. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Prednisone / administration & dosage. Quality of Life. Retrospective Studies. Survival Rate. Vincristine / administration & dosage
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
DAUNORUBICIN
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
PREDNISOLONE
.
Hazardous Substances Data Bank.
MERCAPTOPURINE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
NOVANTRONE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18030012.001).
[ISSN]
0385-0684
[Journal-full-title]
Gan to kagaku ryoho. Cancer & chemotherapy
[ISO-abbreviation]
Gan To Kagaku Ryoho
[Language]
jpn
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin; BHAC-DMPV protocol; PAME protocol
5.
Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S, Andersson B, Champlin RE, De Lima M:
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia.
Bone Marrow Transplant
; 2005 Jul;36(2):157-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed
acute myelogenous leukemia
.
The major cause of failure after allogeneic hematopoietic stem cell transplantation (HSCT) for
acute myelogenous leukemia
(
AML
) is disease relapse or progression.
We analyzed the outcome of second HSCT for treatment of patients with relapsed, refractory
AML
/myelodysplastic syndrome (MDS) at our institution.
In all, 25 (35%) patients received salvage chemotherapy prior to the second transplant procedure and only two (3%) patients were in complete
remission
at the time of the second transplant.
A total of 20 patients (28%) had low
leukemia
burden as measured by the absence of peripheral blood blasts and <or=5% blasts in the bone marrow at the time of the second transplant.
Although, the overall median survival after the second transplant was 6 months, a subset of patients who had low
leukemia
burden at the time of the second transplant had a 5-year survival of 25 vs 12% in those with a high
leukemia
burden.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ prevention & control. Salvage Therapy. Stem Cell Transplantation. Tumor Burden
[MeSH-minor]
Adolescent.
Adult
. Aged. Bone Marrow / pathology. Disease-Free Survival. Female. Humans. Male. Middle Aged. Recurrence. Retrospective Studies
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15937511.001).
[ISSN]
0268-3369
[Journal-full-title]
Bone marrow transplantation
[ISO-abbreviation]
Bone Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
6.
Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, Briel J, Jones RJ, Wright JJ, Colevas AD:
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Clin Cancer Res
; 2007 Aug 1;13(15 Pt 1):4467-73
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk
acute myelogenous leukemia
.
In a phase I study of flavopiridol followed by 1-beta-d-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for adults with relapsed and refractory
acute myelogenous
leukemias (
AML
) was 31%.
We have now completed a phase II study of sequential flavopiridol, ara-C, and mitoxantrone in 62 adults with poor-risk
AML
.
Complete remissions (CR) were achieved in 12 of 15 (75%) newly diagnosed secondary
AML
, 18 of 24 (75%) first relapse after short CR (median CR, 9 months, including prior allotransplant), and 2 of 13 (15%) primary refractory but 0 of 10 multiply refractory
AML
.
CONCLUSIONS: Flavopiridol has anti-
AML
activity directly and in combination with ara-C and mitoxantrone.
This timed sequential regimen induces durable CRs in a significant proportion of adults with newly diagnosed secondary
AML
(including complex cytogenetics) and adults with
AML
in first relapse after short first CR.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Leukemia
,
Myeloid
,
Acute
/ drug therapy
[MeSH-minor]
Adult
. Aged. Cytarabine / administration & dosage. Disease-Free Survival. Female. Flavonoids / administration & dosage. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Mitoxantrone / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Piperidines / administration & dosage. Prognosis.
Remission
Induction. Salvage Therapy. Survival Rate
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
NOVANTRONE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17671131.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Grant]
United States / NCRR NIH HHS / RR / M01-RR0052; United States / NCI NIH HHS / CA / U01 CA70095
[Publication-type]
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Flavonoids; 0 / Piperidines; 04079A1RDZ / Cytarabine; 45AD6X575G / alvocidib; BZ114NVM5P / Mitoxantrone
7.
Johny A, Song KW, Nantel SH, Lavoie JC, Toze CL, Hogge DE, Forrest DL, Sutherland HJ, Le A, Nitta JY, Barnett MJ, Smith CA, Shepherd JD, Nevill TJ:
Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide.
Biol Blood Marrow Transplant
; 2006 Apr;12(4):480-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Early stem cell transplantation for refractory
acute leukemia
after salvage therapy with high-dose etoposide and cyclophosphamide.
Primary refractory
acute leukemia
(AL) has a poor prognosis, although some patients can be salvaged with allogeneic stem cell transplantation (SCT).
Induction of complete
remission
(CR) with conventional chemotherapy before SCT may improve outcome in this patient population.
Forty-two patients had
acute myelogenous leukemia
(
AML
), 13 patients had
acute
lymphoblastic
leukemia
(ALL), and 4 patients had
acute
biphenotypic
leukemia
.
CR1 rates were similar in
AML
(54%) and ALL/
acute
biphenotypic
leukemia
(67%; P = .52), and analysis of baseline characteristics did not reveal any predictors of response to VP/Cy.
In the allogeneic SCT group, 5-year EFS was 52% for
AML
patients and 14% for ALL patients (P = .04), and only male sex was predictive of a favorable outcome (P = .03).
[MeSH-major]
Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage.
Leukemia
/ mortality. Salvage Therapy / mortality. Stem Cell Transplantation
[MeSH-minor]
Adolescent.
Adult
. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged.
Remission
Induction. Retrospective Studies. Survival Rate
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Childhood Leukemia
.
MedlinePlus Health Information.
consumer health - Leukemia
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16545732.001).
[ISSN]
1083-8791
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide
8.
Yin CC, Cortes J, Barkoh B, Hayes K, Kantarjian H, Jones D:
t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
Cancer
; 2006 Apr 15;106(8):1730-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
t(3;21)(q26;q22) in
myeloid
leukemia
: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
BACKGROUND: The t(3;21)(q26;q22) translocation is associated with
myeloid
leukemias and results in a chimeric oncoprotein containing AML1/RUNX1 variably fused to EAP, MDS1, and/or EVI1.
RESULTS: In all 16 patients with chronic myeloproliferative disorders, including 14 with chronic
myelogenous leukemia
(CML), the occurrence of t(3;21) heralded
myeloid
blast transformation.
Among 10 cases of t(3;21)-associated
acute
myeloid
leukemia
, 8 were secondary tumors after chemotherapy for other neoplasms that had been treated with regimens including fludarabine and 5-fluorouracil in 3 patients each and etoposide in 2 patients.
The immunophenotype of the blasts in all 22 tested cases was similar, with uniform expression of
myeloid
markers and CD34 and variable expression of CD7 and CD9, but minimal morphological
myeloid
maturation.
Among the patients with CMPD, 8 died of disease (at a median of 6.5 mos) and 5 achieved disease
remission
with bone marrow transplantation.
Among patients with
acute
myeloid
leukemia
/myelodysplastic syndrome, 7 died of disease (at a median of 2 mos) and 2 had persistent
leukemia
with short follow-up.
[MeSH-major]
Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / adverse effects. Chromosomes, Human, Pair 21 / drug effects. Chromosomes, Human, Pair 3 / drug effects. Hydroxyurea / adverse effects.
Leukemia
,
Myeloid
/ chemically induced.
Leukemia
,
Myeloid
/ genetics. Lymphocyte Activation / drug effects. Myeloproliferative Disorders / drug therapy. Oncogene Proteins, Fusion / analysis. Translocation, Genetic / drug effects
[MeSH-minor]
Adult
. Aged. Bone Marrow / pathology. Core Binding Factor Alpha 2 Subunit / genetics. DNA-Binding Proteins / genetics. Female. Humans. Male. Middle Aged. Neoplasm Proteins / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
HYDROXYUREA
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2006 American Cancer Society
(PMID = 16532439.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA16672
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA-Binding Proteins; 0 / MECOM protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / RUNX1 protein, human; 0 / Transcription Factors; X6Q56QN5QC / Hydroxyurea
9.
Kim JG, Sohn SK, Kim DH, Baek JH, Lee NY, Suh JS, Chae SC, Lee KS, Lee KB:
Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia.
Leuk Lymphoma
; 2005 Jun;46(6):885-91
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinical implications of angiogenic factors in patients with
acute
or chronic
leukemia
: hepatocyte growth factor levels have prognostic impact, especially in patients with
acute
myeloid
leukemia
.
The present study evaluated the serum levels of known angiogenic factors and analysed their prognostic significance in patients with
acute
or chronic
leukemia
.
Enzyme-linked immunosorbent assays (ELISAs) were performed to quantify the basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), tumor necrosis factor-alpha (TNF-alpha), angiogenin, and matrix metalloproteinase-9 (MMP-9) in stored samples obtained before treatment from patients with
acute
myeloid
leukemia
(
AML
; 30 patients),
acute
lymphoblastic
leukemia
(ALL; 10 patients), and chronic
myelogenous leukemia
(CML; 14 patients).
The HGF levels were also higher in patients with
AML
than in healthy individuals, plus there was a significant correlation between the HGF level and the white blood cell count, monocyte count, and serum level of lactate dehydrogenase (LDH) in patients with
AML
.
In a univariate analysis, age and HGF level were both found to be significant parameters predictive for an achievement of complete
remission
(CR) in patients with
AML
.
The
leukemia
-free survival (LFS) rate for
AML
patients with a lower HGF concentration was better than that for
AML
patients with a higher HGF concentration (1 year LFS rates=75.0% vs. 37.5%, P=0.065).
The HGF concentration was an independent prognostic factor for an achievement of CR, plus higher HGF concentrations were associated with a lower survival in patients with
AML
.
[MeSH-major]
Hepatocyte Growth Factor / blood.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / blood.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / therapy.
Leukemia
,
Myeloid
,
Acute
/ blood.
Leukemia
,
Myeloid
,
Acute
/ therapy
[MeSH-minor]
Adolescent.
Adult
. Aged. Biomarkers, Tumor / metabolism. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neovascularization, Pathologic. Prognosis.
Remission
Induction
Genetic Alliance.
consumer health - Chronic Myeloid Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16019534.001).
[ISSN]
1029-2403
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 67256-21-7 / Hepatocyte Growth Factor
10.
Shima T, Yoshimoto G, Miyamoto T, Yoshida S, Kamezaki K, Takenaka K, Iwasaki H, Harada N, Nagafuji K, Teshima T, Shimono N, Akashi K:
Disseminated tuberculosis following second unrelated cord blood transplantation for acute myelogenous leukemia.
Transpl Infect Dis
; 2009 Feb;11(1):75-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Disseminated tuberculosis following second unrelated cord blood transplantation for
acute myelogenous leukemia
.
Here we report the case of a 43-year-old Japanese woman with
acute myelogenous leukemia
who underwent 2 unrelated cord blood transplantations (UCBT), terminating in fatal disseminated tuberculosis (TB).
The patient did not achieve
remission
despite intensive chemotherapy, and subsequently underwent UCBT with a standard conditioning regimen.
[MeSH-major]
Bacteremia / microbiology. Cord Blood Stem Cell Transplantation / adverse effects.
Leukemia
,
Myeloid
,
Acute
/ therapy. Mycobacterium tuberculosis / isolation & purification. Tuberculosis, Pulmonary / microbiology
[MeSH-minor]
Adult
. Antitubercular Agents / therapeutic use. Fatal Outcome. Female. Humans
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Transplantation
.
Genetic Alliance.
consumer health - Tuberculosis
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19000153.001).
[ISSN]
1399-3062
[Journal-full-title]
Transplant infectious disease : an official journal of the Transplantation Society
[ISO-abbreviation]
Transpl Infect Dis
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Antitubercular Agents
11.
Kröger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T, Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT):
Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Bone Marrow Transplant
; 2006 Jan;37(2):183-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Autologous stem cell transplantation for therapy-related
acute
myeloid
leukemia
and myelodysplastic syndrome.
We report the results of 65 patients with treatment-related myelodysplastic syndrome (MDS)/
acute myelogenous leukemia
(
AML
) who were transplanted from an autograft and reported to the EBMT.
The primary disease was solid tumors (n = 37), Hodgkin's disease (n = 13),
non
-Hodgkin's lymphoma (n = 10),
acute
lymphoblastic
leukemia
(n = 2) or myeloproliferative syndromes (n = 3).
The types of MDS were as follows: RAEB (n = 1; 2%), RAEB-t (n = 3; 5%), or
AML
(n = 56; 87%).
Lower relapse rate was seen in patients transplanted in first complete
remission
(CR1 vs
non
-CR1: 3 years: 48 vs 89%; P = 0.05).
Autologous transplantation may cure a substantial number of patients with treatment-related MDS/
AML
, especially if they are in CR1 and of younger age.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ mortality.
Leukemia
,
Myeloid
,
Acute
/ therapy. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / therapy. Stem Cell Transplantation
[MeSH-minor]
Adolescent.
Adult
. Age Factors. Aged. Child. Child, Preschool. Disease-Free Survival. Female. Graft Survival. Humans. Incidence. Male. Middle Aged. Recurrence.
Remission
Induction. Survival Rate. Transplantation, Autologous
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Bone Marrow Transplant. 2007 Apr;39(8):509; author reply 509-10
[
17322936.001
]
(PMID = 16299545.001).
[ISSN]
0268-3369
[Journal-full-title]
Bone marrow transplantation
[ISO-abbreviation]
Bone Marrow Transplant.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
England
12.
Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE:
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
Blood
; 2007 Feb 15;109(4):1387-94
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated
acute myelogenous leukemia
.
Outcomes for older adults with
acute myelogenous leukemia
(
AML
) are poor due to both disease and host-related factors.
In this phase 2 study, we tested the oral farnesyltransferase inhibitor tipifarnib in 158 older adults with previously untreated, poor-risk
AML
.
Complete
remission
(CR) was achieved in 22 patients (14%); partial
remission
or hematologic improvement occurred in 15 patients, for an overall response rate of 23%.
Tipifarnib is active and well tolerated in older adults with poor-risk
AML
and may impart a survival advantage in those patients who experience a clinical response.
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 2002 Dec 15;100(13):4325-36
[
12393746.001
]
[Cites]
Blood. 2003 Mar 1;101(5):1692-7
[
12411300.001
]
[Cites]
Blood. 2003 Dec 15;102(13):4527-34
[
12947010.001
]
[Cites]
Blood Rev. 2004 Mar;18(1):39-63
[
14684148.001
]
[Cites]
J Clin Oncol. 1999 Nov;17(11):3631-52
[
10550163.001
]
[Cites]
Oncogene. 1999 Dec 9;18(52):7514-26
[
10602510.001
]
[Cites]
Invest New Drugs. 1999;17(3):241-58
[
10665477.001
]
[Cites]
J Clin Oncol. 2004 Apr 1;22(7):1287-92
[
15051776.001
]
[Cites]
J Clin Oncol. 1989 Sep;7(9):1268-74
[
2475589.001
]
[Cites]
Cancer Res. 1992 May 15;52(10):2847-53
[
1581898.001
]
[Cites]
Cancer Res. 1994 Jun 15;54(12):3229-32
[
8205544.001
]
[Cites]
N Engl J Med. 1995 Jun 22;332(25):1671-7
[
7760868.001
]
[Cites]
Blood. 1995 Jul 15;86(2):457-62
[
7605984.001
]
[Cites]
Hematol Oncol Clin North Am. 2000 Feb;14(1):251-67
[
10680081.001
]
[Cites]
Cancer Res. 2000 Apr 1;60(7):1871-7
[
10766174.001
]
[Cites]
Clin Cancer Res. 2000 Jun;6(6):2318-25
[
10873082.001
]
[Cites]
Mol Cell Biol. 2000 Aug;20(16):6105-13
[
10913192.001
]
[Cites]
J Biol Chem. 2000 Sep 29;275(39):30451-7
[
10852915.001
]
[Cites]
Blood. 2000 Dec 15;96(13):4075-83
[
11110676.001
]
[Cites]
Exp Cell Res. 2001 Jan 1;262(1):17-27
[
11120601.001
]
[Cites]
Cancer Res. 2001 Jan 1;61(1):131-7
[
11196150.001
]
[Cites]
Blood. 2001 Jun 1;97(11):3361-9
[
11369625.001
]
[Cites]
Blood. 2001 Aug 1;98(3):548-53
[
11468148.001
]
[Cites]
Blood. 2001 Sep 1;98(5):1302-11
[
11520775.001
]
[Cites]
Cancer Res. 2002 Jan 15;62(2):450-8
[
11809695.001
]
[Cites]
Blood. 2002 Jul 1;100(1):29-35
[
12070004.001
]
[Cites]
Blood. 2002 Aug 15;100(4):1224-32
[
12149202.001
]
[Cites]
Blood. 2002 Oct 1;100(7):2292-302
[
12239137.001
]
[Cites]
Cancer Res. 1995 Aug 1;55(15):3295-304
[
7614464.001
]
[Cites]
Cancer Res. 1995 Nov 15;55(22):5302-9
[
7585592.001
]
[Cites]
Cancer Res. 1997 Feb 15;57(4):708-13
[
9044849.001
]
[Cites]
Blood. 1997 May 1;89(9):3323-9
[
9129038.001
]
[Cites]
Blood. 1997 Oct 15;90(8):2952-61
[
9376575.001
]
[Cites]
Blood. 1997 Oct 15;90(8):2969-77
[
9376577.001
]
[Cites]
J Clin Oncol. 1998 Mar;16(3):872-81
[
9508168.001
]
[Cites]
Blood. 1998 May 15;91(10):3607-15
[
9572995.001
]
[Cites]
Oncogene. 1998 Sep 17;17(11 Reviews):1439-45
[
9779989.001
]
[Cites]
N Engl J Med. 1998 Dec 3;339(23):1649-56
[
9834301.001
]
[Cites]
Leukemia. 1999 Jun;13(6):843-9
[
10360370.001
]
[Cites]
Blood. 1999 Aug 1;94(3):1086-99
[
10419902.001
]
[Cites]
Cancer. 2006 Mar 1;106(5):1090-8
[
16435386.001
]
[Cites]
Blood. 2006 May 1;107(9):3481-5
[
16455952.001
]
(PMID = 17082323.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / U01 CA070095; United States / NCI NIH HHS / CA / U01 CA69854; United States / NCI NIH HHS / CA / U01 CA70095
[Publication-type]
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / DNAJA1 protein, human; 0 / HSP40 Heat-Shock Proteins; 0 / Quinolones; 192185-72-1 / tipifarnib; EC 2.5.1.29 / Farnesyltranstransferase
[Other-IDs]
NLM/ PMC1794070
13.
Medeiros BC, Minden MD, Schuh AC, Schimmer AD, Yee K, Lipton JH, Messner HA, Gupta V, Chun K, Xu W, Das P, Kamel-Reid S, Brandwein JM:
Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years).
Leuk Lymphoma
; 2007 Jan;48(1):65-71
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Characteristics and outcomes of
acute myelogenous leukemia
patients with very late relapse (>5 years).
The clinical characteristics and outcome of 15 patients with
acute myelogenous leukemia
(
AML
) who experienced relapse at least 5 years after induction of complete
remission
(very late-relapse
AML
) are described.
The median duration of first complete
remission
(CR-1) was 9 years (range 5.2 - 11.5 years).
We conclude that very late-relapse
AML
is a rare event, and that reinduction in these patients is associated with very high CR rates and a potential cure fraction.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ diagnosis
[MeSH-minor]
Adolescent.
Adult
. Aged. Female. Humans. Male. Middle Aged. Prognosis. Recurrence.
Remission
Induction. Retrospective Studies. Survival Analysis
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Leuk Lymphoma. 2007 Jan;48(1):3-4
[
17325840.001
]
(PMID = 17325849.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
14.
Karp JE, Blackford A, Smith BD, Alino K, Seung AH, Bolaños-Meade J, Greer JM, Carraway HE, Gore SD, Jones RJ, Levis MJ, McDevitt MA, Doyle LA, Wright JJ:
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Leuk Res
; 2010 Jul;34(7):877-82
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk
acute myelogenous leukemia
.
In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed
acute myelogenous leukemia
(
AML
) with multiple poor-risk features.
Thirty patients (67%) achieved complete
remission
(CR) and 4 (9%) died.
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
Allopurinol
.
Hazardous Substances Data Bank.
NOVANTRONE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 Elsevier Ltd. All rights reserved.
[Cites]
N Engl J Med. 2009 Sep 24;361(13):1235-48
[
19776405.001
]
[Cites]
Blood. 2009 Apr 23;113(17):4063-73
[
19144992.001
]
[Cites]
N Engl J Med. 2009 Sep 24;361(13):1249-59
[
19776406.001
]
[Cites]
J Natl Cancer Inst. 2000 Mar 1;92(5):376-87
[
10699068.001
]
[Cites]
Cell Death Differ. 2001 Jul;8(7):715-24
[
11464216.001
]
[Cites]
J Biol Chem. 2001 Aug 24;276(34):31793-9
[
11431468.001
]
[Cites]
Genome Biol. 2001;2(10):RESEARCH0041
[
11597333.001
]
[Cites]
Clin Cancer Res. 2002 Nov;8(11):3527-38
[
12429644.001
]
[Cites]
Blood. 2002 Dec 15;100(13):4325-36
[
12393746.001
]
[Cites]
Leuk Res. 2003 Apr;27(4):313-21
[
12531222.001
]
[Cites]
Clin Cancer Res. 2003 Jan;9(1):307-15
[
12538483.001
]
[Cites]
Cancer Res. 2003 Apr 15;63(8):1822-33
[
12702569.001
]
[Cites]
J Clin Oncol. 2003 Dec 15;21(24):4642-9
[
14673054.001
]
[Cites]
Am J Med. 1969 Sep;47(3):351-66
[
5258033.001
]
[Cites]
Ann Intern Med. 1975 Jan;82(1):54-7
[
16553.001
]
[Cites]
Medicine (Baltimore). 1980 Nov;59(6):409-25
[
7003298.001
]
[Cites]
Blood. 1989 Oct;74(5):1499-506
[
2676014.001
]
[Cites]
Biochem Pharmacol. 1993 Nov 17;46(10):1831-40
[
8250970.001
]
[Cites]
Cancer Res. 1996 Jul 1;56(13):2973-8
[
8674031.001
]
[Cites]
Cancer Res. 1996 Nov 1;56(21):4856-61
[
8895733.001
]
[Cites]
Cancer Res. 1997 Aug 15;57(16):3375-80
[
9269999.001
]
[Cites]
Cancer Res. 1999 Sep 15;59(18):4634-41
[
10493518.001
]
[Cites]
Clin Cancer Res. 2005 Dec 1;11(23):8403-12
[
16322302.001
]
[Cites]
Mol Cancer Ther. 2006 Jan;5(1):138-48
[
16432172.001
]
[Cites]
Blood. 2006 May 1;107(9):3481-5
[
16455952.001
]
[Cites]
Leuk Lymphoma. 2006 Apr;47(4):697-706
[
16690529.001
]
[Cites]
Blood. 2007 Jan 15;109(2):399-404
[
17003373.001
]
[Cites]
Blood. 2007 Mar 1;109(5):1810-6
[
17095617.001
]
[Cites]
J Clin Oncol. 2007 May 10;25(14):1908-15
[
17488990.001
]
[Cites]
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4467-73
[
17671131.001
]
[Cites]
N Engl J Med. 2008 May 1;358(18):1909-18
[
18450602.001
]
[Cites]
Blood. 2009 Mar 19;113(12):2637-45
[
18981292.001
]
[Cites]
Blood. 2009 Apr 23;113(17):4052-62
[
19144991.001
]
[CommentIn]
Leuk Res. 2010 Jul;34(7):856-7
[
20378170.001
]
(PMID = 19962759.001).
[ISSN]
1873-5835
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P30 CA06973-44; United States / NCI NIH HHS / CA / U01 CA069854; United States / NCRR NIH HHS / RR / M01-RR0052; United States / NCI NIH HHS / CA / U01 CA70095; United States / NCI NIH HHS / CA / CA069854-05; United States / NCI NIH HHS / CA / U01 CA070095; United States / NCRR NIH HHS / RR / M01 RR000052; United States / NCI NIH HHS / CA / U01 CA069854-05
[Publication-type]
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
0 / Flavonoids; 0 / Piperidines; 0 / Polyamines; 04079A1RDZ / Cytarabine; 45AD6X575G / alvocidib; 63CZ7GJN5I / Allopurinol; 9YCX42I8IU / Sevelamer; BZ114NVM5P / Mitoxantrone
[Other-IDs]
NLM/ NIHMS158765; NLM/ PMC2875369
15.
Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A:
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.
Blood
; 2005 Feb 1;105(3):973-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Leukemic transformation in myelofibrosis with
myeloid
metaplasia: a single-institution experience with 91 cases.
Among 2333 consecutive patients with myelofibrosis with
myeloid
metaplasia (MMM) seen at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic transformation (LT).
All episodes of LT were
myeloid
in origin (
acute
myeloid
leukemia
[
AML
]) with all French-American-British (FAB) subtypes represented except M3; the most frequent subtypes were M7 (25.4%), M0 (22.4%), and M2 (17.9%).
Twenty-four patients received
AML
-like induction chemotherapy that resulted in no complete
remission
: 41% reverted into chronic-phase disease and the incidence of treatment-related mortality was 33%.
[MeSH-major]
Leukemia
/ drug therapy.
Leukemia
/ pathology.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / drug therapy.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / pathology. Myelodysplastic Syndromes / pathology. Primary Myelofibrosis / pathology
[MeSH-minor]
Adult
. Age of Onset. Aged. Aged, 80 and over. Cell Transformation, Neoplastic. Female. Humans. Male. Middle Aged. Reference Values. Treatment Outcome
Genetic Alliance.
consumer health - Myelofibrosis
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15388582.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
16.
Rudd E, Göransdotter Ericson K, Zheng C, Uysal Z, Ozkan A, Gürgey A, Fadeel B, Nordenskjöld M, Henter JI:
Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies.
J Med Genet
; 2006 Apr;43(4):e14
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Three patients experienced long periods (> or = 1 year)
in remission
without specific treatment, which is very uncommon in this disease.
Two of the six patients harbouring STX11 gene defects developed myelodysplastic syndrome (MDS) or
acute myelogenous
leukaemia (
AML
).
These results suggest that STX11 gene mutations may be associated with secondary malignancies (MDS/
AML
), and that there is segregation of specific clinical features in FHL patients with an underlying genotype.
[MeSH-major]
Leukemia
,
Myeloid
/ genetics. Lymphohistiocytosis, Hemophagocytic / diagnosis. Lymphohistiocytosis, Hemophagocytic / genetics. Mutation. Myelodysplastic Syndromes / genetics. Qa-SNARE Proteins / genetics
[MeSH-minor]
Acute
Disease.
Adult
. Aged, 80 and over. Child. Child, Preschool. DNA Mutational Analysis. Female. Genotype. Humans. Infant. Male. Pedigree. Phenotype. Psychomotor Disorders / complications. Psychomotor Disorders / genetics.
Remission
, Spontaneous
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
SciCrunch.
OMIM: Data: Gene Annotation
.
SciCrunch.
Clinical Genomic Database: Data: Gene Annotation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Haematol. 2005 Mar;128(6):739-50
[
15755277.001
]
[Cites]
Hum Mol Genet. 2005 Mar 15;14(6):827-34
[
15703195.001
]
[Cites]
Blood. 2005 Jun 1;105(11):4424-8
[
15728124.001
]
[Cites]
Br J Haematol. 2005 Jun;129(5):658-66
[
15916689.001
]
[Cites]
Blood. 2005 Jun 15;105(12):4700-6
[
15755897.001
]
[Cites]
Science. 1999 Dec 3;286(5446):1957-9
[
10583959.001
]
[Cites]
J Exp Med. 2000 Sep 4;192(5):755-60
[
10974040.001
]
[Cites]
Eur J Cell Biol. 2000 Nov;79(11):771-80
[
11139139.001
]
[Cites]
Am J Hum Genet. 2001 Mar;68(3):590-7
[
11179007.001
]
[Cites]
Br J Haematol. 2002 Feb;116(2):346-9
[
11841437.001
]
[Cites]
Int J Hematol. 2002 Feb;75(2):174-7
[
11939264.001
]
[Cites]
Br J Haematol. 2002 Jun;117(4):965-72
[
12060139.001
]
[Cites]
Blood. 2002 Oct 1;100(7):2367-73
[
12239144.001
]
[Cites]
Blood. 2002 Oct 15;100(8):2891-8
[
12351400.001
]
[Cites]
Cell. 2003 Nov 14;115(4):461-73
[
14622600.001
]
[Cites]
J Med Genet. 2004 Feb;41(2):137-44
[
14757862.001
]
[Cites]
Blood. 2004 Aug 1;104(3):735-43
[
15069016.001
]
[Cites]
Nat Immunol. 2004 Oct;5(10):996-1002
[
15454923.001
]
[Cites]
J Med Genet. 2004 Oct;41(10):763-7
[
15466010.001
]
[Cites]
Eur J Pediatr. 1983 Jun-Jul;140(3):221-30
[
6354720.001
]
[Cites]
N Engl J Med. 1989 Jul 20;321(3):136-42
[
2787477.001
]
[Cites]
Semin Oncol. 1991 Feb;18(1):29-33
[
1992521.001
]
[Cites]
Acta Paediatr Scand. 1991 Mar;80(3):269-77
[
2035321.001
]
[Cites]
Pediatr Hematol Oncol. 1993 Apr-Jun;10(2):163-8
[
8318372.001
]
[Cites]
Hematol Oncol Clin North Am. 1998 Apr;12(2):417-33
[
9561910.001
]
[Cites]
J Cell Sci. 1999 Mar;112 ( Pt 6):845-54
[
10036234.001
]
[Cites]
Br J Haematol. 1999 Aug;106(2):406-15
[
10460599.001
]
[Cites]
Br J Cancer. 2004 Dec 13;91(12):1990-2
[
15570305.001
]
[Cites]
Immunol Rev. 2005 Feb;203:165-79
[
15661029.001
]
[Cites]
Blood. 2005 May 1;105(9):3442-8
[
15632205.001
]
(PMID = 16582076.001).
[ISSN]
1468-6244
[Journal-full-title]
Journal of medical genetics
[ISO-abbreviation]
J. Med. Genet.
[Language]
eng
[Publication-type]
Letter; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Qa-SNARE Proteins
[Other-IDs]
NLM/ PMC2563216
17.
Zhang Y, Gu J, Wang M, Ma L, Wang XL, He B, Sun M:
[Study on the role of angiogenesis and related factors in leukemias].
Zhonghua Xue Ye Xue Za Zhi
; 2005 Mar;26(3):175-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: To observe the bone marrow angiogenesis
in leukemia
and evaluate the expression and role of endostatin (ES), vascular endothelial growth factor (VEGF) and its receptor (VEGFR)
in leukemia
patients.
The expression of VEGFR
in leukemia
cells was determined by flow cytometry (FCM).
RESULTS: The bone marrow microvessel density (MVD) in 26 cases of
acute leukemia
(AL) [(20.78 +/- 7.75)/high-power field (HP)] and 5 chronic
myelogenous leukemia
(CML) [(28.67 +/- 7.32)/HP] at newly diagnosed stage was significantly higher than that in the control group [(9.29 +/- 3.53)/HP, P < 0.01].
The bone marrow MVD in the complete
remission
(CR) groups, (11.33 +/- 5.66)/HP for AL and (17.00 +/- 8.04)/HP for CML, was significantly lower than that of newly diagnosed groups (P < 0.05 and < 0.01).
No significant difference was found between the
remission
groups and the control group (P > 0.05).
CONCLUSIONS:
Leukemia
patients at newly diagnosed stage had remarkable angiogenesis in bone marrow and elevated plasma ES and VEGF concentrations.
[MeSH-major]
Endostatins / blood.
Leukemia
/ blood. Neovascularization, Pathologic / blood. Vascular Endothelial Growth Factor A / blood
[MeSH-minor]
Acute
Disease. Adolescent.
Adult
. Aged. Aged, 80 and over. Bone Marrow / blood supply. Bone Marrow / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Humans. Immunohistochemistry.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / blood.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / pathology. Male. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Receptors, Vascular Endothelial Growth Factor / metabolism. Young
Adult
. von Willebrand Factor / metabolism
MedlinePlus Health Information.
consumer health - Childhood Leukemia
.
MedlinePlus Health Information.
consumer health - Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15946533.001).
[ISSN]
0253-2727
[Journal-full-title]
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
[ISO-abbreviation]
Zhonghua Xue Ye Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / Endostatins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / von Willebrand Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
18.
Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF:
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
J Clin Oncol
; 2005 Oct 1;23(28):7013-23
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Five patients died from
acute
toxicity.
Four patients developed treatment-related myelodysplasia/
acute myelogenous leukemia
, and three patients died while
in remission
from MCL.
[MeSH-minor]
Administration, Oral.
Adult
. Age Factors. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Rituximab. Treatment Outcome. Vincristine / administration & dosage
Genetic Alliance.
consumer health - Mantle cell lymphoma
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
DEXAMETHASONE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
J Clin Oncol. 2006 Feb 1;24(4):724
(PMID = 16145068.001).
[ISSN]
0732-183X
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Clinical Trial; Clinical Trial, Phase II; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
19.
Rowe JM:
Consolidation therapy: what should be the standard of care?
Best Pract Res Clin Haematol
; 2008 Mar;21(1):53-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Adults 18-60 years old with
acute myelogenous leukemia
(
AML
) should undergo some form of postremission therapy, however, how much and what kinds of postremission chemotherapy remain unclear.
However, the median age of
AML
patients approaches 70 years; this is a group of patients who often reach minimal disease, but with a median disease-free survival of only 4 to 5 months, regardless of their cytogenetics, and are therefore an ideal patient group for clinical studies.
[MeSH-major]
Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage.
Leukemia
,
Myeloid
,
Acute
/ drug therapy. Neoplasm Recurrence, Local / prevention & control
[MeSH-minor]
Adolescent.
Adult
. Age Factors. Chemotherapy, Adjuvant / methods. Clinical Trials as Topic. Disease-Free Survival. Humans. Middle Aged.
Remission
Induction
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
CYTARABINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18342812.001).
[ISSN]
1521-6926
[Journal-full-title]
Best practice & research. Clinical haematology
[ISO-abbreviation]
Best Pract Res Clin Haematol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
[Number-of-references]
17
20.
Zhang YL, Ren JH, Guo XN, Zhang JN, Wang Y, Qiao SK, Lin FR:
[Expression of c-fes gene in leukemia cells and its clinical significance].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 2009 Dec;17(6):1429-33
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Expression of c-fes gene
in leukemia
cells and its clinical significance].
This study was purposed to investigate the expression of c-fes gene
in leukemia
patients and its clinical significance.
The expression of c-fes mRNA in bone marrow cells from 121 cases of
acute
and chronic
leukemia
patients, and the expression of c-fes mRNA in peripheral blood mononuclear cells of 20 normal persons were detected by real time-quantitative reverse transcription polymerase chain reaction (RQ-PCR).
The results showed that the level of c-fes mRNA in
AML
patients was higher than that in normal controls [(48.017 +/- 57.170) x 10(-3) vs (0.152 +/- 0.398) x 10(-3)] (p < 0.0001); but there was no significant differences of level of c-fes mRNA between samples of ALL and normal controls(0.047 +/- 0.068) x 10(-3) vs(0.152 +/- 0.398) x 10(-3) (p>0.05); the level of c-fes mRNA in CML patients was higher than that in normal persons (21.605 +/- 24.818) x 10(-3) vs (0.152 +/- 0.398) x 10(-3) (p < 0.0001).
In
AML
patients, c-fes gene was expressed higher in M(2) (80.77%) and M(3) (92.86%) patients.
The
remission
rate of
AML
(except M(3))patients who had expression of c-fes gene was 81.08%, which was higher than that of patients with no expression of c-fes gene (40.00%).
It is concluded that c-fes gene expression was found in
myeloid
leukemias, whereas low or no expression in
lymphocytic
leukemias.
All
AML
(except M(3))patients with high level of c-fes mRNA may get good prognosis.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20030920.001).
[ISSN]
1009-2137
[Journal-full-title]
Zhongguo shi yan xue ye xue za zhi
[ISO-abbreviation]
Zhongguo Shi Yan Xue Ye Xue Za Zhi
[Language]
CHI
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / RNA, Messenger; EC 2.7.10.2 / FES protein, human; EC 2.7.10.2 / Proto-Oncogene Proteins c-fes
21.
Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F:
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
Cancer
; 2009 Jan 1;115(1):101-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Therapy-related
acute myelogenous leukemia
and myelodysplastic syndrome in patients with
acute
lymphoblastic
leukemia
treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
BACKGROUND: Secondary malignancies including
myeloid
neoplasms occur infrequently
in acute
lymphoblastic
leukemia
(ALL) and to the authors' knowledge have not been as well documented in adults as in children.
RESULTS: Sixteen patients (2.49%) developed secondary
acute myelogenous leukemia
(
AML
) (6 patients) or myelodysplastic syndrome (MDS) (10 patients).
Karyotype at time of
AML
/MDS diagnosis was -5, -7 in 9 patients, normal in 1 patient, complex in 1 patient, inv(11) in 1 patient, t(4;11) in 1 patient, del(20) in 1 patient, and unavailable in 2 patients.
Secondary
AML
/MDS developed at a median of 32 months after ALL diagnosis.
Cytarabine plus anthracycline-based treatment was given to 12 patients with
AML
and high-risk MDS.
Response to treatment was complete
remission in
3 patients, partial
remission in
6 patients, and no response in 6 patients; 1 patient was untreated.
Eight patients (1 with
AML
and 7 with MDS) underwent allogeneic stem cell transplantation, and all but 2 died at a median of 3 months (range, 0.5-11 months) after transplantation.
The median overall survival after a diagnosis of secondary
AML
and MDS was 9.25 months (range, 1+ to 26+ months).
CONCLUSIONS: Secondary
AML
and MDS occur infrequently
in adult
patients with de novo ALL treated with the hyper-CVAD regimens, and response to therapy is poor.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Leukemia
,
Myeloid
,
Acute
/ chemically induced. Myelodysplastic Syndromes / chemically induced. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / drug therapy
[MeSH-minor]
Adolescent.
Adult
. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Middle Aged. Vincristine / administration & dosage
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
DEXAMETHASONE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2008 American Cancer Society.
(PMID = 19090005.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P30 CA016672
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
[Other-IDs]
NLM/ NIHMS629435; NLM/ PMC4180242
22.
Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N, Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group:
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
Br J Haematol
; 2008 Nov;143(4):503-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive
acute
lymphoblastic
leukaemia undergoing imatinib-combined chemotherapy.
The clinical significance of minimal residual disease (MRD) is uncertain in patients with Philadelphia chromosome-positive
acute
lymphoblastic
leukaemia (Ph+ ALL) treated with imatinib-combined chemotherapy.
Here we report the results of prospective MRD monitoring in 100
adult
patients.
Ninety-seven patients (97%) achieved complete
remission
(CR), and the relapse-free survival (RFS) rate was 46% at 3 years.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Fusion Proteins, bcr-abl / analysis.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / drug therapy
[MeSH-minor]
Adolescent.
Adult
. Benzamides. Disease-Free Survival. Female. Hematopoietic Stem Cell Transplantation. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm, Residual. Piperazines / administration & dosage. Prognosis. Prospective Studies. Pyrimidines / administration & dosage. Recurrence. Reverse Transcriptase Polymerase Chain Reaction / methods. Treatment Outcome. Young
Adult
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
IMATINIB MESYLATE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Br J Haematol. 2009 Sep;146(5):576-7
[
19555375.001
]
(PMID = 18986386.001).
[ISSN]
1365-2141
[Journal-full-title]
British journal of haematology
[ISO-abbreviation]
Br. J. Haematol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
23.
Thomas X, Dombret H:
Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia.
Hematology
; 2007 Feb;12(1):15-28
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with
acute myelogenous leukemia
.
Increasing the intensity of induction chemotherapy has generated considerable recent interest in the treatment of
acute
myeloid
leukemia
.
Achieving complete
remission
is a sine qua
non
condition for prolonged disease-free survival and may affect long-term outcome.
Here we review the results of timed-sequential chemotherapy, used as induction regimen in de novo, relapsed or refractory
AML
or used as post-
remission
therapy, and compare them with those from other types of regimens.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / administration & dosage.
Leukemia
,
Myeloid
/ drug therapy
[MeSH-minor]
Acute
Disease. Adolescent.
Adult
. Animals. Antimetabolites, Antineoplastic / administration & dosage. Bone Marrow Diseases / chemically induced. Cell Cycle / drug effects. Child. Cytarabine / pharmacology. Disease-Free Survival. Drug Administration Schedule. Drug Resistance, Neoplasm. Flavonoids / administration & dosage. Flavonoids / pharmacology. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / pharmacology. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Humans. Middle Aged. Piperidines / administration & dosage. Piperidines / pharmacology. Premedication. Prognosis. Rats.
Remission
Induction / methods. Retrospective Studies. Salvage Therapy. Treatment Outcome
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Hazardous Substances Data Bank.
CYTARABINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17364988.001).
[ISSN]
1607-8454
[Journal-full-title]
Hematology (Amsterdam, Netherlands)
[ISO-abbreviation]
Hematology
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 0 / Flavonoids; 0 / Piperidines; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 45AD6X575G / alvocidib; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
[Number-of-references]
127
24.
Weisberg E, Kung AL, Wright RD, Moreno D, Catley L, Ray A, Zawel L, Tran M, Cools J, Gilliland G, Mitsiades C, McMillin DW, Jiang J, Hall-Meyers E, Griffin JD:
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.
Mol Cancer Ther
; 2007 Jul;6(7):1951-61
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Studies suggest that these proteins may be a viable target
in leukemia
because they have been found to be variably expressed
in acute
leukemias and are associated with chemosensitivity, chemoresistance, disease progression,
remission
, and patient survival.
Another promising therapeutic target, FLT3, is mutated in about one third of
acute myelogenous leukemia
(
AML
) patients; promising results have recently been achieved in clinical trials investigating the effects of the protein tyrosine kinase inhibitor PKC412 on
AML
patients harboring mutations in the FLT3 protein.
Of growing concern, however, is the development of drug resistance resulting from the emergence of point mutations in targeted tyrosine kinases used for treatment of
acute leukemia
patients.
[MeSH-major]
Antineoplastic Agents / pharmacology. Biomimetic Materials / pharmacology. Carrier Proteins.
Leukemia
/ drug therapy. Mitochondrial Proteins. Mutant Proteins / metabolism. Oligopeptides / pharmacology. fms-Like Tyrosine Kinase 3 / metabolism
MedlinePlus Health Information.
consumer health - Leukemia
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17620426.001).
[ISSN]
1535-7163
[Journal-full-title]
Molecular cancer therapeutics
[ISO-abbreviation]
Mol. Cancer Ther.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA36167; United States / NCI NIH HHS / CA / CA66996; United States / NIDDK NIH HHS / DK / DK50654
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Carrier Proteins; 0 / Diablo protein, mouse; 0 / Inhibitor of Apoptosis Proteins; 0 / LBW242; 0 / Mitochondrial Proteins; 0 / Mutant Proteins; 0 / Oligopeptides; 120685-11-2 / 4'-N-benzoylstaurosporine; EC 2.7.10.1 / Flt3 protein, mouse; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; H88EPA0A3N / Staurosporine
25.
Liu Y, Ke XY, Ma J, Shen ZX, Zhang XH, Du X, Zhao YM, Lv JQ, Zhan ZM, Zeng XY, Xu XH, Lu ZS:
[Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Zhonghua Zhong Liu Za Zhi
; 2006 Sep;28(9):706-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Multicenter randomized control trial on safety of domestic idarubicin for
acute leukemia
].
OBJECTIVE: To evaluate the safety of domestically produced idarubicin in the treatment of
acute leukemia
by a multicenter randomized control trial.
METHODS: This trial was carried out in the hemotologica department of five hospitals throughout China, with hospitalized patients who suffered from
acute myelogenous leukemia
(
AML
except M3 type) ,
acute
lymphocytic
leukemia
( ALL) , chronic
myelogenous leukemia
-blast (CML-blast) , totally 155 patients.
In this study, 155
leukemia
patients were randomly grouped into: 1. test group treated using domestic idarubicin, 2. control group using imported idarubicin.
The
acute myelogenous leukemia
regimen included idarubicin 8 mg/m(2), dl -3 plus cytosine arabinoside 100 mg/m(2), dl - 7 for 1-2 cycles.
The regimen for
acute
lymphocytic
leukemia
was idarubicin 8 mg/m2, dl - 3; vincristine 2 mg/mr, dl; cyclophosphamide 750 mg/m2, dl ; plus prednisone 60 mg/m(2),dl - 14 for 1-2 cycles.
The incidence of
non
-hematological toxicities in domestic idarubicin group and imported idarubicin group was 84.
Discontinuation of treatment due to
non
-hematological toxicity was not neccessary.
CONCLUSION: Domestic idarubicin is comparable to imported counterpart in efficiency and safety for the treatment of
acute leukemia
.
The most severe side effects of domestic idarubicin is hematological toxicity, which should be closely observed and treated in time, while its
non
-hematological toxicity is tolerable.
[MeSH-major]
Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Idarubicin / administration & dosage.
Leukemia
,
Myeloid
,
Acute
/ drug therapy. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / drug therapy
[MeSH-minor]
Adolescent.
Adult
. Aged. Agranulocytosis / chemically induced. Blast Crisis / drug therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Female. Humans. Male. Middle Aged. Mucositis / chemically induced. Nausea / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects.
Remission
Induction. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17274381.001).
[ISSN]
0253-3766
[Journal-full-title]
Zhonghua zhong liu za zhi [Chinese journal of oncology]
[ISO-abbreviation]
Zhonghua Zhong Liu Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
[Publication-country]
China
[Chemical-registry-number]
0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ZRP63D75JW / Idarubicin
26.
Derbel O, Cannas G, Le QH, Elhamri M, Chelghoum Y, Nicolas-Virelizier E, Nicolini F, Troncy J, Barraco F, Michallet M, Thomas X:
A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule.
Hematology
; 2010 Jun;15(3):125-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk
acute
myeloid
leukemia
by the EMA 2000 schedule.
Dose intensity has been demonstrated to be one determinant for treatment efficacy in younger adults with high-risk (relapsed and refractory)
acute myelogenous leukemia
.
Thirty-six patients reached a complete
remission
, while nine obtained a partial
remission
.
The major
non
-hematologic toxicities were severe infections but despite this 23 remitters could proceed to their post-
remission
treatment, although 13 did not because of severe toxicity or early relapse.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / adverse effects. Granulocyte Colony-Stimulating Factor / administration & dosage.
Leukemia
,
Myeloid
,
Acute
/ blood.
Leukemia
,
Myeloid
,
Acute
/ drug therapy. Neutropenia / drug therapy
[MeSH-minor]
Adult
. Cytarabine / administration & dosage. Cytarabine / adverse effects. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Filgrastim. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Prognosis. Recombinant Proteins.
Remission
Induction. Survival Analysis. Treatment Outcome. Young
Adult
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
Filgrastim
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
NOVANTRONE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20557669.001).
[ISSN]
1607-8454
[Journal-full-title]
Hematology (Amsterdam, Netherlands)
[ISO-abbreviation]
Hematology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; PVI5M0M1GW / Filgrastim
27.
Bao F, Munker R, Lowery C, Martin S, Shi R, Veillon DM, Cotelingam JD, Nordberg ML:
Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias.
Mol Diagn Ther
; 2007;11(4):239-45
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: For Philadelphia chromosome positive (Ph+) leukemias (chronic
myelogenous leukemia
[CML],
acute
lymphoblastic
leukemia
[ALL], and rare other leukemias), both allogeneic transplantation and treatment with tyrosine kinase inhibitors offer chances of molecular
remission
(the molecular marker being consistently undetectable).
Molecular
remission
is defined as a reduction in the quantification of BCR-ABL transcripts to an undetectable level by molecular diagnostic methods, and is considered as a surrogate marker for cure or long-term disease control.
[MeSH-major]
Fusion Proteins, bcr-abl / metabolism. In Situ Hybridization, Fluorescence / methods.
Leukemia
/ diagnosis.
Leukemia
/ metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods
[MeSH-minor]
Adult
. Aged. Blood Cell Count. Female. Follow-Up Studies. Humans. Leukocytes. Male. Middle Aged
MedlinePlus Health Information.
consumer health - Leukemia
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Haematologica. 2006 Apr;91(4):513-21
[
16533723.001
]
[Cites]
Leuk Lymphoma. 2006 Mar;47(3):397-402
[
16396761.001
]
[Cites]
Leuk Res. 2007 Apr;31(4):483-91
[
16945414.001
]
[Cites]
Blood Rev. 2006 Jan;20(1):29-41
[
16426942.001
]
[Cites]
Curr Opin Hematol. 2005 Jan;12(1):33-9
[
15604889.001
]
[Cites]
Semin Hematol. 2001 Jul;38(3 Suppl 8):22-7
[
11526598.001
]
[Cites]
Blood. 2005 Apr 1;105(7):2640-53
[
15618470.001
]
[Cites]
J Exp Clin Cancer Res. 2004 Jun;23(2):295-9
[
15354415.001
]
[Cites]
N Engl J Med. 1999 Apr 29;340(17):1330-40
[
10219069.001
]
[Cites]
Ann Oncol. 2006 Mar;17(3):495-502
[
16403813.001
]
[Cites]
Br J Haematol. 1998 Jun;101(3):552-7
[
9633901.001
]
[Cites]
Leukemia. 2002 Jan;16(1):53-9
[
11840263.001
]
[Cites]
Clin Cancer Res. 2005 May 1;11(9):3425-32
[
15867244.001
]
[Cites]
Eur J Haematol. 2004 Oct;73(4):243-50
[
15347310.001
]
[Cites]
Hematology Am Soc Hematol Educ Program. 2006;:211-8
[
17124063.001
]
[Cites]
Curr Opin Hematol. 2003 Jul;10(4):284-9
[
12799534.001
]
[Cites]
Eur J Haematol. 2002 May;68(5):272-80
[
12144533.001
]
[Cites]
Blood. 2000 Jan 15;95(2):404-8
[
10627442.001
]
[Cites]
Blood. 2003 Jun 15;101(12):4701-7
[
12576334.001
]
(PMID = 17705578.001).
[ISSN]
1177-1062
[Journal-full-title]
Molecular diagnosis & therapy
[ISO-abbreviation]
Mol Diagn Ther
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
New Zealand
[Chemical-registry-number]
EC 2.7.10.2 / Fusion Proteins, bcr-abl
28.
Sisler IY, Koehler E, Koyama T, Domm JA, Ryan R, Levine JE, Pulsipher MA, Haut PR, Schultz KR, Taylor DS, Frangoul HA:
Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study.
Biol Blood Marrow Transplant
; 2009 Dec;15(12):1620-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with
acute myelogenous leukemia
beyond first complete
remission
: a pediatric blood and marrow transplant consortium (PBMTC) study.
Total body irradiation (TBI)-based conditioning regimens for pediatric patients with
acute myelogenous leukemia
(
AML
) beyond first complete
remission
(CR1) are controversial.
We retrospectively evaluated 151 pediatric patients with
AML
beyond CR1, comparing outcomes in 90 patients who received a TBI-based conditioning regimen and 61 patients who received a Bu-based conditioning regimen.
There were no differences between the 2 groups with respect to age, sex, duration of CR1, time from most recent
remission
to transplantation, or donor source.
Our study provides no evidence of an advantage to using TBI in children with
AML
beyond CR1.
[MeSH-major]
Antineoplastic Agents, Alkylating / therapeutic use. Busulfan / therapeutic use. Hematopoietic Stem Cell Transplantation / methods.
Leukemia
,
Myeloid
,
Acute
/ therapy. Transplantation Conditioning / methods
[MeSH-minor]
Adolescent.
Adult
. Bone Marrow Transplantation / methods. Bone Marrow Transplantation / mortality. Child. Child, Preschool. Cohort Studies. Cord Blood Stem Cell Transplantation / adverse effects. Cord Blood Stem Cell Transplantation / methods. Disease-Free Survival. Female. Humans. Infant. Male. Multivariate Analysis.
Remission
Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Whole-Body Irradiation. Young
Adult
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
BUSULFAN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19896086.001).
[ISSN]
1523-6536
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; G1LN9045DK / Busulfan
29.
Gutierrez-Aguirre CH, Cantú-RodrÃguez OG, Gonzalez-Llano O, Salazar-Riojas R, Martinez-González O, Jaime-Pérez JC, Morales-Toquero A, TarÃn-Arzaga LC, Ruiz-Argüelles GJ, Gómez-Almaguer D:
Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
Hematology
; 2007 Jun;12(3):193-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Non
-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory
acute
myeloblastic
leukemia
. The Mexican experience.
Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective strategy for preventing relapse of
acute myelogenous leukemia
(
AML
).
We analyzed the outcome of 31 primary
AML
patients who received a reduced-intensity conditioning regimen for allogeneic HSCT in first or second
remission
.
Thirty-one
AML
patients, 20 in first complete
remission
(FCR), 8 in second complete
remission
(SCR) and 3 in a partial
remission
(SPR) were included.
All patients showed
myeloid
engraftment (neutrophils >0.5 x 10(9)/l) after a median of 13 days in FCR group and 15 days in SCR group.
Conclusions. Reduced-intensity conditioning followed by allogeneic HSCT can induce stable
remission in
primary
AML
patients transplanted in FCR.
A high relapse rate was documented in patients with refractory or relapsed
AML
.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods.
Leukemia
,
Myeloid
,
Acute
/ therapy
[MeSH-minor]
Adolescent.
Adult
. Busulfan / administration & dosage. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cyclosporine / administration & dosage. Graft Survival. Graft vs Host Disease / drug therapy. Graft vs Host Disease / prevention & control. Humans. Mexico. Middle Aged. Recurrence. Salvage Therapy / methods. Transplantation Conditioning / methods. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
FLUDARABINE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
BUSULFAN
.
Hazardous Substances Data Bank.
VIDARABINE
.
Hazardous Substances Data Bank.
CYCLOSPORIN A
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17558694.001).
[ISSN]
1607-8454
[Journal-full-title]
Hematology (Amsterdam, Netherlands)
[ISO-abbreviation]
Hematology
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
30.
Balleisen S, Kuendgen A, Hildebrandt B, Haas R, Germing U:
Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
Leuk Res
; 2009 Sep;33(9):1189-93
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic relevance of achieving cytogenetic
remission in
patients with
acute myelogenous leukemia
or high-risk myelodysplastic syndrome following induction chemotherapy.
Cytogenetic findings at diagnosis have influence on prognosis in patients with
acute myelogenous
leukaemia (
AML
) or MDS who undergo induction chemotherapy.
Assessment of
remission
and treatment decisions are based on cytological findings.
We analyzed the prognostic impact of cytogenetic
remission
status in 118 patients with abnormal karyotype who received induction chemotherapy.
Eighty-three patients achieved complete
remission
(CR) and 20 achieved partial
remission
.
Median survival (excluding patients with
AML
M3) of the CCR group was 37 months, as compared to 11 months in patients with persistence of abnormal karyotype (p < 0.0001).
[MeSH-major]
Antineoplastic Agents / therapeutic use.
Leukemia
,
Myeloid
,
Acute
/ drug therapy. Myelodysplastic Syndromes / drug therapy.
Remission
Induction
[MeSH-minor]
Adult
. Aged. Female. Humans. Karyotyping. Male. Middle Aged. Prognosis. Translocation, Genetic
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19428106.001).
[ISSN]
1873-5835
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents
31.
Wang LH, Wang M, Zhou CL, Chen S, Zhang XW, Xing HY, Wang JX:
[Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].
Zhonghua Xue Ye Xue Za Zhi
; 2005 Jun;26(6):335-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Detection of point mutation at second tyrosine kinase domain of FLT3 gene
in acute
myeloid
leukemia
].
OBJECTIVE: To evaluate the prevalence of a novel FLT3 activating mutation in tyrosine kinase domain (TDK)
in acute leukemia
patients and its clinical implication.
METHODS: Genomic DNA from bone marrow mononuclear cells of 143 cases of
acute
myeloid
leukemia
(
AML
), 25
acute
lymphocytic
leukemia
(ALL), 2
acute
hybrid
leukemia
(AHL), 17 myelodysplastic syndromes (MDS) and 7 chronic
myelogenous leukemia
in blast crisis (CML-BC) was screened by polymerase chain reaction (PCR) and gel electrophoresis for FLT3-TKD point mutations.
RESULTS: Among
AML
patients, FLT3-TKD point mutation (FLT3-TKD(+)) rate was 6.3% (9/143), an incidence significantly lower than that of internal tandem duplication (ITD) mutation (37/143, 25.9%, P < 0.01).
In contrast to FLT3-ITD mutation, TKD mutations were not associated with leukocytosis or low complete
remission
rate.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ genetics. fms-Like Tyrosine Kinase 3 / genetics
[MeSH-minor]
Adolescent.
Adult
. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Point Mutation
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16185475.001).
[ISSN]
0253-2727
[Journal-full-title]
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
[ISO-abbreviation]
Zhonghua Xue Ye Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
32.
Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O:
Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
Eur J Haematol
; 2010 Mar;84(3):239-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary human
acute myelogenous leukemia
cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
OBJECTIVES: Angiogenesis seems important for both leukemogenesis and chemosensitivity
in acute myelogenous leukemia
(
AML
).
We investigated the constitutive release of MMPs and TIMPs for a large group of consecutive
AML
patients.
METHODS:
AML
cells were cultured in vitro either alone or together with microvascular endothelial cells, and levels of MMPs and TIMPs were determined in culture supernatants.
RESULTS:
AML
cells showed constitutive release of several MMPs and TIMPs.
MMP-9 release was higher for
AML
cells with monocytic differentiation corresponding to the FAB-subtype M4/M5
AML
; it was mainly released in its inactive form, but endogenously active MMP-9 could be detected even in the presence of the constitutively released TIMP-1/2.
Endothelial cells released relatively high levels of MMP-10, and these levels were further increased by coculture with
AML
cells.
Patients achieving complete hematological
remission
after only one induction cycle showed relatively low constitutive MMP-2 release.
CONCLUSION: We conclude that primary human
AML
cells show constitutive release of both MMPs and TIMPs, and this release may be important for leukemogenesis and possibly also for chemosensitivity.
[MeSH-major]
Leukemia
,
Myeloid
/ pathology. Matrix Metalloproteinases / secretion. Neoplasm Proteins / secretion. Tissue Inhibitor of Metalloproteinases / secretion
[MeSH-minor]
Acute
Disease.
Adult
. Aged. Aged, 80 and over. Angiopoietin-2 / pharmacology. Anthracyclines / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Boronic Acids / pharmacology. Bortezomib. Cells, Cultured / cytology. Chemokines / secretion. Coculture Techniques. Culture Media, Serum-Free / pharmacology. Cytarabine / administration & dosage. Diterpenes / pharmacology. Endothelial Cells / cytology. Female. Humans. Imidazoles / pharmacology. Male. Matrix Metalloproteinase Inhibitors. Middle Aged. NF-kappa B / antagonists & inhibitors. Protease Inhibitors / pharmacology. Pyrazines / pharmacology. Quinoxalines / pharmacology. Receptor, TIE-2 / antagonists & inhibitors. Receptor, TIE-2 / physiology. Recombinant Proteins / pharmacology. Tumor Cells, Cultured / enzymology. Tumor Cells, Cultured / secretion
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
BORTEZOMIB
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19922462.001).
[ISSN]
1600-0609
[Journal-full-title]
European journal of haematology
[ISO-abbreviation]
Eur. J. Haematol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / 3-ingenyl angelate; 0 / 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline; 0 / Angiopoietin-2; 0 / Anthracyclines; 0 / Boronic Acids; 0 / Chemokines; 0 / Culture Media, Serum-Free; 0 / Diterpenes; 0 / Imidazoles; 0 / Matrix Metalloproteinase Inhibitors; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / Protease Inhibitors; 0 / Pyrazines; 0 / Quinoxalines; 0 / Recombinant Proteins; 0 / Tissue Inhibitor of Metalloproteinases; 04079A1RDZ / Cytarabine; 69G8BD63PP / Bortezomib; EC 2.7.10.1 / Receptor, TIE-2; EC 3.4.24.- / Matrix Metalloproteinases
33.
Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H:
Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Cancer
; 2005 Aug 1;104(3):547-54
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Outcome of patients with
acute myelogenous leukemia
after second salvage therapy.
BACKGROUND: Although the prognosis is poor for patients with
acute myelogenous leukemia
(
AML
) who have disease recurrence after frontline therapy, this is a general reflection of first salvage therapies.
The authors analyzed the outcome of patients with
AML
undergoing second salvage therapy, and identified prognostic factors associated with response and survival.
METHODS: The records of 594 patients with
AML
undergoing second salvage therapy from 1980 until 2004 were reviewed.
Salvage therapy included allogeneic stem cell transplantation (SCT) in 74 patients, standard-dose cytosine arabinoside (ara-C) combinations in 30 patients, high-dose ara-C combinations in 171 patients,
non
-ara-C combinations in 73 patients, and Phase I-II single agents in 246 patients.
A multivariate analysis of prognostic factors for CR identified the following 6 independent adverse factors: first CR duration < 6 months; second CR duration < 6 months; salvage therapy not including allogeneic SCT;
non
-inversion 16
AML
; platelet counts < 50 x 10(9)/L, and leukocytosis > 50 x 10(9)/L.
CONCLUSIONS: The current analysis established the outcome and prognostic factors associated with second salvage therapy in
AML
.
[MeSH-major]
Antineoplastic Agents / therapeutic use.
Leukemia
,
Myeloid
,
Acute
/ therapy. Salvage Therapy. Stem Cell Transplantation. Transplantation, Homologous
[MeSH-minor]
Adolescent.
Adult
. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Cytarabine / therapeutic use. Female. Humans. Male. Middle Aged. Prognosis.
Remission
Induction. Survival Rate. Treatment Outcome
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
CYTARABINE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2005 American Cancer Society.
(PMID = 15973664.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine
34.
Kim HR, Shin JH, Lee JN, Lee EY:
[Clinical significance of quantitation of WT1 gene expression for minimal residual disease monitoring of acute myelogenous leukemia].
Korean J Lab Med
; 2007 Oct;27(5):305-12
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Clinical significance of quantitation of WT1 gene expression for minimal residual disease monitoring of
acute myelogenous leukemia
].
BACKGROUND: Following induction chemotherapy for
AML
, a sensitive determination of minimal residual disease (MRD) in patients achieving complete
remission
(CR) should enable the detection of early relapse.
This study was designed to verify if quantitative assessment of the Wilms' tumor (WT1) gene by real time polymerase chain reaction (RQ-PCR) can be used as a marker for MRD detection during the monitoring of
AML
.
METHODS: WT1 gene expression was quantified by RQ-PCR in 31 patients with
AML
at diagnosis (27 patients) and during follow-up (29 patients) relative to ABL control gene.
Longitudinal WT1 gene analysis was performed in 17
AML
patients.
CONCLUSIONS: Quantitation of WT1 gene expression could be used for MRD monitoring of
AML
and for the early detection of relapse, especially in patients lacking specific molecular markers.
[MeSH-major]
Genes, Wilms Tumor.
Leukemia
, Myelomonocytic,
Acute
/ diagnosis. WT1 Proteins / analysis
[MeSH-minor]
Adaptor Proteins, Signal Transducing / analysis.
Adult
. Aged. Aged, 80 and over. Female. Follow-Up Studies. Gene Expression. Humans. Male. Middle Aged. Neoplasm, Residual. Polymerase Chain Reaction. Prognosis. Survival Analysis
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18094593.001).
[ISSN]
1598-6535
[Journal-full-title]
The Korean journal of laboratory medicine
[ISO-abbreviation]
Korean J Lab Med
[Language]
kor
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Korea (South)
[Chemical-registry-number]
0 / Adaptor Proteins, Signal Transducing; 0 / PRAM1 protein, human; 0 / WT1 Proteins
35.
Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Ball E, Cook D, Andresen S, Kuczkowski E, Bolwell B:
CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Bone Marrow Transplant
; 2005 Feb;35(3):247-52
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced
AML
using busulfan-based preparative regimens.
Between March 1993 and June 2002, we treated 33 relapsed
acute myelogenous leukemia
(
AML
) patients with busulfan-based preparative regimens and selective TCD.
Although 67% of evaluable patients developed
acute
GVHD, severe grade III-IV
acute
GVHD only developed in 19%.
The severity of
acute
GVHD correlated with the degree of CD8+ TCD.
Median relapse-free survival was 5 months among 20 patients treated with active
AML
, and 28 months among 13 patients treated in complete
remission
.
Our results confirm that MUD BMT with CD8+ TCD for
AML
is a potentially curative treatment option.
[MeSH-major]
Bone Marrow Transplantation / methods. Busulfan / administration & dosage. CD8-Positive T-Lymphocytes.
Leukemia
,
Myeloid
,
Acute
/ therapy. Lymphocyte Depletion / methods
[MeSH-minor]
Adult
. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Etoposide / therapeutic use. Female. Graft Survival. Graft vs Host Disease / prevention & control. Histocompatibility. Histocompatibility Testing. Humans. Male. Middle Aged. Salvage Therapy / methods. Survival Analysis. Tissue Donors. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Bone Marrow Transplantation
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
Carmustine
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
BUSULFAN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15580282.001).
[ISSN]
0268-3369
[Journal-full-title]
Bone marrow transplantation
[ISO-abbreviation]
Bone Marrow Transplant.
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
England
[Chemical-registry-number]
6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan; U68WG3173Y / Carmustine; CBV protocol
36.
Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S, Dupriez B, Pigneux A, Choufi B, Reman O, Stéphane D, Royer B, Vigier M, Ojeda-Uribe M, Recher C, Dombret H, Huguet F, Rousselot P, Intergroupe Français des Leucémies Myéloïdes Chronique, Group for Research in Adult Acute Lymphoblastic Leukemia:
High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
Leukemia
; 2006 Mar;20(3):400-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive
acute
lymphoblastic
leukemia
and lymphoid blast crisis of chronic
myeloid
leukemia
.
Imatinib combined with high-dose chemotherapy is now becoming the gold standard for treatment of Philadelphia chromosome-positive
acute
leukemias.
Thirty-one patients (18 relapsing or refractory Ph+
acute
lymphoblastic
leukemias and 13 lymphoid blast crisis chronic
myelogenous
leukemias) were enrolled.
Complete
remission
(CR) was obtained in 28 out of 30 assessable patients.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blast Crisis / drug therapy.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / drug therapy. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / drug therapy
Genetic Alliance.
consumer health - Chronic Myeloid Leukemia
.
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
IMATINIB MESYLATE
.
Hazardous Substances Data Bank.
DEXAMETHASONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16437142.001).
[ISSN]
0887-6924
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8A1O1M485B / Imatinib Mesylate
37.
Shen YM, Chao HY, Zhang R, Li WY, Feng YF, Zhu ZL, Xue YQ:
[Detection of JAK2V617F mutation and its clinical significance in 80 patients with M2 acute myelogenous leukemia].
Zhonghua Zhong Liu Za Zhi
; 2009 May;31(5):366-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Detection of JAK2V617F mutation and its clinical significance in 80 patients with M2
acute myelogenous leukemia
].
OBJECTIVE: To explore the prevalence and prognostic significance of JAK2V617F gene mutation
in acute myelogenous leukemia
M2 (
AML
-M2) patients.
RESULTS: Of 80 de novo
AML
-M2 patients, 6 at the time of first diagnosis and 1 at relapse were found to have JAK2V617F gene mutation (8.8%, 7/80).
Morphologically, the whole blood and bone marrow of the 7
AML
-M2 patients with JAK2V617F gene mutation presented a picture of
acute leukemia
instead of myeloproliferative disorders.
Immunophenotypically, bone marrow samples showed
myelogenous
linage expression.
Complete
remission
was obtained in 4 of 5
AML
-M2 patients with JAK2V617F mutation who received treatment, while one patient had no response to the treatment.
CONCLUSION: JAK2V617F gene mutation, as a type-1 mutation, might not be an initial event in the pathogenesis of
acute myelogenous leukemia
, and its presentation does not mean a poor prognosis in de novo
AML
patients.
[MeSH-major]
Janus Kinase 2 / genetics.
Leukemia
,
Myeloid
,
Acute
/ genetics. Mutation
[MeSH-minor]
Adolescent.
Adult
. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. DNA Mutational Analysis. DNA, Neoplasm / genetics. Female. Follow-Up Studies. Humans. Male. Middle Aged.
Remission
Induction. Survival Rate. Young
Adult
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19799086.001).
[ISSN]
0253-3766
[Journal-full-title]
Zhonghua zhong liu za zhi [Chinese journal of oncology]
[ISO-abbreviation]
Zhonghua Zhong Liu Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / DNA, Neoplasm; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
38.
Ruan GR, Li JL, Qin YZ, Li LD, Xie M, Chang Y, Zhang Y, Liu YR, Jiang B, Chen SS, Huang XJ:
Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia.
Ann Hematol
; 2009 Feb;88(2):159-66
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Nucleophosmin mutations in Chinese adults with
acute myelogenous leukemia
.
Recently, mutations in the nucleophosmin (NPM1) gene were detected in 50-60% of
adult acute myelogenous leukemia
(
AML
) patients, mainly with a normal karyotype.
In this study, we detected typical NPM1 mutations (types A, B, D) in untreated Chinese
AML
patients using real-time quantitative polymerase chain reaction (RQ-PCR) followed by sequence analysis.
The detection rate of NPM1 mutations in 220
AML
patients was 16.4%, including 107 (14.2%) with the French-American-British (FAB) subtype M2, 43 (2.3%) with M3, and 52 (30.8%) with M4/M5.
Eight patients were followed up after treatment, and five patients in hematologic
remission
continued to test negative for NPM1 mutations within 2-14 months of follow-up.
The results demonstrated that RQ-PCR was a reliable and sensitive method for detecting NPM1 mutations, for screening
AML
, and for the quantitative analysis of minimal residual diseases.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ epidemiology.
Leukemia
,
Myeloid
,
Acute
/ genetics. Nuclear Proteins / genetics
[MeSH-minor]
Adult
. Aged. Aged, 80 and over. Base Sequence. China / epidemiology. Female. Follow-Up Studies. Gene Dosage / genetics. Humans. Indicator Dilution Techniques. Male. Middle Aged. Mutation / genetics. Plasmids / genetics. Sensitivity and Specificity
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18726096.001).
[ISSN]
1432-0584
[Journal-full-title]
Annals of hematology
[ISO-abbreviation]
Ann. Hematol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Nuclear Proteins; 117896-08-9 / nucleophosmin
39.
Xue SL, Wu DP, Sun AN, Tang XW:
CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases.
Am J Hematol
; 2008 Feb;83(2):167-70
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CAG regimen enables relapsed or refractory T-cell
acute
lymphocytic
leukemia
patients to achieve complete
remission
: a report of six cases.
Patients with either relapsed or refractory T-cell
acute
lymphocytic
leukemia
(T-ALL) are candidates for allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Achieving complete
remission
(CR) in these patients is difficult but crucial for the success of allo-HSCT.
After initial
remission
-induction therapy, two patients achieved CR, one showed a partial
remission
, and all relapsed soon.
The CAG regimen (cytosine arabinoside 10 mg/m(2) subcutaneously every 12 hr, day 1-14; aclarubicin 5-7 mg/m(2) intravenously daily, day 1-8; and concurrent use of G-CSF 200 microg/m(2)/day subcutaneously) was devised originally for the treatment of relapsed
acute myelogenous leukemia
.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Leukemia
-Lymphoma,
Adult
T-Cell / drug therapy
[MeSH-minor]
Aclarubicin / administration & dosage. Adolescent.
Adult
. Antigens, CD / genetics. Cytarabine / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Immunophenotyping. Karyotyping. Male. Middle Aged.
Remission
Induction
Hazardous Substances Data Bank.
CYTARABINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17874449.001).
[ISSN]
0361-8609
[Journal-full-title]
American journal of hematology
[ISO-abbreviation]
Am. J. Hematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 74KXF8I502 / Aclarubicin; CAG protocol
40.
Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H:
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Clin Cancer Res
; 2008 Jun 15;14(12):3906-15
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase II study of dasatinib in Philadelphia chromosome-negative
acute
and chronic
myeloid
diseases, including systemic mastocytosis.
EXPERIMENTAL DESIGN: In this phase 2, open-label study, the efficacy of dasatinib (140 mg/d) was investigated in 67 patients with various Ph-
myeloid
disorders, including SM (n = 33; 28 KIT-D816V positive).
Only two patients, one with SM-myelofibrosis and one with SM-chronic eosinophilic
leukemia
, achieved complete response (elimination of mastocytosis) lasting for 5 and 16 months, respectively.
Complete responses were achieved in two other patients (
acute
myeloid
leukemia
and hypereosinophilic syndrome).
[MeSH-major]
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / drug therapy.
Leukemia
,
Myeloid
,
Acute
/ drug therapy. Mastocytosis, Systemic / drug therapy. Pyrimidines / therapeutic use. Thiazoles / therapeutic use
[MeSH-minor]
Adult
. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Dasatinib. Female. Humans. Male. Middle Aged. Philadelphia Chromosome.
Remission
Induction. Treatment Outcome
Genetic Alliance.
consumer health - Mast cell disease
.
Genetic Alliance.
consumer health - Systemic mastocytosis
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18559612.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P30 CA016672
[Publication-type]
Clinical Trial, Phase II; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Pyrimidines; 0 / Thiazoles; RBZ1571X5H / Dasatinib
[Other-IDs]
NLM/ NIHMS814210; NLM/ PMC5018899
41.
Min WS, Kim HJ, Choi Y, Jeong HY, Kim CC:
Interpretation of interleukin-2 receptor alpha positive cells during induction chemotherapy for adult acute myelogenous leukaemia patients.
Hematol Oncol
; 2007 Jun;25(2):76-83
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Interpretation of interleukin-2 receptor alpha positive cells during induction chemotherapy for
adult acute myelogenous
leukaemia patients.
To correlate clinical outcomes with the expression of interleukin-2 receptor alpha (CD25) positive cells during induction chemotherapy (IC)
in adult
patients with
acute
myeloid
leukaemia (
AML
), we investigated the prognostic importance of subsets of peripheral blood (PB) CD45+CD25+ cells.
Seventy-five patients with newly diagnosed
AML
received the same initial IC; and serial PB samples were taken.
In addition, patients in complete
remission
(CR) (n = 61) demonstrated relatively lower levels of steady PB CD45+CD25+ after standard IC.
[MeSH-major]
Interleukin-2 Receptor alpha Subunit / analysis.
Leukemia
,
Myeloid
,
Acute
/ drug therapy.
Leukemia
,
Myeloid
,
Acute
/ immunology
[MeSH-minor]
Adolescent.
Adult
. Antigens, CD45 / analysis. Female. Humans. Male. Middle Aged. Prognosis
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2007 John Wiley & Sons, Ltd.
(PMID = 17200986.001).
[ISSN]
0278-0232
[Journal-full-title]
Hematological oncology
[ISO-abbreviation]
Hematol Oncol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
42.
Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J:
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Blood
; 2009 May 21;113(21):5058-63
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic
myeloid
leukemia in
accelerated or blast phase.
Second-generation tyrosine kinase inhibitors are effective in Philadelphia chromosome-positive (Ph(+))
acute
lymphoblastic
leukemia
(ALL) and chronic
myeloid
leukemia
(CML).
[MeSH-major]
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / diagnosis.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / drug therapy. Protein Kinase Inhibitors / therapeutic use
[MeSH-minor]
Adolescent.
Adult
. Aged. Benzamides. Blast Crisis. Cytogenetic Analysis. Dasatinib. Female. Humans. Imatinib Mesylate.
Leukemia
,
Myeloid
, Accelerated Phase. Male. Middle Aged. Piperazines / administration & dosage. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma. Prognosis. Pyrimidines / administration & dosage.
Remission
Induction / methods. Survival Analysis. Thiazoles / administration & dosage. Treatment Failure. Young
Adult
Genetic Alliance.
consumer health - Chronic Myeloid Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
IMATINIB MESYLATE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 2006 Sep 15;108(6):1809-20
[
16709930.001
]
[Cites]
N Engl J Med. 2006 Dec 7;355(23):2408-17
[
17151364.001
]
[Cites]
Blood. 2007 Apr 15;109(8):3207-13
[
17185463.001
]
[Cites]
Blood. 2007 May 15;109(10):4143-50
[
17264298.001
]
[Cites]
Blood. 2007 Oct 1;110(7):2309-15
[
17496201.001
]
[Cites]
Blood. 2007 Nov 15;110(10):3540-6
[
17715389.001
]
[Cites]
Br J Haematol. 1998 Apr;101(1):111-8
[
9576191.001
]
[Cites]
Clin Adv Hematol Oncol. 2008 Feb;6(2):113-7
[
18347562.001
]
[Cites]
Leukemia. 2008 Jun;22(6):1200-6
[
18401416.001
]
[Cites]
Semin Hematol. 2003 Jan;40(1):79-86
[
12563614.001
]
[Cites]
Cancer. 2003 Feb 15;97(4):1033-41
[
12569603.001
]
[Cites]
Blood. 2003 Nov 1;102(9):3097-9
[
12842982.001
]
[Cites]
J Clin Oncol. 2003 Dec 15;21(24):4642-9
[
14673054.001
]
[Cites]
Blood. 2008 Feb 15;111(4):1834-9
[
18048643.001
]
(PMID = 19282457.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P30 CA016672
[Publication-type]
Clinical Trial; Journal Article; Multicenter Study
[Publication-country]
United States
[Chemical-registry-number]
0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; RBZ1571X5H / Dasatinib
[Other-IDs]
NLM/ PMC4081366
43.
Lee SH, Park J, Hwang SK:
Isolated recurrence of intracerebral granulocytic sarcoma in acute lymphoblastic leukemia: a case report.
J Neurooncol
; 2006 Oct;80(1):101-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Isolated recurrence of intracerebral
granulocytic
sarcoma
in acute
lymphoblastic
leukemia
: a case report.
Intracranial
granulocytic
sarcoma (chloroma) may occur rarely
in leukemia
.
A 27-year-old male presented with an isolated recurrence of
granulocytic
sarcoma manifesting as an intraaxial mass 27 months after complete
remission
of
acute
lymphoblastic
leukemia
.
The biopsy result indicated that intraaxial
lymphoblastic
leukemia
infiltration had caused CNS relapse.
Although
granulocytic
sarcoma occurs primarily in patients with
acute myelogenous leukemia
, the authors report a rare case of intraparenchymal
granulocytic
sarcoma
in acute
lymphoblastic
leukemia
.
[MeSH-major]
Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / pathology. Sarcoma,
Myeloid
/ pathology
[MeSH-minor]
Adult
. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Headache / etiology. Humans. Intracranial Hypertension / etiology. Intracranial Hypertension / surgery. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Ventriculoperitoneal Shunt. Vision Disorders / etiology
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Radiology. 1994 Mar;190(3):698-702
[
8115614.001
]
[Cites]
Radiology. 1986 Jul;160(1):223-5
[
3459211.001
]
[Cites]
Ann Intern Med. 1995 Sep 1;123(5):351-3
[
7625623.001
]
[Cites]
Cancer. 1981 Sep 15;48(6):1426-37
[
7023656.001
]
[Cites]
Acta Haematol. 1998;99(4):231-3
[
9644303.001
]
[Cites]
Cancer. 1973 Mar;31(3):520-33
[
4511909.001
]
[Cites]
Cancer. 1986 Dec 15;58(12):2697-709
[
3465429.001
]
[Cites]
Cancer. 1973 Apr;31(4):948-55
[
4513297.001
]
[Cites]
J Comput Assist Tomogr. 1987 Nov-Dec;11(6):938-41
[
3500192.001
]
[Cites]
AJNR Am J Neuroradiol. 1996 Sep;17(8):1592-4
[
8883663.001
]
[Cites]
Jpn J Clin Oncol. 1999 Apr;29(4):214-8
[
10340046.001
]
[Cites]
J Neurooncol. 2002 Oct;60(1):31-5
[
12416543.001
]
[Cites]
Bone Marrow Transplant. 1996 Sep;18(3):663-4
[
8879638.001
]
[Cites]
AJNR Am J Neuroradiol. 1991 Mar-Apr;12 (2):259-62
[
1902023.001
]
[Cites]
J Neurooncol. 1998 Jun-Jul;38(2-3):167-80
[
9696368.001
]
[Cites]
Clin Neurol Neurosurg. 1986;88(2):135-9
[
3463444.001
]
[Cites]
J Comput Assist Tomogr. 1979 Apr;3(2):226-33
[
285087.001
]
[Cites]
Neurology. 1982 Jan;32(1):77-80
[
6948173.001
]
(PMID = 16645713.001).
[ISSN]
0167-594X
[Journal-full-title]
Journal of neuro-oncology
[ISO-abbreviation]
J. Neurooncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
44.
Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C:
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
Clin Cancer Res
; 2005 Sep 15;11(18):6641-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory
acute leukemia
.
PURPOSE: To assess the maximum tolerated dose, toxicities, pharmacokinetics, and antileukemic activity of topotecan and carboplatin in adults with recurrent or refractory
acute
leukemias.
Patients achieving a complete
remission
received up to two additional courses for consolidation.
Among 45 evaluable patients, there were 7 complete remissions, 2 partial remissions, 1 incomplete complete
remission
, and 1 reversion to chronic-phase chronic
myelogenous leukemia
.
The complete
remission
rate in a heavily pretreated population was 16% (33% at the highest three dose levels).
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Leukemia
/ drug therapy
[MeSH-minor]
Acute
Disease.
Adult
. Aged. Bone Marrow Cells / drug effects. Bone Marrow Cells / metabolism. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carboplatin / pharmacokinetics. Cell Cycle Proteins / metabolism. Combined Modality Therapy. DNA Topoisomerases, Type I / metabolism. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. HL-60 Cells. Hematopoietic Stem Cell Transplantation. Humans. Immunoblotting. Infusions, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local. Proliferating Cell Nuclear Antigen / metabolism. Topotecan / administration & dosage. Topotecan / adverse effects. Topotecan / pharmacokinetics. Treatment Outcome
MedlinePlus Health Information.
consumer health - Leukemia
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
Topotecan
.
Hazardous Substances Data Bank.
CARBOPLATIN
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16166443.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01 CA73709; United States / NCI NIH HHS / CA / U01 CA69854; United States / NCI NIH HHS / CA / U01 CA69912
[Publication-type]
Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Cell Cycle Proteins; 0 / Proliferating Cell Nuclear Antigen; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; EC 5.99.1.2 / DNA Topoisomerases, Type I
45.
Mori T, Aisa Y, Watanabe R, Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S:
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Biol Blood Marrow Transplant
; 2008 Jun;14(6):651-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo
acute myelogenous leukemia
with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
We retrospectively evaluated the efficacy and safety of total body irradiation (TBI) and granulocyte colony-stimulating factor (G-CSF)-combined high-dose cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with de novo
acute myelogenous leukemia
(
AML
).
At HSCT, 35 patients were in the first or second complete
remission
(CR1/2), and 15 patients were not
in remission
(n = 14) or in the third CR (n = 1).
The 5-year estimated overall survival (OS) and disease-free survival (DFS) rates were 85.5% (95% confidence interval [CI], 73.7%-97.3%) and 82.1% (95% CI, 69.0%-95.2%) in patients with
AML
in the first or second CR, 46.7% (95% CI, 21.4%-72.0%), and 40.0% (95% CI, 15.3%-64.7%) in patients with
AML
in other stages.
These results suggest that G-CSF-combined high-dose cytarabine could be a promising component of the conditioning regimen for allogeneic HSCT for
AML
, providing a high DFS and low TRM.
[MeSH-major]
Hematopoietic Stem Cell Transplantation.
Leukemia
,
Myeloid
,
Acute
/ surgery. Peripheral Blood Stem Cell Transplantation. Transplantation Conditioning / methods
[MeSH-minor]
Adolescent.
Adult
. Bone Marrow Transplantation / adverse effects. Bone Marrow Transplantation / mortality. Cytarabine / administration & dosage. Disease-Free Survival. Female. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Infusions, Intravenous. Kaplan-Meier Estimate.
Leukemia
, Myelomonocytic,
Acute
/ mortality.
Leukemia
, Myelomonocytic,
Acute
/ surgery. Male. Middle Aged. Recombinant Proteins / administration & dosage.
Remission
Induction. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Whole-Body Irradiation
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
CYTARABINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18489990.001).
[ISSN]
1523-6536
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6WS4C399GB / lenograstim
46.
Seiter K, Liu D, Feldman E, Shi Q, Qureshi A, Arshad M, Walia T, Naseer N, Baskind P, Ahmed T:
Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution.
Leuk Lymphoma
; 2006 Mar;47(3):425-32
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed
acute myelogenous leukemia
. Twelve year results from a single institution.
This report provides long-term results of the treatment of patients with newly-diagnosed
AML
with a single high dose of mitoxantrone combined with once daily cytarabine.
The overall complete
remission
rate was 64%, with responses in 78% of patients less than 60 years of age and 51% of patients 60 years of age or older.
For a sub-set of patients who would be eligible for most US trials, the complete
remission
rate was 84% in younger patients and 60% in older patients.
[MeSH-major]
Leukemia
,
Myeloid
,
Acute
/ diagnosis.
Leukemia
,
Myeloid
,
Acute
/ drug therapy. Mitoxantrone / therapeutic use
[MeSH-minor]
Adult
. Age Factors. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cytarabine / administration & dosage. Diagnosis, Differential. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged.
Remission
Induction. Survival Analysis. Treatment Outcome
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
NOVANTRONE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16396765.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Clinical Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone
47.
Ruiz-Argüelles GJ, Morales-Toquero A, Manzano C, Ruiz-Delgado GJ, Jaramillo P, Gonzalez-Carrillo ML, Reyes-Núñez V:
t(8;21) (q22;q22) acute myelogenous leukemia in Mexico: a single institution experience.
Hematology
; 2006 Aug;11(4):235-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
t(8;21) (q22;q22)
acute myelogenous leukemia in
Mexico: a single institution experience.
We analyze the prevalence and clinical features of a group of patients with t(8;21) (q22;q22)
acute
myeloblastic
leukemia
, identified in a single institution in México over a 10-year period.
According to the French-American-British (FAB) morphological classification of
leukemia
, the morphology was M2 in four cases, M4 in three cases, M3 in one case and M0 in one.
In addition to the
myeloid
markers, lymphoid markers were identified in 6 patients.
Patients were induced to
remission
with combined chemotherapy and three subsequently underwent bone marrow transplantation (BMT).
In this single-center experience in México, we found that the t(8;21) (q22;q22) variant of
leukemia
was more frequent than in Caucasian populations, that the co-expression of lymphoid markers in the blast cells is very frequent and that this malignancy is associated with a relatively good prognosis.
[MeSH-major]
Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 8 / genetics. Core Binding Factor Alpha 2 Subunit / genetics.
Leukemia
,
Myeloid
/ genetics. Oncogene Proteins, Fusion / genetics. Peripheral Blood Stem Cell Transplantation / statistics & numerical data. Translocation, Genetic
[MeSH-minor]
Acute
Disease. Adolescent.
Adult
. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Mexico / epidemiology. Middle Aged. Prevalence. Prospective Studies.
Remission
Induction. Salvage Therapy. Transplantation, Autologous / statistics & numerical data. Transplantation, Homologous / statistics & numerical data. Treatment Outcome
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17178661.001).
[ISSN]
1607-8454
[Journal-full-title]
Hematology (Amsterdam, Netherlands)
[ISO-abbreviation]
Hematology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 04079A1RDZ / Cytarabine; 80168379AG / Doxorubicin
48.
Basak G, Torosian T, Snarski E, Niesiobedzka J, Majewski M, Gronkowska A, Urbanowska E, Jedrzejczak W:
Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia.
Ann Transplant
; 2010 Apr-Jun;15(2):68-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Hematopoietic stem cell transplantation for T315I-mutated chronic
myelogenous leukemia
.
BACKGROUND: The T315I mutation of BCR/ABL gene is known to produce complete resistance of chronic
myelogenous leukemia
(CML) to all currently available BCR/ABL inhibitors.
Despite satisfactory hematological
remission
, he failed to achieve complete cytogenetic
remission
within the first year of treatment.
The course of transplantation was complicated by staphylococcal sepsis, grade I skin
acute
GvHD and limited chronic skin GVHD.
However, the goal of alloSCT was achieved and the patient remains in complete molecular
remission
at week +68 post-transplantation.
[MeSH-major]
Genes, abl. Hematopoietic Stem Cell Transplantation.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / genetics.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / therapy. Mutation, Missense
[MeSH-minor]
Adult
. Amino Acid Substitution. Drug Resistance, Neoplasm / genetics. Fusion Proteins, bcr-abl / antagonists & inhibitors. Fusion Proteins, bcr-abl / genetics. Humans.
Leukemia
,
Myeloid
, Accelerated Phase / drug therapy.
Leukemia
,
Myeloid
, Accelerated Phase / genetics.
Leukemia
,
Myeloid
, Accelerated Phase / therapy. Male. Protein Kinase Inhibitors / pharmacology.
Remission
Induction. Transplantation, Homologous
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20657522.001).
[ISSN]
2329-0358
[Journal-full-title]
Annals of transplantation
[ISO-abbreviation]
Ann. Transplant.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Poland
[Chemical-registry-number]
0 / Protein Kinase Inhibitors; EC 2.7.10.2 / Fusion Proteins, bcr-abl
49.
Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P, Accorsi P, Confalonieri G, Tavecchia L, Verga L, Ravagnani F, Iacone A, Pogliani EM, Pioltelli P:
Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions.
Transfus Apher Sci
; 2009 Aug;41(1):33-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Patients' characteristics, including age, sex, stage of the underlying disease (complete or partial
remission
), diagnosis, previously administered radio/chemotherapy regimens, time-lapse from last chemotherapy before mobilization and mobilization schedule (including dose of GF) were considered as possibly predictive of poor or failed mobilization.
[MeSH-minor]
Adult
. Antigens, CD34 / blood. Follow-Up Studies. Hematopoiesis. Hematopoietic Stem Cell Mobilization / methods. Humans.
Leukemia
,
Lymphocytic
, Chronic, B-Cell / surgery.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / surgery.
Leukemia
,
Myeloid
,
Acute
/ surgery. Lymphoma,
Non
-Hodgkin / surgery. Multiple Myeloma / surgery. Retrospective Studies. Survival Analysis
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19540167.001).
[ISSN]
1473-0502
[Journal-full-title]
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
[ISO-abbreviation]
Transfus. Apher. Sci.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD34
50.
Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE:
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.
Biol Blood Marrow Transplant
; 2008 Jun;14(6):672-84
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in
AML
/MDS.
To account for improved supportive care and other unidentified factors that may affect outcome ("period" effects), 78
acute myelogenous leukemia
(
AML
) patients receiving Melphalan-Flu (MF), treated in parallel during this time (1997-2004) were used to estimate the period effect.
Patients transplanted with Bu-Flu in the first complete
remission
(CR1) had a 3-year overall survival and event-free-survival (EFS) of 78% and 74%, respectively, whereas CR1 patients younger than age 41 had a 3-year EFS of 83%.
These results support replacing BuCy +/- ATG with Bu-Flu +/- rabbit-antithymocyte globulin (ATG), and warrant a prospective comparison between allogeneic HSCT and conventional induction/consolidation chemotherapy for
AML
in CR1.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
MELPHALAN
.
Hazardous Substances Data Bank.
FLUDARABINE
.
Hazardous Substances Data Bank.
BUSULFAN
.
Hazardous Substances Data Bank.
VIDARABINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18489993.001).
[ISSN]
1523-6536
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / 2P01 CA55164; United States / NCI NIH HHS / CA / P01 CA055164-160020; United States / NCI NIH HHS / CA / 2P30CA16672-26; United States / NCI NIH HHS / CA / P01 CA055164
[Publication-type]
Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antilymphocyte Serum; 0 / Antineoplastic Agents; 0 / Myeloablative Agonists; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
[Other-IDs]
NLM/ NIHMS52878; NLM/ PMC4230823
51.
Khalil F, Cualing H, Cogburn J, Miles L:
The criteria for bone marrow recovery post-myelosuppressive therapy for acute myelogenous leukemia: a quantitative study.
Arch Pathol Lab Med
; 2007 Aug;131(8):1281-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The criteria for bone marrow recovery post-myelosuppressive therapy for
acute myelogenous leukemia
: a quantitative study.
OBJECTIVE: To study the rate of recovery of bone marrow in patients given myelosuppressive therapy for
acute myelogenous leukemia
, establish the histologic criteria of recovered marrow, and correlate the recovery pattern with those patients who received a bone marrow transplant by using histology, peripheral blood, immunophenotyping, and computerized morphometry and mathematical slope equation.
These patients were divided into 2 groups: 1 group of 28 cases diagnosed with
acute
myeloid
leukemia
, the majority treated with cytarabine (Ara-C) infusion for 7 days and daunorubicin intravenously daily for 3 days (7+3 regimen), and the other control group of 23 cases treated with chemotherapy or allogeneic bone marrow transplantation for a variety of hematologic malignancies.
We used morphometry to calculate the cellularity and
myeloid
to erythroid ratio and quantified megakaryocytes CD10 versus time from day 14 onward.
After regenerative hyperplasia, the cellularity plateaus, the
myeloid
to erythroid ratio, and the megakaryocytes even out with platelet normalization, and the early CD10+ B cells rise from day 40 onward, P = .01.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / physiology. Bone Marrow Transplantation.
Leukemia
,
Myeloid
/ drug therapy.
Leukemia
,
Myeloid
/ physiopathology
[MeSH-minor]
Acute
Disease.
Adult
. Aged. Aged, 80 and over. Biopsy. Blood Cell Count. Combined Modality Therapy. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Humans. Image Processing, Computer-Assisted. Immunophenotyping. Male. Middle Aged. Recovery of Function.
Remission
Induction. Time Factors
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Bone Marrow Transplantation
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
DAUNORUBICIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17683190.001).
[ISSN]
1543-2165
[Journal-full-title]
Archives of pathology & laboratory medicine
[ISO-abbreviation]
Arch. Pathol. Lab. Med.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
52.
Fujita A, Fujisawa S, Hyo R, Kuwabara H, Yamazaki E, Tomita N, Ishigatsubo Y:
[Discrepant results of ABO type of red cells and serum in a patient with acute myelogenous leukemia].
Rinsho Ketsueki
; 2008 Jan;49(1):51-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Discrepant results of ABO type of red cells and serum in a patient with
acute myelogenous leukemia
].
A 42-year-old woman was admitted to our hospital with
acute myelogenous leukemia
.
After receiving one cycle of induction therapy, she achieved complete
remission
and blood group A antigen was proven on her red blood cells.
[MeSH-major]
ABO Blood-Group System / immunology. Blood Grouping and Crossmatching.
Leukemia
,
Myeloid
,
Acute
/ blood
[MeSH-minor]
Adult
. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Female. Humans.
Remission
Induction
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
DAUNORUBICIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18277597.001).
[ISSN]
0485-1439
[Journal-full-title]
[Rinshō ketsueki] The Japanese journal of clinical hematology
[ISO-abbreviation]
Rinsho Ketsueki
[Language]
jpn
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / ABO Blood-Group System; 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
53.
Lee SH, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K:
Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
Biol Blood Marrow Transplant
; 2005 Feb;11(2):122-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Infused CD34+ cell dose predicts long-term survival
in acute myelogenous leukemia
patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete
remission
.
Allogeneic stem cell transplantation (ASCT) has improved the outcome of
acute myelogenous leukemia
(
AML
).
To further improve the treatment outcome of ASCT in
AML
, finding a modifiable prognostic factor is mandatory.
We evaluated the effect of CD34(+) cell dose on survival in allogeneic bone marrow transplantation (BMT) from HLA-matched sibling donors for
AML
patients in first complete
remission
(CR1).
The high CD34(+) cell dose patients had better overall survival (5-year overall survival rate, 75% +/- 6% vs 52% +/- 9%; P = .01) and
leukemia
-free survival (5-year
leukemia
-free survival rate, 70% +/- 6% vs 44% +/- 9%; P = .04).
CD34(+) cell dose was the only independent prognostic factor in overall survival and
leukemia
-free survival.
There were no differences in the engraftment of neutrophil and platelet, grade II-IV
acute
graft-versus-host disease (GVHD), extensive-stage chronic GVHD, and transplant-related mortality between the high and low CD34(+) cell dose groups.
We confirmed that high CD34(+) cell dose favorably affects the outcomes in allogeneic BMT for
AML
.
The effort to attain a high CD34(+) cell dose should be pursued during bone marrow harvest in allogeneic BMT for
AML
in CR1.
[MeSH-major]
Antigens, CD34 / analysis. Bone Marrow Cells / cytology. Bone Marrow Transplantation.
Leukemia
,
Myeloid
,
Acute
. Tissue Donors
[MeSH-minor]
Adolescent.
Adult
. Disease-Free Survival. Female. Humans. Leukocyte Count. Male. Middle Aged. Recurrence. Siblings. Transplantation, Homologous. Treatment Outcome
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Bone Marrow Transplantation
.
MedlinePlus Health Information.
consumer health - Organ Donation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15682073.001).
[ISSN]
1083-8791
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD34
54.
Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK, Radich JP, Maloney DG, Agura E, Bruno B, Epner EM, Chauncey TR, Blume KG, Niederwieser D, Sandmaier BM:
Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.
Leukemia
; 2005 Jun;19(6):990-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A total of 24 patients (median age 58; range, 27-71 years) with chronic
myeloid
leukemia
(CML) in first chronic (CP1) (n=14), second chronic (n=4), or accelerated phase (n=6) who were not candidates for conventional hematopoietic cell transplantation (HCT), received nonmyeloablative HCT from HLA-matched siblings a median of 28.5 (range, 11-271) months after diagnosis.
With a median follow-up of 36 (range, 4-49) months, 13 of 24 patients (54%) were alive and in complete
remission
.
The proportions of grade II, III, and IV
acute
GVHD were 38, 4, and 8%, respectively.
This study shows encouraging
remission
rates for patients with CML not eligible for conventional allografting.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Organ Donation
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
FLUDARABINE
.
Hazardous Substances Data Bank.
VIDARABINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15800667.001).
[ISSN]
0887-6924
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA18029; United States / NCI NIH HHS / CA / CA78902; United States / NCI NIH HHS / CA / CA49605; United States / NCI NIH HHS / CA / CA15704; United States / NCI NIH HHS / CA / P01 CA078902
[Publication-type]
Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
55.
Konuma T, Tomonari A, Takahashi S, Ooi J, Tsukada N, Yamada T, Sato H, Nagayama H, Iseki T, Tojo A, Asano S:
Early-onset thyrotoxicosis after unrelated cord blood transplantation for acute myelogenous leukemia.
Int J Hematol
; 2006 May;83(4):348-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Early-onset thyrotoxicosis after unrelated cord blood transplantation for
acute myelogenous leukemia
.
Patient 1 is a 32-year-old woman with
acute myelogenous leukemia
(
AML
)-M5a who underwent CBT.
Patient 2 is a 42-year-old man with
AML
-M4 who underwent CBT.
[MeSH-major]
Autoimmune Diseases / blood. Cord Blood Stem Cell Transplantation.
Leukemia
,
Myeloid
,
Acute
. Thyrotoxicosis / blood
[MeSH-minor]
Adult
. Autoantibodies / blood. Autoantibodies / immunology. Female. Humans. Iodide Peroxidase / immunology. Male.
Remission
, Spontaneous. Thyroxine / blood. Thyroxine / immunology. Transplantation, Homologous. Triiodothyronine / blood. Triiodothyronine / immunology
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Autoimmune Diseases
.
Hazardous Substances Data Bank.
LEVOTHYROXINE
.
Hazardous Substances Data Bank.
LIOTHYRONINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Haematol. 1997 Aug;98(2):453-7
[
9266950.001
]
[Cites]
J Clin Endocrinol Metab. 1992 Jan;74(1):3-5
[
1727826.001
]
[Cites]
Transplantation. 2001 Feb 15;71(3):406-11
[
11233902.001
]
[Cites]
J Clin Endocrinol Metab. 2004 Nov;89(11):5810-4
[
15531546.001
]
[Cites]
Br J Haematol. 1993 Dec;85(4):778-82
[
7918043.001
]
[Cites]
Transplantation. 1987 Sep;44(3):463-4
[
3307069.001
]
[Cites]
Bone Marrow Transplant. 2000 Dec;26(12):1347-9
[
11223977.001
]
[Cites]
Bone Marrow Transplant. 1990 Jul;6(1):49-51
[
2390632.001
]
[Cites]
Br J Haematol. 2001 Dec;115(3):660-3
[
11736951.001
]
[Cites]
Bone Marrow Transplant. 1995 Jan;15(1):71-6
[
7742758.001
]
[Cites]
Br J Haematol. 1990 Jan;74(1):118-9
[
2310693.001
]
[Cites]
N Engl J Med. 1985 Feb 28;312(9):546-52
[
3881675.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Jul;88(7):2965-71
[
12843128.001
]
[Cites]
Blood. 2004 Dec 1;104(12):3813-20
[
15280199.001
]
[Cites]
Blood. 2004 Jan 15;103(2):489-91
[
12933570.001
]
[Cites]
Bone Marrow Transplant. 1992 Oct;10(4):397-8
[
1422500.001
]
(PMID = 16757437.001).
[ISSN]
0925-5710
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Japan
[Chemical-registry-number]
0 / Autoantibodies; 06LU7C9H1V / Triiodothyronine; EC 1.11.1.8 / Iodide Peroxidase; Q51BO43MG4 / Thyroxine
56.
Sakhinia E, Faranghpour M, Liu Yin JA, Brady G, Hoyland JA, Byers RJ:
Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow.
Br J Haematol
; 2005 Jul;130(2):233-48
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Routine expression profiling of microarray gene signatures
in acute
leukaemia by real-time PCR of human bone marrow.
Reverse transcription polymerase chain reaction (RT-PCR) measurement of Indicator genes for
acute
myeloid
leukaemia (
AML
) and
acute
lymphoblastic
leukaemia (ALL) was used to determine gene signatures.
The expression profile of the 17 top-ranked genes distinguishing
AML
and ALL were measured by RT-PCR in five ALL, 26
AML
, 12
AML
remission
, four chronic
myeloid
leukaemia (CML) and nine morphologically normal BM samples.
All but two of the genes measured showed similar expression in
AML
and ALL to that reported previously.
Specifically, c-MYB (P </= 0.04) was significantly increased in ALL in the total fraction, whilst HOXA9 (P </= 0.19) and cystatin c (P </= 0.01) were increased in
AML
in the CD34(+) and CD34(-) fractions, respectively. c-MYB, hSNF2, RBAP48, HKRT-1, LYN, CD33, Adipsin and HOXA9 were increased in
AML
compared with
remission
AML
, indicating an ability to determine disease activity.
[MeSH-major]
Gene Expression Profiling / methods.
Leukemia
,
Myeloid
/ genetics. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / genetics
[MeSH-minor]
Acute
Disease.
Adult
. Antigens, CD34 / analysis. Bone Marrow Cells / metabolism. Cluster Analysis. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Humans.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / diagnosis.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / genetics. Male. Middle Aged. Oligonucleotide Array Sequence Analysis.
Remission
Induction. Reverse Transcriptase Polymerase Chain Reaction / methods
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16029452.001).
[ISSN]
0007-1048
[Journal-full-title]
British journal of haematology
[ISO-abbreviation]
Br. J. Haematol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD34; 0 / DNA, Neoplasm
57.
Ferrara F, Izzo T, Criscuolo C, Riccardi C, Muccioli G, Viola A, Pane F, Palmieri S:
Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
Biol Blood Marrow Transplant
; 2010 Jul;16(7):1018-24
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Favorable outcome in patients with
acute myelogenous leukemia
with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
Mutations of the nucleophosmin gene (NPM1), in the absence of concurrent FLT3-internal tandem duplication (FLT3-ITD) have impressive prognostic value in patients with
acute myelogenous leukemia
(
AML
), carrying normal karyotype (NK).
In this study we describe treatment results from a series of 19 patients with NPM+/FLT3- autografted in first complete
remission
(CR) after conditioning with a regimen, named BuI, based on high-dose continuous infusion of idarubicin and Busulfan.
Ninety-nine consecutive patients (median age of 54 years) with NK
AML
autografted in first CR were analyzed.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Leukemia
,
Myeloid
,
Acute
/ genetics.
Leukemia
,
Myeloid
,
Acute
/ therapy. Mutation. Nuclear Proteins / genetics. Stem Cell Transplantation. Transplantation Conditioning / methods
[MeSH-minor]
Adolescent.
Adult
. Aged. Busulfan / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Prognosis. Treatment Outcome. Young
Adult
. fms-Like Tyrosine Kinase 3 / genetics
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
BUSULFAN
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20172040.001).
[ISSN]
1523-6536
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; G1LN9045DK / Busulfan; ZRP63D75JW / Idarubicin
58.
Breccia M, Palandri F, Iori AP, Colaci E, Latagliata R, Castagnetti F, Torelli GF, Usai S, Valle V, Martinelli G, Rosti G, Foà R, Baccarani M, Alimena G:
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Leuk Res
; 2010 Feb;34(2):143-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic
myeloid
leukemia
resistant to imatinib.
Philadelphia-positive chronic
myeloid
leukemia
(Ph+ CML) patients who are resistant to imatinib are commonly treated with second-generation tyrosine kinase inhibitors (TKIs).
Three patients experienced
acute
and chronic graft-versus-host disease.
[MeSH-major]
Hematopoietic Stem Cell Transplantation / methods.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / therapy. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / administration & dosage. Thiazoles / administration & dosage
[MeSH-minor]
Adolescent.
Adult
. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzamides. Dasatinib. Drug Resistance, Neoplasm. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Piperazines.
Remission
Induction / methods. Transplantation, Homologous. Treatment Outcome. Young
Adult
Genetic Alliance.
consumer health - Chronic Myeloid Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
Hazardous Substances Data Bank.
IMATINIB MESYLATE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 Elsevier Ltd. All rights reserved.
[CommentIn]
Leuk Res. 2010 Feb;34(2):137-8
[
19651441.001
]
(PMID = 19481800.001).
[ISSN]
1873-5835
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; RBZ1571X5H / Dasatinib
59.
Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR:
Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.
Blood
; 2010 Nov 18;116(20):4251-61
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic
in acute myelogenous leukemia
and myelodysplasia.
We hypothesized that comprehensive profiling of C&Ckine expression
in leukemia
would provide greater insight compared with individual analyses.
We used multiplex array technology to simultaneously measure the level of 27 C&Ckines in serum from 176
acute myelogenous leukemia
(
AML
) and 114 myelodysplastic syndrome (MDS) patients and 19 normal controls.
C&Ckine levels in
AML
and MDS differed significantly from normal controls (5 higher, 13 lower) but were similar to each other for 24 of 27 analytes, with interleukin-8 and interleukin-13 higher in
AML
and vascular endothelial growth factor A higher in MDS.
Levels did not correlate with age, gender, infection, or blood counts; however, 3 correlated with specific cytognetic abnormalities in
AML
.
In newly diagnosed
AML
, 8 C&Ckine signatures, distinct from the normal control signature, were observed.
These signatures had prognostic impact, affecting
remission
, primary resistance, relapse rates, and overall survival, individually (P = .003) and in multivariable analysis (P = .004).
These patterns suggest specific therapeutic interventions to investigate in subsets of
AML
patients.
In conclusion, C&Ckine expression in
AML
and MDS differs from normal, is similar with one another, and forms recurrent patterns of expression with prognostic relevance.
[MeSH-major]
Chemokines / blood.
Leukemia
,
Myeloid
,
Acute
/ blood.
Leukemia
,
Myeloid
,
Acute
/ diagnosis. Myelodysplastic Syndromes / blood. Myelodysplastic Syndromes / diagnosis
[MeSH-minor]
Adult
. Aged. Aged, 80 and over. Cluster Analysis. Cytogenetic Analysis. Female. Humans. Male. Middle Aged. Multivariate Analysis. Principal Component Analysis. Prognosis. Survival Analysis. Treatment Outcome. Young
Adult
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer. 2002 Nov 1;95(9):1923-30
[
12404286.001
]
[Cites]
Acta Haematol. 1996;96(3):155-61
[
8876613.001
]
[Cites]
Clin Diagn Lab Immunol. 2003 Jan;10(1):133-9
[
12522051.001
]
[Cites]
Leukemia. 2003 Apr;17(4):716-30
[
12682629.001
]
[Cites]
Nat Rev Cancer. 2004 Jan;4(1):11-22
[
14708024.001
]
[Cites]
Clin Immunol. 2004 Mar;110(3):206-21
[
15047199.001
]
[Cites]
Best Pract Res Clin Haematol. 2004 Dec;17(4):653-61
[
15494301.001
]
[Cites]
Blood. 1987 Apr;69(4):1161-6
[
3103713.001
]
[Cites]
J Clin Invest. 1991 Mar;87(3):838-41
[
1705566.001
]
[Cites]
Blood. 1992 Apr 15;79(8):1938-45
[
1373331.001
]
[Cites]
Blood Rev. 1992 Sep;6(3):149-56
[
1422283.001
]
[Cites]
Blood. 1993 Jan 15;81(2):281-92
[
8422455.001
]
[Cites]
Leukemia. 1997 Dec;11(12):2049-54
[
9447819.001
]
[Cites]
Br J Haematol. 1998 Sep;102(4):1025-34
[
9734654.001
]
[Cites]
Cytokines Cell Mol Ther. 1998 Sep;4(3):187-98
[
9825844.001
]
[Cites]
J Biopharm Stat. 2005;15(3):437-63
[
15920890.001
]
[Cites]
Leuk Lymphoma. 2005 Jun;46(6):885-91
[
16019534.001
]
[Cites]
Br J Haematol. 2005 Sep;130(5):709-15
[
16115126.001
]
[Cites]
Cancer Treat Res. 2005;126:103-27
[
16209064.001
]
[Cites]
Exp Hematol. 2005 Oct;33(10):1109-17
[
16219533.001
]
[Cites]
Eur J Haematol. 2005 Dec;75(6):485-91
[
16313260.001
]
[Cites]
Ann Clin Lab Sci. 2006 Winter;36(1):7-15
[
16501231.001
]
[Cites]
Blood. 2006 Oct 1;108(7):2358-65
[
16763210.001
]
[Cites]
Cancer Biomark. 2005;1(6):259-69
[
17192050.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):102-7
[
17220337.001
]
[Cites]
Haematologica. 2007 Mar;92(3):332-41
[
17339182.001
]
[Cites]
Clin Cancer Res. 2007 Apr 15;13(8):2385-91
[
17438097.001
]
[Cites]
Oncogene. 2007 Oct 15;26(47):6724-37
[
17934481.001
]
[Cites]
Oncogene. 2007 Oct 15;26(47):6738-49
[
17934482.001
]
[Cites]
Blood. 2008 May 1;111(9):4788-96
[
18252861.001
]
[Cites]
Blood. 2008 May 1;111(9):4797-808
[
18270328.001
]
[Cites]
Cancer. 2008 Oct 1;113(7):1605-13
[
18683214.001
]
[Cites]
Blood. 2009 Jan 1;113(1):154-64
[
18840713.001
]
[Cites]
Leuk Res. 1996 Nov-Dec;20(11-12):891-900
[
9009245.001
]
[Cites]
Br J Cancer. 1999 Dec;81(8):1398-401
[
10604739.001
]
[Cites]
Oncogene. 2000 Feb 3;19(5):624-31
[
10698507.001
]
[Cites]
Cytokine. 2000 Jun;12(6):699-707
[
10843748.001
]
[Cites]
Lancet. 2001 Feb 17;357(9255):539-45
[
11229684.001
]
[Cites]
Trends Immunol. 2002 Aug;23(8):403-8
[
12133803.001
]
[Cites]
Oncology. 2002;63(1):64-9
[
12187073.001
]
[Cites]
Leukemia. 1994 May;8(5):798-805
[
8182937.001
]
[Cites]
Blood. 1995 Dec 15;86(12):4594-602
[
8541550.001
]
[Cites]
Leukemia. 1996 Jun;10(6):925-31
[
8667646.001
]
[Cites]
Science. 1996 Nov 1;274(5288):782-4
[
8864118.001
]
[Cites]
Nature. 2002 Dec 19-26;420(6917):860-7
[
12490959.001
]
(PMID = 20679526.001).
[ISSN]
1528-0020
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P01 CA108631; United States / NCI NIH HHS / CA / P30 CA016672
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Chemokines
[Other-IDs]
NLM/ PMC4081283
60.
Thomas X, Elhamri M, Chelghoum Y, Reman O, Arnaud P, Raffoux E, Le QH, Tavernier E, Dombret H, Michallet M:
Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
Ann Hematol
; 2005 Jun;84(6):376-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk
acute
myeloid
leukemia
: results of the EMA 2000 trial.
Following a dose-escalation study performed to assess the maximally tolerated dose of high-dose mitoxantrone in a single injection combined with chemotherapy, a phase II trial (EMA 2000 regimen) was performed in patients with refractory or relapsed
acute myelogenous leukemia
(
AML
) between October 2000 and December 2003.
Overall, 39 patients (63%) achieved complete
remission
(CR).
Four patients died during
remission
induction, and 19 patients had resistant disease.
The predominant
non
-hematologic toxicity was infection, with 53% severe infections.
EMA chemotherapy using a single injection of mitoxantrone is effective in the treatment of high-risk
AML
.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Leukemia
,
Myeloid
/ drug therapy
[MeSH-minor]
Acute
Disease. Adolescent.
Adult
. Aged. Bone Marrow Transplantation. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Infection / etiology. Infusions, Intravenous. Life Tables. Male. Middle Aged. Mitoxantrone / administration & dosage. Prognosis.
Remission
Induction. Risk. Stomatitis / chemically induced. Survival Analysis. Treatment Outcome
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Hazardous Substances Data Bank.
NOVANTRONE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15782343.001).
[ISSN]
0939-5555
[Journal-full-title]
Annals of hematology
[ISO-abbreviation]
Ann. Hematol.
[Language]
eng
[Publication-type]
Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
[Publication-country]
Germany
[Chemical-registry-number]
BZ114NVM5P / Mitoxantrone
61.
Walther JU, Pohl I, Rausch A, Fuehrer M:
Proliferation studies on chromosome preparations of bone marrow in hematological disease.
Oncol Rep
; 2006 Oct;16(4):893-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The disorders studied were:
Acute
lymphoblastic
leukemia
(ALL) (N=107), chronic
myeloid
leukemia
(CML) (N=166) and aplastic anemia in childhood (AA) (N=39).
The most important findings include: i) ALL: Immunological subtypes can be differentiated according to their proliferation profile; there is a striking difference between childhood and
adult
ALL in proliferation activity; most importantly initial proliferation is much higher in patients who will relapse than in those with stable
remission
.
[MeSH-major]
Bone Marrow Cells / cytology. Chromosomes / ultrastructure. Hematologic Neoplasms / drug therapy.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / metabolism. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / metabolism
[MeSH-minor]
Adolescent.
Adult
. Anemia, Aplastic. Bone Marrow / metabolism. Cell Line, Tumor. Cell Proliferation. Child. History, Ancient. Humans. Prognosis
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16969511.001).
[ISSN]
1021-335X
[Journal-full-title]
Oncology reports
[ISO-abbreviation]
Oncol. Rep.
[Language]
eng
[Publication-type]
Historical Article; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
62.
Usuki K, Urabe A, Ikeda Y, Ohashi Y, Mizoguchi H, Takaku F, Japan IL-11 Study Group:
A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia.
Int J Hematol
; 2007 Jan;85(1):59-69
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11
in acute myelogenous leukemia
.
To investigate the efficacy of using recombinant human interleukin 11 (rhIL-11) to reduce the need for platelet transfusions, we performed a randomized, double-blind phase II/III study with 110
acute myelogenous leukemia
(
AML
) patients in the first complete
remission
.
These results show that rhIL-11 does not reduce the platelet transfusion requirement in
AML
patients, but the retrospective analysis confirms the previous finding that rhIL-11 reduces infection in patients undergoing chemotherapy.
[MeSH-major]
Interleukin-11 / administration & dosage.
Leukemia
,
Myeloid
,
Acute
/ drug therapy
[MeSH-minor]
Adolescent.
Adult
. Double-Blind Method. Female. Humans. Infection / drug therapy. Infection / etiology. Male. Middle Aged. Placebos. Platelet Transfusion. Recombinant Proteins / therapeutic use. Retrospective Studies. Stomatitis / drug therapy. Stomatitis / etiology
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 1999 May 15;93(10):3467-72
[
10233899.001
]
[Cites]
Lancet. 1991 Nov 16;338(8777):1223-6
[
1682642.001
]
[Cites]
Br J Haematol. 1995 Oct;91(2):319-26
[
8547068.001
]
[Cites]
Transfusion. 1998 Jul;38(7):625-36
[
9683100.001
]
[Cites]
Br J Haematol. 2005 Jan;128(1):49-58
[
15606549.001
]
[Cites]
J Clin Oncol. 2001 Nov 1;19(21):4165-72
[
11689585.001
]
[Cites]
N Engl J Med. 1995 Jan 26;332(4):217-23
[
7808487.001
]
[Cites]
Blood. 1988 Sep;72(3):970-7
[
3416080.001
]
[Cites]
Leukemia. 1999 Jul;13(7):1018-27
[
10400417.001
]
[Cites]
Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):765-9
[
1825140.001
]
[Cites]
Ann Hematol. 2003 Nov;82(11):677-83
[
14530872.001
]
[Cites]
N Engl J Med. 1997 Dec 25;337(26):1870-5
[
9407153.001
]
[Cites]
Blood. 1996 May 1;87(9):3607-14
[
8611684.001
]
[Cites]
Blood. 1998 May 15;91(10):3607-15
[
9572995.001
]
[Cites]
Br J Haematol. 2002 Jan;116(1):103-12
[
11841402.001
]
[Cites]
J Clin Oncol. 1997 Nov;15(11):3368-77
[
9363868.001
]
[Cites]
Blood. 1994 Mar 15;83(6):1499-506
[
8123841.001
]
[Cites]
Blood. 1997 Dec 15;90(12):4710-8
[
9389686.001
]
[Cites]
J Clin Oncol. 2001 Mar 1;19(5):1519-38
[
11230498.001
]
[Cites]
N Engl J Med. 1997 Feb 6;336(6):404-9
[
9010146.001
]
[Cites]
Br J Haematol. 1987 Mar;65(3):265-9
[
3567081.001
]
[Cites]
Blood. 1993 Jan 1;81(1):27-34
[
8417798.001
]
[Cites]
Blood. 1999 Dec 1;94(11):3694-701
[
10572081.001
]
[Cites]
Eur J Haematol. 1993 Mar;50(3):160-7
[
8472811.001
]
[Cites]
Blood. 1992 Jan 15;79(2):327-31
[
1370382.001
]
[Cites]
Blood. 1993 Feb 15;81(4):901-8
[
8427998.001
]
[Cites]
Leukemia. 1996 Jun;10(6):964-9
[
8667653.001
]
[Cites]
Biol Blood Marrow Transplant. 1998;4(3):134-41
[
9923411.001
]
[Cites]
Blood. 2002 Jun 15;99(12 ):4343-9
[
12036860.001
]
[Cites]
Ann Intern Med. 1997 May 1;126(9):673-81
[
9139552.001
]
[Cites]
J Clin Oncol. 1997 Aug;15(8):2954-65
[
9256140.001
]
[Cites]
Oral Oncol. 2000 Jul;36(4):373-81
[
10899677.001
]
[Cites]
Blood. 2000 Apr 15;95(8):2530-5
[
10753831.001
]
[Cites]
Blood. 1997 Jun 1;89(11):3897-908
[
9166826.001
]
[Cites]
Proc Natl Acad Sci U S A. 1990 Oct;87(19):7512-6
[
2145578.001
]
[Cites]
Semin Hematol. 1998 Jul;35(3):253-60
[
9685171.001
]
[Cites]
Lancet. 2003 Jan 25;361(9354):275-80
[
12559860.001
]
[Cites]
N Engl J Med. 1990 Jun 7;322(23):1646-51
[
2342524.001
]
[Cites]
Blood. 1993 Mar 15;81(6):1586-92
[
8453105.001
]
[Cites]
Blood. 1996 Mar 1;87(5):1710-7
[
8634416.001
]
[Cites]
Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S53-5
[
15250022.001
]
[Cites]
Blood. 1991 Sep 15;78(6):1448-51
[
1832057.001
]
[Cites]
Blood. 1996 May 1;87(9):3615-24
[
8611685.001
]
[Cites]
Blood. 1994 Jan 1;83(1):33-7
[
8274749.001
]
(PMID = 17261503.001).
[ISSN]
0925-5710
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
[Publication-country]
Japan
[Chemical-registry-number]
0 / Interleukin-11; 0 / Placebos; 0 / Recombinant Proteins
63.
Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A:
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Cancer
; 2005 Apr 15;103(8):1659-69
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: The advent of imatinib has considerably changed the treatment of chronic
myeloid
leukemia
(CML).
METHODS: The authors evaluated long-term outcome, rates of response, and resistance in 300 patients with BCR-ABL-positive leukemias (CML in chronic phase after failure to respond to interferon-alpha [CP], n = 139; accelerated phase [AP], n = 80;
myeloid
blast crisis [BC], n = 76; lymphoid BC and Philadelphia chromosome-positive
acute
lymphoblastic
leukemia
, n = 5) who entered clinical trials with imatinib in a single center after an observation time of 4.5 years.
RESULTS: In CP, hematologic
remission
was achieved in 97% and major (MCR) and complete cytogenetic
remission
(CCR) in 61% and 49% of patients, respectively.
In
myeloid
BC, the median survival period after the start of imatinib and after diagnosis of BC was 6 and 9 months, respectively.
Hematologic resistance occurred in 25%, 41%, and 92% of patients in CP, AP, and
myeloid
BC, respectively, and was associated with BCR-ABL mutations in 45% of patients and with clonal evolution in 58% of patients.
[MeSH-major]
Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Fusion Proteins, bcr-abl / metabolism.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / drug therapy. Neoplasm Recurrence, Local / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
[MeSH-minor]
Adolescent.
Adult
. Aged. Benzamides. Blast Crisis. Cytogenetic Analysis. Female. Humans. Imatinib Mesylate. Interferon-alpha / adverse effects. Male. Middle Aged. Mutation. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / drug therapy. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / genetics. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / pathology. Protein-Tyrosine Kinases / antagonists & inhibitors.
Remission
Induction. Salvage Therapy. Survival Rate. Treatment Outcome
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
Hazardous Substances Data Bank.
IMATINIB MESYLATE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2005 American Cancer Society.
(PMID = 15747376.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Benzamides; 0 / Interferon-alpha; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
64.
Ataergin S, Arpaci F, Cetin T, Guran S, Yakicier C, Beyzadeoglu M, Ozet A:
Donor cell leukemia in a patient developing 11 months after an allogeneic bone marrow transplantation for chronic myeloid leukemia.
Am J Hematol
; 2006 May;81(5):370-3
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Donor cell
leukemia in
a patient developing 11 months after an allogeneic bone marrow transplantation for chronic
myeloid
leukemia
.
A 38-year-old female with chronic
myeloid
leukemia
underwent an allogeneic bone marrow transplantation from her full-matched brother.
Eleven months later, she readmitted with an
acute leukemia
that was shown to be of donor origin.
The patient never achieved a
remission
even after chemotherapies with cytarabine and mitoxantrone, donor lymphocyte infusion, and second allogeneic peripheral blood stem cell transplantation.
Donor cell
leukemia
(DCL) is sometimes misdiagnosed as relapse by clinicians and the real incidence may be higher than expected.
Cytogenetic and molecular techniques may be helpful to clarify the issue of the
leukemia
.
The current case is another case of DCL reported in the literature after an allogeneic transplant for a kind of
leukemia
.
[MeSH-major]
Bone Marrow Transplantation.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / etiology.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / surgery. Transplantation Chimera / genetics
[MeSH-minor]
Adult
. Chromosomes, Human, Y. Fatal Outcome. Female. Humans. Male. Philadelphia Chromosome. Tissue Donors. Transplantation, Homologous
Genetic Alliance.
consumer health - Chronic Myeloid Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Bone Marrow Transplantation
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2006 Wiley-Liss, Inc.
[ErratumIn]
Am J Hematol. 2007 Feb;82(2):177
(PMID = 16628734.001).
[ISSN]
0361-8609
[Journal-full-title]
American journal of hematology
[ISO-abbreviation]
Am. J. Hematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
65.
Das-Gupta EP, Russell NH, Shaw BE, Pearce RM, Byrne JL:
Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.
Biol Blood Marrow Transplant
; 2007 Jun;13(6):724-33
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Long-term outcome of unrelated donor transplantation for
AML
using myeloablative conditioning incorporating pretransplant Alemtuzumab.
The outcome of 55 patients who underwent matched unrelated donor (MUD) transplantation for
acute myelogenous leukemia
(
AML
) following a conditioning regimen of cyclophosphamide and total-body irradiation (TBI) with the addition of Alemtuzumab 10 mg/kg/day on days -5 to -1 is described.
Forty-one patients were transplanted in complete
remission
(CR) (20 in CR1, 20 in CR2, and 1 in CR3), and 14 were not
in remission
at the time of transplantation as they were refractory to chemotherapy either at induction or at relapse.
The group consisted of
adult
patients with a median age of 37 years.
Grade II-IV
acute
GVHD occurred in only 2 patients.
The 5-year cumulative survival for the whole group was 38% and was 49% for those
in remission
at transplantation.
Seven of the 12 patients transplanted in CR1 with adverse risk cytogenetics remain alive and
in remission
, and the predicted 5-year overall survival (OS) for this group is 50%.
These results support the use of Alemtuzumab for unrelated donor hematopoietic stem cell transplant (HSCT) for poor risk
AML
in CR1 and for relapsed
AML
in CR2.
The addition of Alemtuzumab is highly effective in preventing both rejection and severe
acute
and extensive chronic GVHD without an increased relapse risk.
[MeSH-major]
Antibodies, Monoclonal / administration & dosage. Antibodies, Neoplasm / administration & dosage. Hematopoietic Stem Cell Transplantation / methods.
Leukemia
,
Myeloid
/ therapy. Transplantation Conditioning / methods
[MeSH-minor]
Acute
Disease. Adolescent.
Adult
. Antibodies, Monoclonal, Humanized. Cause of Death. Cyclophosphamide / therapeutic use. Female. Graft Rejection / prevention & control. Graft vs Host Disease / prevention & control. Histocompatibility Testing. Humans. Longitudinal Studies. Male. Middle Aged. Myeloablative Agonists / therapeutic use. Survival Analysis. Tissue Donors. Treatment Outcome. Whole-Body Irradiation
Genetic Alliance.
consumer health - Transplantation
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17531783.001).
[ISSN]
1083-8791
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Myeloablative Agonists; 3A189DH42V / alemtuzumab; 8N3DW7272P / Cyclophosphamide
66.
Silva PM, Lourenço GJ, Bognone RA, Delamain MT, Pinto-Junior W, Lima CS:
Inherited pericentric inversion of chromosome 16 in chronic phase of chronic myeloid leukaemia.
Leuk Res
; 2006 Jan;30(1):115-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Inherited pericentric inversion of chromosome 16 in chronic phase of chronic
myeloid
leukaemia.
The simultaneous occurrence of two specific acquired chromosomal abnormalities in chronic or
acute
leukaemias is rare.
In chronic
myeloid
leukaemia (CML), characterised by the t(9;22)(q34;q11), the inv(16)(p13q22) has been described associated with the acceleration of disease or onset of blast crisis.
We report on a patient with chronic phase of CML and both acquired t(9;22)(q34;q11) and inherited inv(16)(p13q22), who obtained a complete
remission
of the disease after bone marrow transplant.
[MeSH-major]
Blast Crisis / pathology. Chromosome Inversion. Chromosomes, Human, Pair 16. Genetic Diseases, Inborn / pathology.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / pathology
[MeSH-minor]
Adult
. Bone Marrow Transplantation. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 9. Female. Humans.
Remission
Induction. Translocation, Genetic
Genetic Alliance.
consumer health - Chromosome 16
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Genetic Disorders
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16054690.001).
[ISSN]
0145-2126
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
67.
Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S:
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
Biol Blood Marrow Transplant
; 2005 Feb;11(2):108-14
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic factors for outcomes of patients with refractory or relapsed
acute myelogenous leukemia
or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
Allogeneic progenitor cell transplantation is the only curative therapy for patients with refractory
acute myelogenous leukemia
or myelodysplastic syndromes.
Patients were selected if they had undergone an allogeneic transplantation between January 1988 and January 2002 and were not
in remission
or first untreated relapse at the time of transplantation.
These data support the use of allogeneic transplantation for patients with relapsed or refractory
acute myelogenous leukemia
/myelodysplastic syndromes and suggest that optimal immune suppression early after transplantation is essential for long-term survival even in patients with refractory
myeloid
leukemias.
[MeSH-major]
Bone Marrow Transplantation.
Leukemia
,
Myeloid
,
Acute
/ therapy. Myelodysplastic Syndromes / therapy
[MeSH-minor]
Adult
. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Transplantation, Homologous. Treatment Outcome
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Bone Marrow Transplantation
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15682071.001).
[ISSN]
1083-8791
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
68.
Van Der Jagt R, Robinson KS, Belch A, Yetisir E, Wells G, Larratt L, Shustik C, Gluck S, Stewart K, Sheridan D, Canadian Leukemia Studies Group:
Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.
Leuk Lymphoma
; 2006 Apr;47(4):697-706
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide
in adult acute myelogenous leukemia
: 10 year follow-up of a study by the Canadian
Leukemia
Studies Group.
PURPOSE: The Canadian
Leukemia
Studies Group (CLSG) sought to test the safety and efficacy of response-adapted,
non
-cross resistant chemotherapy in de novo
acute
myeloid
leukemia
(
AML
).
As consolidation, patients achieving complete
remission
(CR) with IDAC were given 1 further cycle of IDAC and 1 cycle of NOVE.
RESULTS: 76% of all patients achieved
remission
after IDAC +/- NOVE, 81% in patients aged < or =60 years and 67% in patients aged >60.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Idarubicin / administration & dosage.
Leukemia
,
Myeloid
,
Acute
/ drug therapy
[MeSH-minor]
Adult
. Aged. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Time Factors
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
NOVANTRONE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16690529.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin
69.
Rodriguez V, Anderson PM, Litzow MR, Erlandson L, Trotz BA, Arndt CA, Khan SP, Wiseman GA:
Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.
Leuk Lymphoma
; 2006 Aug;47(8):1583-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for
acute myelogenous leukemia
.
In four patients, aged 15 - 20 years, with high-risk
acute
myeloid
leukemia
(
AML
), high-dose samarium 153-labelled ethylenediaminetetramethylenephosphonate (153Sm-EDTMP) was used for targeted marrow irradiation before preparative chemotherapy conditioning regimens and allogeneic (three patients) or autologous (one patient) hematopoietic stem cell transplantation.
Complete cytogenetic and morphologic
remission
of
AML
was evident on follow-up marrow aspirate and biopsy specimens from all patients.
In two of the four study patients, the disease remains in complete
remission
and the patients have an excellent quality of life (Eastern Cooperative Oncology Group performance status 0; no medications) and no organ toxicity more than 2 years and more than 4 years, respectively, after their blood and bone marrow transplantations.
Thus, in adolescents and adults, 153Sm-EDTMP may provide a relatively simple and effective means for using irradiation to eliminate
AML
within the marrow.
[MeSH-major]
Hematopoietic Stem Cell Transplantation / methods.
Leukemia
,
Myeloid
,
Acute
/ radiotherapy. Radioisotopes / therapeutic use. Samarium / therapeutic use
[MeSH-minor]
Adolescent.
Adult
. Bone Marrow / pathology. Bone Marrow / radiation effects. Dose-Response Relationship, Radiation. Humans. Organometallic Compounds / administration & dosage. Organometallic Compounds / therapeutic use. Organophosphorus Compounds / administration & dosage. Organophosphorus Compounds / therapeutic use. Quality of Life.
Remission
Induction / methods. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
Samarium, Elemental
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16966270.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 0 / Radioisotopes; 122575-21-7 / samarium ethylenediaminetetramethylenephosphonate; 42OD65L39F / Samarium
70.
Cohen PR:
Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.
Orphanet J Rare Dis
; 2007;2:34
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Sweet's syndrome--a comprehensive review of an
acute
febrile neutrophilic dermatosis.
Sweet's syndrome (the eponym for
acute
febrile neutrophilic dermatosis) is characterized by a constellation of clinical symptoms, physical features, and pathologic findings which include fever, neutrophilia, tender erythematous skin lesions (papules, nodules, and plaques), and a diffuse infiltrate consisting predominantly of mature neutrophils that are typically located in the upper dermis.
The malignancy-associated Sweet's syndrome (MASS) can occur as a paraneoplastic syndrome in patients with an established cancer or individuals whose Sweet's syndrome-related hematologic dyscrasia or solid tumor was previously undiscovered; MASS is most commonly related to
acute myelogenous leukemia
.
The symptoms and lesions of Sweet's syndrome may resolved spontaneously, without any therapeutic intervention; however, recurrence may follow either spontaneous
remission
or therapy-induced clinical resolution.
[MeSH-minor]
Adult
. Aged. Female. Humans. Male. Middle Aged
Genetic Alliance.
consumer health - Neutrophilic dermatosis, acute febrile
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Arch Dermatol. 1971 Jan;103(1):81-4
[
5539508.001
]
[Cites]
Dermatologica. 1971;143(3):153-9
[
5131096.001
]
[Cites]
Australas J Dermatol. 1971 Dec;12(3):172-7
[
5146931.001
]
[Cites]
Arch Dermatol. 1975 Nov;111(11):1461-3
[
1239237.001
]
[Cites]
Am J Med. 1976 Sep;61(3):424-32
[
961707.001
]
[Cites]
J Rheumatol. 1977 Summer;4(2):201-6
[
881698.001
]
[Cites]
S Afr Med J. 1978 Feb 18;53(7):253-6
[
653521.001
]
[Cites]
South Med J. 1978 Nov;71(11):1350-2
[
280960.001
]
[Cites]
Rev Prat. 1999 Feb 15;49(4):356-8
[
10319682.001
]
[Cites]
J Am Acad Dermatol. 1999 May;40(5 Pt 2):838-41
[
10321630.001
]
[Cites]
Br J Dermatol. 1999 Jun;140(6):1174-5
[
10354095.001
]
[Cites]
Am J Hematol. 1999 Jun;61(2):126-9
[
10367792.001
]
[Cites]
Pediatr Cardiol. 1999 Jul-Aug;20(4):295-7
[
10368458.001
]
[Cites]
Am J Dermatopathol. 1999 Jun;21(3):247-52
[
10380046.001
]
[Cites]
Pediatr Infect Dis J. 1999 Jun;18(6):568-70
[
10391198.001
]
[Cites]
Br J Dermatol. 1999 Jul;141(1):169-70
[
10417544.001
]
[Cites]
Arch Neurol. 1999 Aug;56(8):1010-3
[
10448808.001
]
[Cites]
Br J Dermatol. 1964 Aug-Sep;76:349-56
[
14201182.001
]
[Cites]
Br J Dermatol. 2004 Nov;151(5):1096-100
[
15541094.001
]
[Cites]
Int J Dermatol. 2004 Dec;43(12):938-41
[
15569025.001
]
[Cites]
Ann Rheum Dis. 2005 Jan;64(1):168-9
[
15608327.001
]
[Cites]
J Am Acad Dermatol. 2005 Feb;52(2):367-9
[
15692491.001
]
[Cites]
Orbit. 2005 Mar;24(1):55-7
[
15764119.001
]
[Cites]
Arch Dermatol. 2005 Mar;141(3):368-70
[
15781678.001
]
[Cites]
Can J Ophthalmol. 2005 Feb;40(1):90-2
[
15825540.001
]
[Cites]
J Am Acad Dermatol. 2005 May;52(5):901-5
[
15858487.001
]
[Cites]
J Am Acad Dermatol. 2005 May;52(5):927-8
[
15858502.001
]
[Cites]
Neurology. 2005 May 24;64(10):1756-61
[
15911805.001
]
[Cites]
Hautarzt. 1988 Oct;39(10):658-61
[
3069805.001
]
[Cites]
Am J Dermatopathol. 1989 Apr;11(2):99-111
[
2653084.001
]
[Cites]
J Am Acad Dermatol. 1989 Apr;20(4):677-80
[
2715414.001
]
[Cites]
J Am Acad Dermatol. 1989 Aug;21(2 Pt 2):339-43
[
2526826.001
]
[Cites]
Am J Hematol. 1989 Oct;32(2):134-7
[
2667344.001
]
[Cites]
Cutis. 1989 Aug;44(2):125-9
[
2758862.001
]
[Cites]
Cutis. 1989 Aug;44(2):157-9
[
2758865.001
]
[Cites]
Clin Exp Dermatol. 1988 Sep;13(5):344-6
[
3256451.001
]
[Cites]
Br J Dermatol. 2006 Nov;155(5):1103-4
[
17034566.001
]
[Cites]
Int J Dermatol. 2006 Oct;45(10):1254-5
[
17040460.001
]
[Cites]
Int J Dermatol. 2006 Nov;45(11):1365-8
[
17076728.001
]
[Cites]
J Am Acad Dermatol. 2006 Dec;55(6):1066-71
[
17097401.001
]
[Cites]
Int J Dermatol. 2007 Jan;46(1):106-11
[
17214733.001
]
[Cites]
Australas J Dermatol. 2007 Feb;48(1):50-3
[
17222305.001
]
[Cites]
J Am Acad Dermatol. 2007 Feb;56(2 Suppl):S61-2
[
17224394.001
]
[Cites]
Br J Dermatol. 2007 Mar;156(3):480-5
[
17300237.001
]
[Cites]
Intern Med. 2007;46(4):153-4
[
17301507.001
]
[Cites]
Arch Dermatol. 2007 Feb;143(2):275-6
[
17310019.001
]
[Cites]
Rev Med Liege. 2006 Dec;61(12):834-6
[
17313120.001
]
[Cites]
Presse Med. 2007 Mar;36(3 Pt 1):419-24
[
17321363.001
]
[Cites]
J Dermatol. 2007 Apr;34(4):243-7
[
17352721.001
]
[Cites]
J Dermatol. 2007 Apr;34(4):258-61
[
17352724.001
]
[Cites]
J Am Acad Dermatol. 2007 Apr;56(4):690-3
[
17367621.001
]
[Cites]
Ann Dermatol Venereol. 2007 Feb;134(2):151-4
[
17375012.001
]
[Cites]
CA Cancer J Clin. 2007 Mar-Apr;57(2):90-104
[
17392386.001
]
[Cites]
Actas Dermosifiliogr. 2007 Mar;98(2):102-4
[
17397596.001
]
[Cites]
Am J Dermatopathol. 2007 Apr;29(2):125-33
[
17414432.001
]
[Cites]
J Neurol. 2003 Jun;250(6):770-1
[
12862039.001
]
[Cites]
Actas Dermosifiliogr. 2005 Jun;96(5):315-6
[
16476395.001
]
[Cites]
Clin Exp Dermatol. 2006 Mar;31(2):206-7
[
16487091.001
]
[Cites]
J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S122-6
[
16488324.001
]
[Cites]
Arch Dermatol. 2006 Feb;142(2):235-40
[
16490855.001
]
[Cites]
Korean J Intern Med. 2005 Dec;20(4):346-8
[
16491836.001
]
[Cites]
Clin Rheumatol. 2006 Mar;25(2):268-72
[
15902518.001
]
[Cites]
J Otolaryngol. 2006 Apr;35(2):144-7
[
16527036.001
]
[Cites]
J Infect. 2006 May;52(5):e155-7
[
16213026.001
]
[Cites]
J Eur Acad Dermatol Venereol. 2006 Apr;20(4):401-5
[
16643136.001
]
[Cites]
Int J Dermatol. 2006 Jun;45(6):677-80
[
16796626.001
]
[Cites]
Int J Dermatol. 2006 Jun;45(6):702-8
[
16796632.001
]
[Cites]
Arch Dermatol. 2006 Aug;142(8):1070-1
[
16924066.001
]
[Cites]
Arch Dermatol. 2006 Sep;142(9):1170-6
[
16983004.001
]
[Cites]
Br J Haematol. 2006 Oct;135(2):148
[
16856884.001
]
[Cites]
Br J Dermatol. 2006 Nov;155(5):1089-90
[
17034556.001
]
[Cites]
Br J Dermatol. 2006 Nov;155(5):1099-101
[
17034564.001
]
[Cites]
J Am Acad Dermatol. 1998 Dec;39(6):940-3
[
9843005.001
]
[Cites]
Br J Dermatol. 1998 Sep;139(3):555-6
[
9767320.001
]
[Cites]
Eur J Dermatol. 1998 Oct-Nov;8(7):503-5
[
9854164.001
]
[Cites]
Br J Dermatol. 1998 Oct;139(4):744-5
[
9892926.001
]
[Cites]
Br J Dermatol. 1998 Nov;139(5):930-1
[
9892977.001
]
[Cites]
Otolaryngol Head Neck Surg. 1998 Dec;119(6):709-10
[
9852556.001
]
[Cites]
Arch Dermatol. 1999 Jan;135(1):62-6
[
9923783.001
]
[Cites]
J Rheumatol. 1999 Feb;26(2):440-2
[
9972982.001
]
[Cites]
J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):275-9
[
10025763.001
]
[Cites]
J Am Acad Dermatol. 1999 Feb;40(2 Pt 2):331-4
[
10025862.001
]
[Cites]
Cutis. 1999 Mar;63(3):177-9
[
10190073.001
]
[Cites]
Br J Dermatol. 1999 Mar;140(3):565-6
[
10233302.001
]
[Cites]
Ann Thorac Surg. 2004 Jul;78(1):341-3
[
15223465.001
]
[Cites]
Ann Dermatol Venereol. 2004 Apr;131(4):369-72
[
15258512.001
]
[Cites]
J Am Acad Dermatol. 2004 Sep;51(3):474-5
[
15337997.001
]
[Cites]
J Eur Acad Dermatol Venereol. 2004 Nov;18(6):716-7
[
15482306.001
]
[Cites]
J Eur Acad Dermatol Venereol. 2004 Nov;18(6):745-6
[
15482319.001
]
[Cites]
Int J Dermatol. 2004 Oct;43(10):720-2
[
15485526.001
]
[Cites]
Int J Dermatol. 2004 Oct;43(10):772-7
[
15485540.001
]
[Cites]
Gynecol Oncol. 2004 Nov;95(2):396-9
[
15491764.001
]
[Cites]
J Am Acad Dermatol. 1994 Apr;30(4):639-42
[
8157792.001
]
[Cites]
Br J Haematol. 1994 Feb;86(2):415-7
[
7515269.001
]
[Cites]
Clin Exp Dermatol. 1994 May;19(3):274-7
[
8033398.001
]
[Cites]
Br J Haematol. 1994 Mar;86(3):645-8
[
7519039.001
]
[Cites]
J Dermatol. 1994 May;21(5):341-6
[
8051321.001
]
[Cites]
Int J Dermatol. 1994 Jun;33(6):425-32
[
8056477.001
]
[Cites]
Acta Derm Venereol. 1994 May;74(3):229-30
[
7915473.001
]
[Cites]
J Am Acad Dermatol. 1994 Oct;31(4):535-56; quiz 557-60
[
8089280.001
]
[Cites]
Br J Dermatol. 1979 Jan;100(1):93-9
[
427014.001
]
[Cites]
Dermatologica. 1980;160(5):341-7
[
7364144.001
]
[Cites]
Br J Dermatol. 1981 Oct;105(4):483
[
7295564.001
]
[Cites]
Postgrad Med. 1982 Jan;71(1):55-60
[
7054779.001
]
[Cites]
S Afr Med J. 1982 Sep 4;62(11):375-8
[
7112306.001
]
[Cites]
Clin Rheum Dis. 1982 Aug;8(2):427-41
[
6754235.001
]
[Cites]
Br J Dermatol. 1983 Jan;108(1):99-101
[
6821647.001
]
[Cites]
J Pediatr. 1983 Feb;102(2):243-8
[
6822929.001
]
[Cites]
Cancer. 1983 Apr 15;51(8):1518-26
[
6572088.001
]
[Cites]
Arch Dermatol. 1983 Jul;119(7):610-1
[
6574727.001
]
[Cites]
J Am Acad Dermatol. 1983 Jul;9(1):77-81
[
6886108.001
]
[Cites]
Cutis. 1983 Aug;32(2):152-4
[
6617253.001
]
[Cites]
Arch Intern Med. 1983 Oct;143(10):1993-5
[
6625786.001
]
[Cites]
Arch Neurol. 1983 Dec;40(13):829
[
6639416.001
]
[Cites]
J Am Acad Dermatol. 1983 Nov;9(5):751-8
[
6358279.001
]
[Cites]
Arch Dermatol. 1984 Feb;120(2):245-7
[
6696481.001
]
[Cites]
Blut. 1984 May;48(5):297-305
[
6722359.001
]
[Cites]
Arch Dermatol. 1985 Jun;121(6):789-91
[
4004304.001
]
[Cites]
Dermatologica. 1985;171(2):102-5
[
4043468.001
]
[Cites]
Presse Med. 1985 Sep 14;14(30):1599-601
[
2995962.001
]
[Cites]
Lupus. 2005;14(5):399-402
[
15934441.001
]
[Cites]
South Med J. 2005 May;98(5):570-2
[
15954518.001
]
[Cites]
J Am Acad Dermatol. 2005 Aug;53(2 Suppl 1):S135-8
[
16021163.001
]
[Cites]
Arch Dermatol. 2005 Jul;141(7):834-42
[
16027297.001
]
[Cites]
Arch Dermatol. 2005 Jul;141(7):881-4
[
16027305.001
]
[Cites]
Arch Dermatol. 2005 Jul;141(7):887-9
[
16027306.001
]
[Cites]
Arch Dermatol. 2005 Jul;141(7):893-5
[
16027307.001
]
[Cites]
Clin Dev Immunol. 2005 Jun;12(2):145-9
[
16050146.001
]
[Cites]
Int J Dermatol. 2005 Aug;44(8):677-80
[
16101872.001
]
[Cites]
Retina. 2005 Sep;25(6):800-2
[
16141877.001
]
[Cites]
J Eur Acad Dermatol Venereol. 2005 Sep;19(5):597-9
[
16164716.001
]
[Cites]
J Eur Acad Dermatol Venereol. 2005 Sep;19(5):634-7
[
16164726.001
]
[Cites]
Br J Haematol. 2005 Oct;131(2):142
[
16197442.001
]
[Cites]
Digestion. 2005;72(2-3):195-200
[
16179788.001
]
[Cites]
Acta Gastroenterol Belg. 2005 Jul-Sep;68(3):376-9
[
16268426.001
]
[Cites]
Ann Dermatol Venereol. 2005 Nov;132(11 Pt 1):883-5
[
16327718.001
]
[Cites]
Int J Dermatol. 2005 Nov;44(11):946-7
[
16336530.001
]
[Cites]
Pediatr Dermatol. 2005 Nov-Dec;22(6):525-9
[
16354254.001
]
[Cites]
Pediatr Dermatol. 2005 Nov-Dec;22(6):530-5
[
16354255.001
]
[Cites]
J Indian Med Assoc. 2005 Aug;103(8):433-5
[
16363199.001
]
[Cites]
J Assoc Physicians India. 2005 Aug;53:728-30
[
16398086.001
]
[Cites]
Leuk Res. 2006 Mar;30(3):364
[
16157374.001
]
[Cites]
Int J Dermatol. 2005 Dec;44(12):1051-3
[
16409276.001
]
[Cites]
Arch Dermatol. 2006 Jan;142(1):57-63
[
16415387.001
]
[Cites]
Int J Dermatol. 2006 Jan;45(1):51-2
[
16426377.001
]
[Cites]
Int J Dermatol. 2006 Jan;45(1):70-80
[
16426383.001
]
[Cites]
Ann Dermatol Venereol. 2005 Dec;132(12 Pt 1):1003-6
[
16446647.001
]
[Cites]
Haematologica. 2005 Dec;90(12 Suppl):ECR43
[
16464758.001
]
[Cites]
South Med J. 2007 Oct;100(10):1057-8
[
17943059.001
]
[Cites]
Pediatrics. 1999 Nov;104(5 Pt 1):1142-4
[
10545563.001
]
[Cites]
Clin Exp Dermatol. 1999 Sep;24(5):368-71
[
10564323.001
]
[Cites]
Australas J Dermatol. 1999 Nov;40(4):204-7
[
10570557.001
]
[Cites]
J Clin Oncol. 1988 Dec;6(12):1887-97
[
3058878.001
]
[Cites]
J Am Acad Dermatol. 1988 Dec;19(6):983-1005
[
3060489.001
]
[Cites]
Am Fam Physician. 1989 Mar;39(3):199-204
[
2646883.001
]
[Cites]
Ann Intern Med. 1989 Apr 1;110(7):573-4
[
2923392.001
]
[Cites]
Semin Oncol. 1997 Jun;24(3):334-59
[
9208889.001
]
[Cites]
J Am Acad Dermatol. 1997 Jul;37(1):123-4
[
9216537.001
]
[Cites]
Clin Exp Dermatol. 1997 Jan;22(1):54-6
[
9330058.001
]
[Cites]
Int J Dermatol. 1997 Sep;36(9):717-8
[
9352420.001
]
[Cites]
Br J Dermatol. 1997 Oct;137(4):609-13
[
9390341.001
]
[Cites]
Thorac Cardiovasc Surg. 1997 Oct;45(5):247-8
[
9402666.001
]
[Cites]
Med Clin (Barc). 1997 Nov 1;109(15):588-91
[
9441195.001
]
[Cites]
Int J Dermatol. 1997 Nov;36(11):837-44
[
9427076.001
]
[Cites]
Br J Dermatol. 1989 Sep;121(3):413-5
[
2803964.001
]
[Cites]
J Pediatr. 1989 Nov;115(5 Pt 1):726-9
[
2809903.001
]
[Cites]
J Pediatr. 1989 Nov;115(5 Pt 1):730-4
[
2809904.001
]
[Cites]
Vestn Dermatol Venerol. 1989;(11):67-9
[
2618175.001
]
[Cites]
Neth J Med. 1990 Feb;36(1-2):62-8
[
2278538.001
]
[Cites]
J Rheumatol. 1990 May;17(5):682-4
[
2193156.001
]
[Cites]
Rev Clin Esp. 1990 Apr;186(6):264-9
[
2203115.001
]
[Cites]
Am J Med. 1990 Sep;89(3):396
[
2203266.001
]
[Cites]
J Am Acad Dermatol. 1990 Aug;23(2 Pt 1):247-9
[
2212120.001
]
[Cites]
J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):503-7
[
2212153.001
]
[Cites]
Int J Dermatol. 1990 Dec;29(10):737
[
2269574.001
]
[Cites]
Acta Haematol. 1990;84(4):207-8
[
2125789.001
]
[Cites]
Dermatologica. 1991;182(1):43-6
[
1826487.001
]
[Cites]
Br J Dermatol. 1991 Apr;124(4):348-53
[
2025555.001
]
[Cites]
J R Soc Med. 1991 May;84(5):307-8
[
2041012.001
]
[Cites]
Acta Derm Venereol. 1991;71(1):77-9
[
1676226.001
]
[Cites]
Ann Dermatol Venereol. 1990;117(11):858-60
[
2099706.001
]
[Cites]
Australas J Dermatol. 1991;32(1):55-9
[
1834046.001
]
[Cites]
Am J Med. 1991 Nov;91(5):553-4
[
1951419.001
]
[Cites]
Dermatologica. 1991;183(3):230-3
[
1743390.001
]
[Cites]
Acta Derm Venereol. 2003;83(4):290-1
[
12926802.001
]
[Cites]
Br J Dermatol. 2003 Sep;149(3):675-7
[
14511020.001
]
[Cites]
Int J Dermatol. 2003 Oct;42(10):761-78
[
14521689.001
]
[Cites]
Med Clin (Barc). 2003 Oct 4;121(11):437
[
14563281.001
]
[Cites]
J Am Acad Dermatol. 2003 Nov;49(5):907-9
[
14576675.001
]
[Cites]
Lancet. 2003 Oct 25;362(9393):1374
[
14585639.001
]
[Cites]
Korean J Intern Med. 2003 Sep;18(3):187-90
[
14619389.001
]
[Cites]
Br J Dermatol. 2003 Oct;149(4):884
[
14616386.001
]
[Cites]
Contact Dermatitis. 2003 Jul;49(1):42
[
14641120.001
]
[Cites]
J Cutan Pathol. 2004 Jan;31(1):72-6
[
14675289.001
]
[Cites]
J Cutan Pathol. 2004 Feb;31(2):189-94
[
14690466.001
]
[Cites]
Int J Dermatol. 2004 Jan;43(1):57-9
[
14693024.001
]
[Cites]
QJM. 2004 Jan;97(1):55-6
[
14702513.001
]
[Cites]
J Am Acad Dermatol. 2004 Feb;50(2):280-5
[
14726888.001
]
[Cites]
Clin Nucl Med. 2004 Feb;29(2):91-2
[
14734904.001
]
[Cites]
Eye (Lond). 2004 Feb;18(2):214; discussion 214-6
[
14762428.001
]
[Cites]
J Laryngol Otol. 2004 Jan;118(1):48-9
[
14979973.001
]
[Cites]
J Eur Acad Dermatol Venereol. 2004 Mar;18(2):233
[
15009320.001
]
[Cites]
Leuk Res. 2004 May;28 Suppl 1:S61-3
[
15036943.001
]
[Cites]
Dermatology. 2004;208(2):175
[
15057014.001
]
[Cites]
J Fam Plann Reprod Health Care. 2004 Apr;30(2):115-6
[
15086998.001
]
[Cites]
J Am Acad Dermatol. 2004 May;50(5 Suppl):S90-2
[
15097938.001
]
[Cites]
J Am Acad Dermatol. 2004 May;50(5):798-9
[
15097971.001
]
[Cites]
Int J Dermatol. 2004 Feb;43(2):95-102
[
15125498.001
]
[Cites]
J Pediatr Hematol Oncol. 2004 Mar;26(3):197-9
[
15125614.001
]
[Cites]
Arch Dermatol. 2004 May;140(5):570-4
[
15148101.001
]
[Cites]
J Med Assoc Thai. 2004 May;87(5):567-72
[
15222531.001
]
[Cites]
Am J Hematol. 2004 Jul;76(3):283-5
[
15224368.001
]
[Cites]
Br J Haematol. 1993 Sep;85(1):191-2
[
7504506.001
]
[Cites]
Dermatology. 1993;187(4):303-5
[
8274797.001
]
[Cites]
Acta Derm Venereol. 1993 Oct;73(5):380-1
[
7904408.001
]
[Cites]
J Am Acad Dermatol. 1994 Feb;30(2 Pt 2):293-7
[
8294584.001
]
[Cites]
J Am Acad Dermatol. 1994 Feb;30(2 Pt 2):297-300
[
8294585.001
]
[Cites]
J Cutan Pathol. 1993 Oct;20(5):465-78
[
7507948.001
]
[Cites]
Clin Exp Dermatol. 1994 Jan;19(1):51-2
[
8313637.001
]
[Cites]
South Med J. 1994 Feb;87(2):193-6
[
8115882.001
]
[Cites]
Int J Dermatol. 2001 Dec;40(12):791-3
[
11903682.001
]
[Cites]
Ann Hematol. 2002 Feb;81(2):111-4
[
11907794.001
]
[Cites]
Acta Orthop Belg. 2002 Feb;68(1):68-71
[
11915462.001
]
[Cites]
Gastroenterol Clin Biol. 2002 Mar;26(3):295-7
[
11981477.001
]
[Cites]
Int J Dermatol. 2002 Feb;41(2):107-9
[
11982648.001
]
[Cites]
Clin Pediatr (Phila). 2002 Apr;41(3):175-7
[
11999681.001
]
[Cites]
Br J Dermatol. 2002 Jun;146(6):1087-90
[
12072085.001
]
[Cites]
J Occup Environ Med. 2002 Jun;44(6):491-2
[
12085472.001
]
[Cites]
Leukemia. 1994 Sep;8(9):1596
[
8090038.001
]
[Cites]
Am Fam Physician. 1994 Nov 1;50(6):1273-82
[
7942426.001
]
[Cites]
J Am Acad Dermatol. 1994 Dec;31(6):1045-7
[
7962753.001
]
[Cites]
Pediatr Dermatol. 1994 Sep;11(3):237-40
[
7971558.001
]
[Cites]
J Rheumatol. 1994 Sep;21(9):1766-8
[
7799365.001
]
[Cites]
J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):192-8
[
7829702.001
]
[Cites]
Mayo Clin Proc. 1995 Mar;70(3):234-40
[
7861810.001
]
[Cites]
Leuk Lymphoma. 1994 Oct;15(3-4):261-4
[
7532508.001
]
[Cites]
J Am Acad Dermatol. 1995 Mar;32(3):533-5
[
7868739.001
]
[Cites]
Int J Dermatol. 1995 Jan;34(1):73-4
[
7896497.001
]
[Cites]
Australas J Dermatol. 1994;35(2):91-2
[
7702496.001
]
[Cites]
Dermatology. 1995;190(2):160-3
[
7727840.001
]
[Cites]
Hum Pathol. 1995 Jun;26(6):687-90
[
7774902.001
]
[Cites]
Mayo Clin Proc. 1995 Jun;70(6):605-6
[
7632268.001
]
[Cites]
J Am Acad Dermatol. 1995 Jul;33(1):144-5
[
7601939.001
]
[Cites]
Int J Dermatol. 1995 May;34(5):323-9
[
7607792.001
]
[Cites]
Am J Med. 1995 Aug;99(2):207-16
[
7625426.001
]
[Cites]
Semin Dermatol. 1995 Jun;14(2):173-8
[
7640199.001
]
[Cites]
Postgrad Med J. 1995 Jun;71(836):383
[
7644412.001
]
[Cites]
Acta Derm Venereol. 1995 May;75(3):237-9
[
7653187.001
]
[Cites]
Pediatr Dermatol. 1985 Nov;3(1):40-4
[
3906610.001
]
[Cites]
Dermatol Clin. 1985 Jan;3(1):153-63
[
3912087.001
]
[Cites]
Cutis. 1986 Mar;37(3):167-74
[
3514153.001
]
[Cites]
Am J Med. 1986 Sep;81(3):558-60
[
2944382.001
]
[Cites]
Dermatologica. 1986;173(2):85-9
[
3792603.001
]
[Cites]
Arch Dermatol. 1987 Feb;123(2):251, 254
[
2434033.001
]
[Cites]
J Clin Pathol. 1987 Feb;40(2):175-9
[
3546396.001
]
[Cites]
Am J Med. 1987 Jun;82(6):1220-6
[
3300306.001
]
[Cites]
Cutis. 1987 Aug;40(2):139-42
[
3621997.001
]
[Cites]
J Assoc Physicians India. 2002 Oct;50:1322-3
[
12568224.001
]
[Cites]
Dermatology. 2003;206(2):81-4
[
12592072.001
]
[Cites]
J Cutan Pathol. 2003 Apr;30(4):261-4
[
12680958.001
]
[Cites]
Int J Dermatol. 2003 Jun;42(6):438-43
[
12786869.001
]
[Cites]
Clin Exp Dermatol. 2003 Jul;28(4):377-9
[
12823297.001
]
[Cites]
J Am Acad Dermatol. 2003 Jul;49(1):132-8
[
12833027.001
]
[Cites]
Ann Acad Med Singapore. 2003 May;32(3):411-4
[
12854387.001
]
[Cites]
Clin Exp Dermatol. 1987 Sep;12(5):345-9
[
3446421.001
]
[Cites]
Tunis Med. 2007 Jan;85(1):49-53
[
17424710.001
]
[Cites]
South Med J. 2007 Apr;100(4):414-5
[
17458409.001
]
[Cites]
Ann Pharmacother. 2007 May;41(5):802-11
[
17426076.001
]
[Cites]
Int J Dermatol. 2007 May;46(5):496-9
[
17472681.001
]
[Cites]
Clin Rheumatol. 2007 Jul;26(7):1215-6
[
17294051.001
]
[Cites]
Australas J Dermatol. 2007 May;48(2):105-9
[
17535199.001
]
[Cites]
Int J Dermatol. 2007 Jun;46(6):571-4
[
17550553.001
]
[Cites]
Clin Dermatol. 2007 May-Jun;25(3):326-33
[
17560310.001
]
[Cites]
J Cutan Pathol. 2007 Jul;34(7):526-34
[
17576331.001
]
[Cites]
Ann Hematol. 2007 Aug;86(8):613-4
[
17468870.001
]
[Cites]
Med Sci Monit. 2007 Apr;13(4):CS53-5
[
17392656.001
]
[Cites]
J Am Acad Dermatol. 1996 Dec;35(6):989-90
[
8959963.001
]
[Cites]
J Am Acad Dermatol. 1996 Dec;35(6):995-7
[
8959967.001
]
[Cites]
Arch Dermatol. 1996 Dec;132(12):1507, 1510
[
8961884.001
]
[Cites]
Br J Dermatol. 1997 Jan;136(1):142-4
[
9039324.001
]
[Cites]
Br J Dermatol. 1997 Feb;136(2):296-7
[
9068763.001
]
[Cites]
J Am Acad Dermatol. 1997 Mar;36(3 Pt 1):436-9
[
9091476.001
]
[Cites]
Dermatology. 1997;194(2):182-4
[
9094473.001
]
[Cites]
Int J Dermatol. 1997 Apr;36(4):292-3
[
9169331.001
]
[Cites]
Med Pediatr Oncol. 2003 Feb;40(2):135-6
[
12461805.001
]
[Cites]
Ann Rheum Dis. 2003 Jan;62(1):81-2
[
12480678.001
]
[Cites]
Int J Dermatol. 2002 Dec;41(12):928-30
[
12492993.001
]
[Cites]
Arch Dermatol. 2003 Jan;139(1):101-2
[
12533182.001
]
[Cites]
Arch Dermatol. 2003 Jan;139(1):102
[
12533183.001
]
[Cites]
J Am Acad Dermatol. 1999 Dec;41(6):1033-4
[
10570395.001
]
[Cites]
Br J Ophthalmol. 1998 Mar;82(3):328-9
[
9602638.001
]
[Cites]
Br J Dermatol. 1998 Feb;138(2):365-6
[
9602899.001
]
[Cites]
Clin Exp Dermatol. 1997 Nov;22(6):269-73
[
9604452.001
]
[Cites]
Australas J Dermatol. 1998 May;39(2):116-8
[
9611384.001
]
[Cites]
Dermatology. 1998;196(3):346-7
[
9621146.001
]
[Cites]
Eur Respir J. 1998 Apr;11(4):978-80
[
9623707.001
]
[Cites]
Am J Hematol. 1998 Aug;58(4):337-8
[
9692401.001
]
[Cites]
Med Pediatr Oncol. 1998 Sep;31(3):178-81
[
9722904.001
]
[Cites]
Br J Dermatol. 1998 Jul;139(1):107-10
[
9764159.001
]
[Cites]
Ann Hematol. 1998 Sep;77(3):135-8
[
9797084.001
]
[Cites]
Dermatology. 1998;197(2):195-6
[
9840982.001
]
[Cites]
Intensive Care Med. 1998 Oct;24(10):1106-9
[
9840248.001
]
[Cites]
Br J Dermatol. 1999 Oct;141(4):766-7
[
10583147.001
]
[Cites]
Br J Dermatol. 1999 Nov;141(5):943-4
[
10583195.001
]
[Cites]
J Clin Gastroenterol. 1999 Dec;29(4):349-50
[
10599643.001
]
[Cites]
Clin Exp Dermatol. 1999 Nov;24(6):443-5
[
10606943.001
]
[Cites]
Leuk Res. 2000 Jan;24(1):83-6
[
10634651.001
]
[Cites]
J Am Acad Dermatol. 2000 Feb;42(2 Pt 2):332-4
[
10640926.001
]
[Cites]
Am J Med. 2000 Apr 1;108(5):434-5
[
10759106.001
]
[Cites]
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Apr;89(4):477-9
[
10760730.001
]
[Cites]
J Am Acad Dermatol. 2000 May;42(5 Pt 2):932-5
[
10767709.001
]
[Cites]
Arch Dermatol. 2000 May;136(5):673-4
[
10815868.001
]
[Cites]
Australas J Dermatol. 1991;32(2):61-4
[
1781756.001
]
[Cites]
J Am Acad Dermatol. 1991 Oct;25(4):734
[
1724249.001
]
[Cites]
Arthritis Rheum. 1992 Apr;35(4):484-6
[
1567500.001
]
[Cites]
Dermatologica. 1991;183(4):255-64
[
1809587.001
]
[Cites]
Ann Intern Med. 1992 Jun 15;116(12 Pt 1):996-8
[
1375012.001
]
[Cites]
J Rheumatol. 1992 May;19(5):814-20
[
1613717.001
]
[Cites]
Am Rev Respir Dis. 1992 Jul;146(1):269
[
1626811.001
]
[Cites]
Cutis. 1992 Jun;49(6):448-50
[
1628515.001
]
[Cites]
Intern Med. 1992 May;31(5):686-9
[
1504437.001
]
[Cites]
Aust N Z J Ophthalmol. 1992 Aug;20(3):263-5
[
1449782.001
]
[Cites]
Int J Dermatol. 1992 Sep;31(9):670-1
[
1459771.001
]
[Cites]
Acta Haematol. 1992;88(2-3):154-7
[
1466198.001
]
[Cites]
Br J Dermatol. 1992 Nov;127(5):538-9
[
1467297.001
]
[Cites]
J Am Acad Dermatol. 1992 Nov;27(5 Pt 2):801-4
[
1469130.001
]
[Cites]
Pediatr Dermatol. 1992 Sep;9(3):288-92
[
1488383.001
]
[Cites]
Clin Exp Dermatol. 1993 Jan;18(1):47-9
[
8440052.001
]
[Cites]
Cutis. 1993 Mar;51(3):175-9
[
8444048.001
]
[Cites]
Cutis. 1993 Feb;51(2):112-4
[
8453891.001
]
[Cites]
Int J Dermatol. 1993 Apr;32(4):261-8
[
8486457.001
]
[Cites]
Arch Ophthalmol. 1993 May;111(5):587-8
[
8489431.001
]
[Cites]
Mayo Clin Proc. 1993 Jun;68(6):620-1
[
8497142.001
]
[Cites]
Br J Dermatol. 1993 May;128(5):584-6
[
8504055.001
]
[Cites]
Clin Dermatol. 1993 Jan-Mar;11(1):149-57
[
8339190.001
]
[Cites]
Arch Dermatol. 1993 Aug;129(8):1062-4
[
8352617.001
]
[Cites]
Obstet Gynecol Surv. 1993 Aug;48(8):584-7
[
8371901.001
]
[Cites]
Br J Haematol. 1993 Jun;84(2):356-8
[
7691149.001
]
[Cites]
Cancer. 1993 Nov 1;72(9):2723-31
[
8402496.001
]
[Cites]
Australas J Dermatol. 1993;34(1):31-3
[
8240185.001
]
[Cites]
Korean J Intern Med. 2001 Sep;16(3):218-21
[
11769583.001
]
[Cites]
Dermatology. 2002;204(1):84
[
11834860.001
]
[Cites]
J Dermatol. 2002 Feb;29(2):91-5
[
11890302.001
]
[Cites]
Am J Clin Dermatol. 2002;3(2):117-31
[
11893223.001
]
[Cites]
Int J Dermatol. 2002 Jan;41(1):28-31
[
11895510.001
]
[Cites]
Arch Dermatol. 2002 Mar;138(3):345-9
[
11902985.001
]
[Cites]
Arch Dermatol. 2002 Mar;138(3):361-5
[
11902987.001
]
[Cites]
Arch Dermatol. 2002 Mar;138(3):400-3
[
11902994.001
]
[Cites]
Clin Dermatol. 2000 May-Jun;18(3):265-82
[
10856659.001
]
[Cites]
Arch Intern Med. 2000 Jun 26;160(12):1869
[
10871983.001
]
[Cites]
Acta Derm Venereol. 2000 Mar-Apr;80(2):145-6
[
10877140.001
]
[Cites]
Eur J Haematol. 2000 Jul;65(1):72-3
[
10914942.001
]
[Cites]
Br J Dermatol. 2000 Aug;143(2):449-50
[
10951165.001
]
[Cites]
J Am Acad Dermatol. 2000 Oct;43(4):691-7
[
11004629.001
]
[Cites]
Am J Dermatopathol. 2000 Oct;22(5):429-33
[
11048979.001
]
[Cites]
Postgrad Med J. 2000 Nov;76(901):713-4
[
11060149.001
]
[Cites]
Br J Dermatol. 2000 Oct;143(4):914-6
[
11069494.001
]
[Cites]
Int J Dermatol. 2000 Oct;39(10):795-8
[
11095204.001
]
[Cites]
Br J Dermatol. 2000 Dec;143(6):1322-4
[
11122045.001
]
[Cites]
J Pediatr Hematol Oncol. 2001 Jan;23(1):59-62
[
11196274.001
]
[Cites]
J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):870-4
[
11050599.001
]
[Cites]
J Cutan Pathol. 2001 Feb;28(2):90-6
[
11168757.001
]
[Cites]
J Am Acad Dermatol. 2001 May;44(5):862-4
[
11312438.001
]
[Cites]
Medicine (Baltimore). 2001 May;80(3):173-9
[
11388093.001
]
[Cites]
Acta Derm Venereol. 2001 Jan-Feb;81(1):73-4
[
11411932.001
]
[Cites]
Am J Med. 2001 Jul;111(1):80-1
[
11460854.001
]
[Cites]
J Am Acad Dermatol. 2001 Aug;45(2):300-2
[
11464196.001
]
[Cites]
J Neurol Sci. 2001 Jul 15;188(1-2):95-7
[
11489291.001
]
[Cites]
Arch Dermatol. 2001 Aug;137(8):1106-8
[
11493115.001
]
[Cites]
Yale J Biol Med. 2001 May-Jun;74(3):165-8
[
11501712.001
]
[Cites]
J Am Acad Dermatol. 2001 Sep;45(3):325-61; quiz 362-4
[
11511831.001
]
[Cites]
J Am Acad Dermatol. 2001 Oct;45(4):590-5
[
11568752.001
]
[Cites]
Dis Colon Rectum. 2001 Oct;44(10):1526-9
[
11598485.001
]
[Cites]
Clin Exp Dermatol. 2001 Nov;26(8):668-70
[
11722452.001
]
[Cites]
Dermatology. 1995;190(4):335-7
[
7655121.001
]
[Cites]
J Am Acad Dermatol. 1995 Sep;33(3):393-410; quiz 410-2
[
7544812.001
]
[Cites]
Clin Exp Dermatol. 1995 May;20(3):279-80
[
7671433.001
]
[Cites]
Arch Dermatol. 1995 Oct;131(10):1175-7
[
7574835.001
]
[Cites]
Aust Fam Physician. 1995 Oct;24(10):1867-9
[
8546614.001
]
[Cites]
Am J Med. 1995 Dec;99(6):662-71
[
7503090.001
]
[Cites]
Br J Dermatol. 1995 Sep;133(3):483-6
[
8547011.001
]
[Cites]
Br J Dermatol. 1995 Sep;133(3):490-1
[
8547013.001
]
[Cites]
Lancet. 1996 Mar 9;347(9002):690
[
8596402.001
]
[Cites]
J Am Acad Dermatol. 1996 Mar;34(3):539
[
8609279.001
]
[Cites]
Pediatrics. 1996 Mar;97(3):401-3
[
8604280.001
]
[Cites]
Leukemia. 1996 Apr;10(4):731-4
[
8618455.001
]
[Cites]
J Am Acad Dermatol. 1996 May;34(5 Pt 2):918-23
[
8621829.001
]
[Cites]
Cutis. 1996 Feb;57(2):107-10
[
8646854.001
]
[Cites]
Adv Dermatol. 1996;11:215-52; discussion 253
[
8718480.001
]
[Cites]
Australas J Dermatol. 1996 May;37(2):99-101
[
8687337.001
]
[Cites]
Eur J Cancer B Oral Oncol. 1996 Mar;32B(2):133-6
[
8736177.001
]
[Cites]
Br J Dermatol. 1996 Apr;134(4):705-9
[
8733376.001
]
[Cites]
J Pediatr Hematol Oncol. 1996 Aug;18(3):282-4
[
8689342.001
]
[Cites]
Clin Exp Dermatol. 1996 Mar;21(2):175
[
8759219.001
]
[Cites]
Am J Med. 1996 Aug;101(2):231-3
[
8757366.001
]
[Cites]
Ann Acad Med Singapore. 1996 Mar;25(2):222-7
[
8799010.001
]
[Cites]
J Neurol. 1996 Jul;243(7):556-7
[
8836949.001
]
[Cites]
Int J Dermatol. 1996 Jan;35(1):9-15
[
8838921.001
]
[Cites]
Respir Med. 1996 Jan;90(1):57-9
[
8857328.001
]
[Cites]
J Am Acad Dermatol. 1996 Oct;35(4):629-31
[
8859296.001
]
[Cites]
Haematologica. 1996 Jan-Feb;81(1):54-8
[
8900854.001
]
[Cites]
J Rheumatol. 1996 Nov;23(11):1995-8
[
8923382.001
]
[Cites]
J Cutan Pathol. 2002 May;29(5):301-4
[
12100632.001
]
[Cites]
J Am Acad Dermatol. 2002 Aug;47(2):323-4
[
12140489.001
]
[Cites]
Ann Hematol. 2002 Jul;81(7):397-8
[
12185512.001
]
[Cites]
Br J Dermatol. 2002 Sep;147(3):558-62
[
12207601.001
]
[Cites]
Rheumatology (Oxford). 2002 Sep;41(9):1067-9
[
12209043.001
]
[Cites]
Acta Derm Venereol. 2002;82(3):221
[
12353722.001
]
[Cites]
Am J Psychiatry. 2002 Nov;159(11):1947
[
12411238.001
]
[Cites]
Eur J Radiol. 2002 Nov;44(2):139-42
[
12413682.001
]
(PMID = 17655751.001).
[ISSN]
1750-1172
[Journal-full-title]
Orphanet journal of rare diseases
[ISO-abbreviation]
Orphanet J Rare Dis
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Number-of-references]
435
[Other-IDs]
NLM/ PMC1963326
71.
Yin CC, Abruzzo LV, Qiu X, Apostolidou E, Cortes JE, Medeiros LJ, Lu G:
del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia.
Cancer Genet Cytogenet
; 2009 Jul;192(1):18-23
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic
myelogenous leukemia
.
The del(15q) chromosomal abnormality is known to occur
in acute
leukemias, but has rarely been described in chronic
myelogenous leukemia
(CML).
Bone marrow aspirate smears showed increased blasts in all cases at the time of del(15q) detection, in accelerated phase in two cases and
myeloid
blast phase in three.
Of the three patients who did not receive ASCT, one died, one was in persistent blast phase, and one was in clinical
remission
with molecular evidence of residual disease at 16, 6, and 34 months, respectively, after identification of the del(15q).
Of the two patients who had ASCT, one died and one was in clinical
remission
with molecular evidence of disease at 15 and 64 months, respectively, after identification of the del(15q).
[MeSH-major]
Chromosome Deletion. Chromosomes, Human, Pair 15. Clone Cells / pathology.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / genetics
[MeSH-minor]
Adult
. Bone Marrow Cells / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Chromosome Aberrations. Female. Follow-Up Studies. Gene Frequency. Humans. Karyotyping. Male. Middle Aged
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Mod Pathol. 2004 Jan;17(1):96-103
[
14657955.001
]
[Cites]
Cancer Genet Cytogenet. 2009 Jan 15;188(2):118-23
[
19100517.001
]
[Cites]
Cancer Genet Cytogenet. 2004 Jun;151(2):146-51
[
15172752.001
]
[Cites]
Am J Clin Pathol. 2004 Jun;121(6):836-42
[
15198355.001
]
[Cites]
Hematol Oncol Clin North Am. 2004 Jun;18(3):671-84, x
[
15271399.001
]
[Cites]
Nature. 1973 Jun 1;243(5405):290-3
[
4126434.001
]
[Cites]
Cancer. 1999 Dec 15;86(12):2632-41
[
10594858.001
]
[Cites]
Cancer Res. 2000 Jan 1;60(1):70-3
[
10646855.001
]
[Cites]
Blood. 2000 Nov 15;96(10):3343-56
[
11071626.001
]
[Cites]
Arch Pathol Lab Med. 2001 Mar;125(3):437-9
[
11231500.001
]
[Cites]
Cancer. 2002 Feb 15;94(4):1102-10
[
11920481.001
]
[Cites]
Mod Pathol. 2002 Dec;15(12):1266-72
[
12481006.001
]
[Cites]
Int J Cancer. 2003 Aug 10;106(1):74-7
[
12794759.001
]
[Cites]
Cancer Genet Cytogenet. 2003 Jul 1;144(1):1-5
[
12810248.001
]
[Cites]
Scand J Haematol. 1976 Jul;17(1):17-28
[
1066809.001
]
[Cites]
Cancer. 1979 Apr;43(4):1350-7
[
445335.001
]
[Cites]
Hum Genet. 1981;58(3):285-93
[
6948765.001
]
[Cites]
Cancer. 1985 Feb 1;55(3):535-41
[
3965107.001
]
[Cites]
Leuk Res. 1991;15(8):683-91
[
1654480.001
]
[Cites]
Cancer Genet Cytogenet. 1991 Aug;55(1):35-8
[
1913605.001
]
[Cites]
Leuk Lymphoma. 1993;11 Suppl 1:11-5
[
8251885.001
]
[Cites]
Cancer Genet Cytogenet. 1996 Feb;86(2):124-8
[
8603337.001
]
[Cites]
Baillieres Clin Haematol. 1997 Jun;10(2):223-31
[
9376661.001
]
[Cites]
Leuk Res. 1998 Sep;22(9):845-7
[
9716017.001
]
[Cites]
Curr Opin Hematol. 1998 Jul;5(4):302-8
[
9747637.001
]
[Cites]
N Engl J Med. 1999 Apr 29;340(17):1330-40
[
10219069.001
]
[Cites]
N Engl J Med. 1999 Jul 15;341(3):164-72
[
10403855.001
]
[Cites]
Am J Clin Pathol. 2005 Nov;124(5):807-14
[
16203287.001
]
[Cites]
Cancer. 2006 Apr 15;106(8):1730-8
[
16532439.001
]
[Cites]
J Cell Biochem. 2007 Apr 15;100(6):1376-86
[
17131381.001
]
[Cites]
Cancer. 2008 May 15;112(10):2112-8
[
18348294.001
]
[Cites]
Cancer. 2008 Oct 1;113(7 Suppl):1933-52
[
18798533.001
]
[Cites]
Blood. 2004 Jun 1;103(11):4010-22
[
14982876.001
]
(PMID = 19480932.001).
[ISSN]
1873-4456
[Journal-full-title]
Cancer genetics and cytogenetics
[ISO-abbreviation]
Cancer Genet. Cytogenet.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P30 CA016672
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS627187; NLM/ PMC4167428
72.
Ghez D, Rubio MT, Maillard N, Suarez F, Chandesris MO, Delarue R, Deau-Fischer B, Varet B, Hermine O, Buzyn A:
Rapamycin for refractory acute graft-versus-host disease.
Transplantation
; 2009 Nov 15;88(9):1081-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Rapamycin for refractory
acute
graft-versus-host disease.
Steroid-refractory
acute
graft-versus-host disease (GVHD) remains a significant cause of mortality after allogeneic stem-cell transplantation and therapeutic options are not codified.
METHODS: In this retrospective single-center study, 22 patients were identified, from October 2004 to February 2008, as having received rapamycin for
acute
GVHD refractory to one or more lines of treatment.
RESULTS: Rapamycin resulted in a rapid and sustained complete
remission
of GVHD in 72% of heavily pretreated patients.
CONCLUSION: Despite a small and heterogeneous population of patients, these results are encouraging and provide a rationale for prospective studies that use rapamycin in steroid-refractory
acute
GVHD as a second- or third-line agent.
[MeSH-major]
Graft vs Host Disease / drug therapy. Hematopoietic Stem Cell Transplantation / methods. Immunosuppressive Agents / therapeutic use.
Leukemia
/ surgery. Sirolimus / therapeutic use
[MeSH-minor]
Adolescent.
Adult
. Bacterial Infections / epidemiology. Humans.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / immunology.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / surgery. Middle Aged. Retrospective Studies. Survival Rate. Survivors. Transplantation, Homologous. Treatment Outcome. Young
Adult
MedlinePlus Health Information.
consumer health - Childhood Leukemia
.
MedlinePlus Health Information.
consumer health - Leukemia
.
Hazardous Substances Data Bank.
SIROLIMUS
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19898203.001).
[ISSN]
1534-6080
[Journal-full-title]
Transplantation
[ISO-abbreviation]
Transplantation
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
73.
Sanz J, Sanz MA, Saavedra S, Lorenzo I, Montesinos P, Senent L, Planelles D, Larrea L, MartÃn G, Palau J, Jarque I, MartÃnez J, de la Rubia J, Moscardó F, Romero M, Luna I, Montava A, Cañabate S, Sanz GF:
Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia.
Biol Blood Marrow Transplant
; 2010 Jan;16(1):86-94
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cord blood transplantation from unrelated donors in adults with high-risk
acute
myeloid
leukemia
.
We analyzed the outcome and prognostic factors of 49 adults with high-risk
acute myelogenous leukemia
(
AML
) receiving single-unit CBT from unrelated donors after myeloablative (MA) conditioning at a single institution.
Cumulative incidence of
myeloid
and platelet engraftment was 96% and 73% at a median time of 20 and 62 days, respectively.
Confidence Interval of graft-versus-host disease (GVHD),
acute
GVHD (aGVHD) grade II-IV, III-IV, and extensive chronic GVHD (cGVHD) were 26%, 15%, and 30%, respectively.
Leukemia
-free survival (LFS), nonrelapse mortality (NRM), and relapse at 2 years were 42%, 39%, and 19%, respectively.
Patients transplanted in first complete
remission
(CR1) receiving TNC above 2 x 10(7)/kg had a 4-year LFS of 75%.
These results show that CBT from unrelated donors is a curative treatment for a substantial number of patients with high-risk
AML
, particularly if transplant is performed with highly cellular units in patients in first CR.
[MeSH-major]
Cord Blood Stem Cell Transplantation.
Leukemia
,
Myeloid
,
Acute
/ therapy
[MeSH-minor]
Adolescent.
Adult
. Antigens, CD34 / analysis. Female. Graft vs Host Disease / epidemiology. Histocompatibility Testing. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Risk Factors. Statistics as Topic. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Young
Adult
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
(PMID = 19744570.001).
[ISSN]
1523-6536
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD34
74.
Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D:
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
N Engl J Med
; 2007 Jan 25;356(4):348-59
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Patients with neutropenia resulting from chemotherapy for
acute myelogenous leukemia
or the myelodysplastic syndrome are at high risk for difficult-to-treat and often fatal invasive fungal infections.
Patients received prophylaxis with each cycle of chemotherapy until recovery from neutropenia and complete
remission
, until occurrence of an invasive fungal infection, or for up to 12 weeks, whichever came first.
CONCLUSIONS: In patients undergoing chemotherapy for
acute myelogenous leukemia
or the myelodysplastic syndrome, posaconazole prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival.
[MeSH-minor]
Adolescent.
Adult
. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Female. Humans. Kaplan-Meier Estimate.
Leukemia
,
Myeloid
,
Acute
/ complications.
Leukemia
,
Myeloid
,
Acute
/ drug therapy.
Leukemia
,
Myeloid
,
Acute
/ mortality. Male. Middle Aged. Myelodysplastic Syndromes / complications. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / mortality. Single-Blind Method. Treatment Outcome
MedlinePlus Health Information.
consumer health - Fungal Infections
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Pharmacogenomics Knowledge Base.
meta-databases - Pharmacogenomic Annotation 827852315 for PMID:17251531 [PharmGKB]
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
Hazardous Substances Data Bank.
Itraconazole
.
Hazardous Substances Data Bank.
FLUCONAZOLE
.
SciCrunch.
DrugBank: Data: Chemical
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2007 Massachusetts Medical Society.
[CommentIn]
Nat Clin Pract Oncol. 2007 Sep;4(9):512-3
[
17646862.001
]
[CommentIn]
Curr Infect Dis Rep. 2007 Nov;9(6):446-7
[
17999879.001
]
[CommentIn]
N Engl J Med. 2007 May 24;356(21):2215; author reply 2215-8
[
17526089.001
]
[CommentIn]
N Engl J Med. 2007 May 24;356(21):2214-5; author reply 2215-8
[
17526090.001
]
[CommentIn]
N Engl J Med. 2007 May 24;356(21):2214; author reply 2215-8
[
17522407.001
]
[CommentIn]
N Engl J Med. 2007 Jan 25;356(4):409-11
[
17251538.001
]
(PMID = 17251531.001).
[ISSN]
1533-4406
[Journal-full-title]
The New England journal of medicine
[ISO-abbreviation]
N. Engl. J. Med.
[Language]
eng
[Databank-accession-numbers]
ClinicalTrials.gov/ NCT00044486
[Publication-type]
Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antifungal Agents; 0 / Antineoplastic Agents; 0 / Triazoles; 304NUG5GF4 / Itraconazole; 6TK1G07BHZ / posaconazole; 8VZV102JFY / Fluconazole
75.
Ma W, Kantarjian H, Zhang K, Zhang X, Wang X, Chen C, Donahue AC, Zhang Z, Yeh CH, O'Brien S, Garcia-Manero G, Caporaso N, Landgren O, Albitar M:
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.
BMC Med Genet
; 2010 Nov 16;11:163
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: We genotyped the EPO rS1617640 SNP in 189 patients with MDS, 257 with
acute
myeloid
leukemia
(
AML
), 106 with
acute
lymphoblastic
leukemia
, 97 with chronic
lymphocytic
leukemia
, 353 with chronic
myeloid
leukemia
, and 95 healthy controls.
Clinical and follow up data were available for 112 MDS patients and 186
AML
patients.
There was no correlation between EPO promoter genotype and response to therapy or overall survival in MDS or
AML
.
In the MDS group, the GG genotype was significantly associated with shorter complete
remission
duration, as compared with the TT genotype (P = 0.03).
[MeSH-minor]
Adolescent.
Adult
. Aged. Aged, 80 and over. Case-Control Studies. Genotype. Humans.
Leukemia
,
Lymphocytic
, Chronic, B-Cell.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive.
Leukemia
,
Myeloid
,
Acute
. Middle Aged. Polymorphism, Single Nucleotide. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma. Treatment Outcome. Young
Adult
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Thromb Haemost. 2008 May;99(5):863-73
[
18449415.001
]
[Cites]
Blood. 2008 Jan 15;111(2):485-91
[
18182579.001
]
[Cites]
Leuk Res. 2008 Sep;32(9):1333-7
[
18417212.001
]
[Cites]
J Clin Oncol. 2008 Jul 20;26(21):3607-13
[
18559873.001
]
[Cites]
Semin Oncol. 2008 Aug;35(4):418-29
[
18692692.001
]
[Cites]
Am J Hematol. 2009 Mar;84(3):177-86
[
19195035.001
]
[Cites]
BMC Cancer. 2009;9:140
[
19432957.001
]
[Cites]
Exp Hematol. 2009 Sep;37(9):1007-15
[
19500646.001
]
[Cites]
Blood. 1993 Aug 1;82(3):737-43
[
7687889.001
]
[Cites]
Blood. 2009 Sep 17;114(12):2393-400
[
19564636.001
]
[Cites]
Arch Pathol Lab Med. 2007 Dec;131(12):1789-93
[
18081437.001
]
[Cites]
Acta Microbiol Immunol Hung. 2005;52(3-4):463-75
[
16400883.001
]
[Cites]
Cancer Causes Control. 2005 Oct;16(8):939-53
[
16132803.001
]
[Cites]
Trends Cell Biol. 2005 Mar;15(3):146-55
[
15752978.001
]
[Cites]
Blood. 1996 May 15;87(10):4076-81
[
8639764.001
]
[Cites]
Clin Lymphoma. 2003 Aug;4 Suppl 1:S36-40
[
14556674.001
]
[Cites]
Blood. 2008 Jan 15;111(2):574-82
[
17940203.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 May 13;105(19):6998-7003
[
18458324.001
]
(PMID = 21078205.001).
[ISSN]
1471-2350
[Journal-full-title]
BMC medical genetics
[ISO-abbreviation]
BMC Med. Genet.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
11096-26-7 / Erythropoietin
[Other-IDs]
NLM/ PMC2992491
76.
Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris L, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E:
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
Clin Cancer Res
; 2008 May 15;14(10):3077-82
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase II trial of tipifarnib as maintenance therapy in first complete
remission in
adults with
acute myelogenous leukemia
and poor-risk features.
PURPOSE:
Acute myelogenous leukemia
(
AML
) does not have a high cure rate, particularly in patients with poor-risk features.
Such patients might benefit from additional therapy in complete
remission
(CR).
Tipifarnib is an oral farnesyltransferase inhibitor with activity in
AML
.
We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk
AML
in first CR.
Comparison of CR durations for 25 patients who received two-cycle timed sequential therapy followed by tipifarnib maintenance with 23 historically similar patients who did not receive tipifarnib showed that tipifarnib was associated with DFS prolongation for patients with secondary
AML
and adverse cytogenetics.
CONCLUSIONS: This study suggests that some patients with poor-risk
AML
, including patients with secondary
AML
and adverse cytogenetics, may benefit from tipifarnib maintenance therapy.
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 1999 Dec;17(12):3835-49
[
10577857.001
]
[Cites]
Leukemia. 2007 Sep;21(9):1964-70
[
17581608.001
]
[Cites]
Blood. 2001 Jun 1;97(11):3361-9
[
11369625.001
]
[Cites]
Blood. 2001 Aug 1;98(3):548-53
[
11468148.001
]
[Cites]
Blood. 2001 Sep 1;98(5):1302-11
[
11520775.001
]
[Cites]
Blood. 2001 Sep 1;98(5):1312-20
[
11520776.001
]
[Cites]
Leuk Res. 2003 Apr;27(4):313-21
[
12531222.001
]
[Cites]
Blood. 2003 Mar 1;101(5):1692-7
[
12411300.001
]
[Cites]
Am J Clin Pathol. 2003 May;119(5):672-80
[
12760285.001
]
[Cites]
Blood. 2003 Dec 1;102(12):3880-9
[
12920034.001
]
[Cites]
Blood. 2003 Dec 15;102(13):4527-34
[
12947010.001
]
[Cites]
Blood Rev. 2004 Mar;18(1):39-63
[
14684148.001
]
[Cites]
J Clin Oncol. 2004 Apr 1;22(7):1287-92
[
15051776.001
]
[Cites]
N Engl J Med. 2004 Apr 15;350(16):1605-16
[
15084693.001
]
[Cites]
Blood. 1989 Oct;74(5):1499-506
[
2676014.001
]
[Cites]
Blood. 1992 Apr 15;79(8):1924-30
[
1562720.001
]
[Cites]
Blood. 1997 Oct 15;90(8):2952-61
[
9376575.001
]
[Cites]
J Clin Oncol. 1998 Mar;16(3):872-81
[
9508168.001
]
[Cites]
Leukemia. 1999 Jun;13(6):843-9
[
10360370.001
]
[Cites]
J Clin Oncol. 2005 Mar 20;23(9):1969-78
[
15632409.001
]
[Cites]
Eur J Haematol. 2005 May;74(5):418-23
[
15813916.001
]
[Cites]
J Clin Oncol. 2006 Jun 1;24(16):2480-9
[
16735702.001
]
[Cites]
Blood. 2006 Sep 1;108(5):1677-83
[
16670265.001
]
[Cites]
Blood. 2007 Jan 15;109(2):431-48
[
16960150.001
]
[Cites]
Blood. 2007 Feb 15;109(4):1387-94
[
17082323.001
]
[Cites]
Blood. 2007 May 15;109(10):4158-63
[
17264294.001
]
[Cites]
J Clin Oncol. 2007 May 10;25(14):1908-15
[
17488990.001
]
[Cites]
Hematol Oncol Clin North Am. 2000 Feb;14(1):251-67
[
10680081.001
]
(PMID = 18483374.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA 69854; United States / NCI NIH HHS / CA / U01 CA069854-07; United States / NCI NIH HHS / CA / U01 CA069854; United States / NCI NIH HHS / CA / U01 CA70095; United States / NCI NIH HHS / CA / U01 CA070095
[Publication-type]
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Quinolones; 192185-72-1 / tipifarnib
[Other-IDs]
NLM/ NIHMS281726; NLM/ PMC3074480
77.
Dixit A, Chatterjee T, Mishra P, Kannan M, Choudhry DR, Mahapatra M, Choudhry VP, Saxena R:
Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy.
Clin Appl Thromb Hemost
; 2007 Jul;13(3):292-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Disseminated intravascular coagulation
in acute leukemia
at presentation and during induction therapy.
Between January 2001 and December 2003, 67 patients with
acute leukemia
were evaluated prospectively for hemostatic abnormality at presentation, of which 43 (64.2%) had
acute
lymphoblastic
leukemia
and 24 (35.8%) had
acute myelogenous leukemia
.
Disseminated intravascular coagulation was more often associated with bleeding manifestations
in acute myelogenous leukemia
cases than
in acute
lymphoblastic
leukemia
cases.
It is recommended that all patients with
leukemia
be investigated for disseminated intravascular coagulation at presentation.
[MeSH-major]
Disseminated Intravascular Coagulation / diagnosis. Disseminated Intravascular Coagulation / epidemiology.
Leukemia
,
Myeloid
,
Acute
/ epidemiology. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / epidemiology
[MeSH-minor]
6-Mercaptopurine / therapeutic use. Adolescent.
Adult
. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / therapeutic use. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Female. Humans. Incidence. Male. Methotrexate / therapeutic use. Middle Aged. Partial Thromboplastin Time. Prednisone / therapeutic use. Prospective Studies.
Remission
Induction. Vincristine / therapeutic use
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
MERCAPTOPURINE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
METHOTREXATE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17636191.001).
[ISSN]
1076-0296
[Journal-full-title]
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
[ISO-abbreviation]
Clin. Appl. Thromb. Hemost.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; BFM-86 protocol
78.
Takeuchi K, Hattori T, Masuda S, Usui S, Oka K, Sakaida H, Majima Y:
Cochlear implantation in complete remission in a patient with leukemia.
Acta Otolaryngol
; 2008 Jul;128(7):821-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cochlear implantation in complete
remission in
a patient with
leukemia
.
Patients with
leukemia
have an increased risk of developing sensorineural hearing loss.
This is a retrospective review of a profoundly deafened patient with
acute myelogenous leukemia
who underwent cochlear implantation.
The 26-year-old patient was successfully implanted with a Nucleus cochlear implant in the complete
remission
after peripheral blood stem cell transplantation.
To our knowledge, this is the first reported case of successful cochlear implantation in a patient deafened by
acute myelogenous leukemia
.
[MeSH-major]
Cochlear Implantation / methods. Hearing Loss, Sensorineural / surgery.
Leukemia
,
Myeloid
,
Acute
/ complications
[MeSH-minor]
Adult
. Follow-Up Studies. Humans. Male. Peripheral Blood Stem Cell Transplantation / methods.
Remission
Induction / methods. Speech Perception / physiology
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18568527.001).
[ISSN]
0001-6489
[Journal-full-title]
Acta oto-laryngologica
[ISO-abbreviation]
Acta Otolaryngol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Norway
79.
Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP:
Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.
Leuk Lymphoma
; 2010 Jan;51(1):73-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Report of a phase 1/2 study of a combination of azacitidine and cytarabine
in acute myelogenous leukemia
and high-risk myelodysplastic syndromes.
Cytarabine resistance characterizes relapsed and refractory
acute myelogenous leukemia
(
AML
).
We conducted an adaptively randomized study of a combination of azacitidine, a hypomethylating agent, and cytarabine in 34 patients with
AML
.
However, in this advanced
AML
population, it was difficult to deliver more than one cycle of therapy, and minimal anti-
leukemia
activity was seen in patients with relapsed/refractory disease.
Complete
remission
was achieved in 2 of 6 minimally pre-treated patients.
We conclude that the combination of azacitidine and cytarabine is feasible but has limited activity in relapsed/refractory
AML
.
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
Genetic Alliance.
consumer health - Myelodysplastic syndromes
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
MedlinePlus Health Information.
consumer health - Myelodysplastic Syndromes
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
AZACITIDINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 2000 Dec 1;96(12):3671-4
[
11090046.001
]
[Cites]
Lancet Oncol. 2009 Mar;10(3):223-32
[
19230772.001
]
[Cites]
Oncogene. 2003 Oct 20;22(47):7512-23
[
14576855.001
]
[Cites]
J Clin Oncol. 2003 Dec 15;21(24):4642-9
[
14673054.001
]
[Cites]
Blood. 2004 Mar 1;103(5):1635-40
[
14604977.001
]
[Cites]
Biochim Biophys Acta. 1965 Nov 8;108(3):516-8
[
5867538.001
]
[Cites]
Nat New Biol. 1971 Sep 22;233(38):109-10
[
5285962.001
]
[Cites]
Cancer Res. 1974 Oct;34(10):2482-8
[
4137739.001
]
[Cites]
Biochemistry. 1975 Jan 28;14(2):316-26
[
47243.001
]
[Cites]
Oncology. 1974;30(5):405-22
[
4142650.001
]
[Cites]
Cancer Res. 1975 Oct;35(10):2853-7
[
50882.001
]
[Cites]
Cancer Res. 1976 Mar;36(3):1114-20
[
56229.001
]
[Cites]
Cancer Res. 1978 Aug;38(8):2458-66
[
78761.001
]
[Cites]
Cell. 1980 May;20(1):85-93
[
6156004.001
]
[Cites]
Cancer Res. 1980 Nov;40(11):4000-6
[
6162541.001
]
[Cites]
Science. 1981 Jan 23;211(4480):393-6
[
6164095.001
]
[Cites]
J Biol Chem. 1982 Feb 25;257(4):2041-8
[
6173384.001
]
[Cites]
Cancer Res. 1984 Nov;44(11):5029-37
[
6091869.001
]
[Cites]
Adv Enzyme Regul. 1985;24:335-54
[
2424284.001
]
[Cites]
Semin Oncol. 1987 Jun;14(2 Suppl 1):257-61
[
3035720.001
]
[Cites]
Cancer Chemother Pharmacol. 1989;24(4):203-10
[
2473850.001
]
[Cites]
Blood. 1997 Jul 1;90(1):346-53
[
9207471.001
]
[Cites]
Br J Haematol. 1998 Dec;103(4):1096-103
[
9886326.001
]
[Cites]
Drug Resist Updat. 2004 Aug-Oct;7(4-5):267-78
[
15533764.001
]
[Cites]
J Clin Oncol. 2006 Aug 20;24(24):3895-903
[
16921040.001
]
[Cites]
Cancer Res. 2007 Feb 1;67(3):1370-7
[
17283175.001
]
[Cites]
Clin Cancer Res. 2007 Mar 15;13(6):1634-7
[
17363514.001
]
[Cites]
Clin Cancer Res. 2007 Jul 15;13(14):4225-32
[
17634552.001
]
[Cites]
Biometrics. 2007 Jun;63(2):429-36
[
17688495.001
]
[Cites]
Blood. 2008 Aug 15;112(4):1366-73
[
18523155.001
]
[Cites]
Blood. 2009 Jan 15;113(3):659-67
[
18931345.001
]
[Cites]
J Clin Oncol. 2002 May 15;20(10):2429-40
[
12011120.001
]
(PMID = 20017599.001).
[ISSN]
1029-2403
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA100632-05; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA100632-04; United States / NCI NIH HHS / CA / P50 CA100632-079004; United States / NCI NIH HHS / CA / CA100632-07S1; United States / NCI NIH HHS / CA / P50 CA100632-06S1; United States / NCI NIH HHS / CA / P50 CA100632; United States / NCI NIH HHS / CA / P50 CA100632-069004; United States / NCI NIH HHS / CA / CA100632-04; United States / NCI NIH HHS / CA / CA100632-070006; United States / NCI NIH HHS / CA / CA100632-070001; United States / NCI NIH HHS / CA / CA100632-03; None / None / / P50 CA100632-06; United States / NCI NIH HHS / CA / CA100632-060001; United States / NCI NIH HHS / CA / P50 CA100632-03; United States / NCI NIH HHS / CA / P50 CA100632-06; United States / NCI NIH HHS / CA / CA100632-069004; United States / NCI NIH HHS / CA / P50 CA100632-070001; United States / NCI NIH HHS / CA / CA100632-06S1; United States / NCI NIH HHS / CA / P50 CA100632-010007; United States / NCI NIH HHS / CA / P50 CA100632-070006; None / None / / P50 CA100632-010007; United States / NCI NIH HHS / CA / CA100632; United States / NCI NIH HHS / CA / CA100632-079004; United States / NCI NIH HHS / CA / P50 CA100632-060001; United States / NCI NIH HHS / CA / P50 CA100632-07; United States / NCI NIH HHS / CA / P50 CA100632-060006; United States / NCI NIH HHS / CA / P50 CA100632-05; United States / NCI NIH HHS / CA / CA100632-060006; United States / NCI NIH HHS / CA / P50 CA100632-010001; United States / NCI NIH HHS / CA / P50 CA100632-07S1; United States / NCI NIH HHS / CA / CA100632-07; United States / NCI NIH HHS / CA / CA100632-010001
[Publication-type]
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
04079A1RDZ / Cytarabine; M801H13NRU / Azacitidine
[Other-IDs]
NLM/ NIHMS200831; NLM/ PMC2876330
80.
Moon HW, Shin S, Kim HY, Kim YR, Cho HI, Yoon SS, Park S, Kim BK, Chun H, Kim HC, Park CJ, Min YH, Lee DS:
Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia.
Leukemia
; 2006 Aug;20(8):1408-13
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+
acute myelogenous leukemia
.
We have experienced a number of cases of AML1/ETO+
acute myelogenous leukemia
that showed
remission
based on bone marrow (BM) morphological criteria, but that revealed clonal abnormalities in most cells by fluorescence in situ hybridization (FISH).
Interestingly, most of these cases had
AML
with AML1/ETO rearrangement.
To clarify the possible mechanisms underlying this phenomenon, we investigated the expression levels of G-CSFR in
AML
cells with AML1/ETO rearrangement by flow cytometry and real-time polymerase chain reaction (PCR).
The number of AML1/ETO+ cells expressing G-CSFR at baseline was significantly higher than that of AML1/ETO-
AML
cells (2673 vs 522).
This study reveals that cases showing
remission
after treatment with G-CSF mostly had
leukemia
with AML1/ETO rearrangement.
We recommend that
remission
should be confirmed by FISH, because malignant clones can be differentiated and masked in morphological examination or chromosome test, especially for
AML
with AML1/ETO rearrangement.
[MeSH-major]
Core Binding Factor Alpha 2 Subunit / genetics. Gene Rearrangement. Granulocyte Colony-Stimulating Factor / therapeutic use.
Leukemia
,
Myeloid
,
Acute
/ drug therapy.
Leukemia
,
Myeloid
,
Acute
/ genetics
[MeSH-minor]
Adolescent.
Adult
. Child. Female. Flow Cytometry. Humans. Male. Middle Aged. Neoplasm, Residual. Polymerase Chain Reaction. Receptors, Granulocyte Colony-Stimulating Factor / analysis. Receptors, Granulocyte Colony-Stimulating Factor / genetics
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16791271.001).
[ISSN]
0887-6924
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human; 0 / Receptors, Granulocyte Colony-Stimulating Factor; 143011-72-7 / Granulocyte Colony-Stimulating Factor
81.
Ramanarayanan J, Dunford LM, Baer MR, Sait SN, Lawrence W, McCarthy PL:
Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
Leuk Res
; 2006 Jun;30(6):701-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Chronic
myeloid
leukemia
after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
Therapy-related myelodysplasia and
acute
myeloid
leukemia
are well described, but secondary chronic
myeloid
leukemia
(CML) has only rarely been reported.
We report three patients with CML diagnosed 8, 10 and 2.5 years following Hodgkin's disease,
non
-Hodgkin's lymphoma and chronic
lymphocytic
leukemia
therapy, respectively.
[MeSH-major]
Antineoplastic Agents / administration & dosage. Hematopoietic Stem Cell Transplantation.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / therapy. Neoplasms, Second Primary / therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
[MeSH-minor]
Adult
. Benzamides. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Male. Middle Aged.
Remission
Induction. Time Factors. Transplantation, Homologous
Genetic Alliance.
consumer health - Chronic Myeloid Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
IMATINIB MESYLATE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16330096.001).
[ISSN]
0145-2126
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
82.
Wang Y, Wu D, Sun A, Jin Z, Qiu H, Miao M, Tang X, Fu Z:
Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
Int J Hematol
; 2008 Mar;87(2):167-71
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Allogeneic hematopoietic stem cell transplantation for patients with chronic
myeloid
leukemia in
second chronic phase attained by imatinib after onset of blast crisis.
The prognosis for patients with chronic
myeloid
leukemia
(CML) in blast crisis (BC) remains dismal even with the availability of the BCR-ABL tyrosine kinase inhibitor imatinib, since it only offers short-term benefit in most cases.
Allogeneic hematopoietic stem cell transplantation (HSCT) seems to be a viable option for BC-CML patients who attained
remission
.
After a median follow-up of 24 months (range 8-42), six out of the ten patients were alive in durable complete cytogenetic
remission
, one patient died in relapse 4 months after transplantation, the others died of severe
acute
graft-versus-host disease and associated infections.
[MeSH-major]
Antineoplastic Agents / therapeutic use. Blast Crisis / drug therapy. Hematopoietic Stem Cell Transplantation.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / therapy. Neoplasm Recurrence, Local / therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
[MeSH-minor]
Adolescent.
Adult
. Benzamides. Cohort Studies. Female. Humans. Imatinib Mesylate. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies. Transplantation, Homologous
Genetic Alliance.
consumer health - Chronic Myeloid Leukemia
.
Genetic Alliance.
consumer health - Leukemia, Myeloid
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
Hazardous Substances Data Bank.
IMATINIB MESYLATE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 2006 Jun 15;354(24):2531-41
[
16775234.001
]
[Cites]
Blood. 2006 Apr 15;107(8):3065-73
[
16380454.001
]
[Cites]
Am J Med. 1980 Aug;69(2):204-17
[
6996481.001
]
[Cites]
Blood. 2002 May 15;99(10):3547-53
[
11986206.001
]
[Cites]
N Engl J Med. 1999 Apr 29;340(17):1330-40
[
10219069.001
]
[Cites]
Blood. 2007 Apr 15;109(8):3207-13
[
17185463.001
]
[Cites]
Bone Marrow Transplant. 1996 May;17 Suppl 3:S7-9
[
8769691.001
]
[Cites]
N Engl J Med. 1986 Mar 20;314(12):729-35
[
3513012.001
]
[Cites]
Bone Marrow Transplant. 1995 Jun;15(6):825-8
[
7581076.001
]
[Cites]
Haematologica. 2003 Nov;88(11):1213-20
[
14607749.001
]
[Cites]
Blood. 1997 Jun 1;89(11):4226-35
[
9166868.001
]
[Cites]
Cancer. 1999 Dec 15;86(12):2632-41
[
10594858.001
]
[Cites]
Am J Med. 1993 Jan;94(1):69-74
[
8420302.001
]
[Cites]
Blood. 2002 Oct 1;100(7):2374-86
[
12239145.001
]
[Cites]
Haematologica. 2006 Apr;91(4):452-9
[
16585011.001
]
[Cites]
Blood. 2006 Sep 15;108(6):1809-20
[
16709930.001
]
[Cites]
Leuk Lymphoma. 2007 Feb;48(2):295-301
[
17325889.001
]
[Cites]
N Engl J Med. 2003 Mar 13;348(11):994-1004
[
12637609.001
]
[Cites]
Br J Haematol. 2000 Jun;109(4):722-8
[
10929021.001
]
[Cites]
Blood. 2002 May 15;99(10):3530-9
[
11986204.001
]
[Cites]
Bone Marrow Transplant. 2005 Sep;36(5):417-24
[
16007105.001
]
[Cites]
Blood. 2006 Aug 15;108(4):1421-3
[
16601247.001
]
[Cites]
Cancer. 2007 Apr 15;109(8):1543-9
[
17340589.001
]
(PMID = 18288566.001).
[ISSN]
0925-5710
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
83.
Sivendran S, Gruenstein S, Malone AK, Najfeld V:
Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma.
J Hematol Oncol
; 2010;3:25
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Ring chromosome 18 abnormality
in acute myelogenous leukemia
: the clinical dilemma.
Considering that ring chromosomes are rare
in acute myelogenous leukemia
(
AML
), it is difficult to risk stratify patient prognosis, particularly when the ring chromosome occurs as the sole abnormality.
Here we report a case of a ring chromosome 18 abnormality in a patient with newly diagnosed
AML
with monocytic differentiation.
The patient received induction chemotherapy and subsequent allogeneic cord blood transplant from a sex-matched donor, and remained in hematologic and cytogenetic
remission
for 120 days post transplant.
Although r(18) chromosomal abnormalities were not classified in the recent updated evidence-and expert opinion-based recommendations for the diagnosis and management of
AML
(likely due to the small number of reported cases), the patient was treated as high risk with stem cell transplantation.
[MeSH-major]
Chromosome Aberrations. Chromosomes, Human, Pair 18 / genetics.
Leukemia
,
Myeloid
,
Acute
/ genetics.
Leukemia
,
Myeloid
,
Acute
/ therapy. Ring Chromosomes
[MeSH-minor]
Adult
. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cord Blood Stem Cell Transplantation. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Treatment Outcome
Genetic Alliance.
consumer health - Chromosome 18
.
Genetic Alliance.
consumer health - Chromosome 18, Ring
.
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 2000 Dec 15;96(13):4075-83
[
11110676.001
]
[Cites]
Cytogenet Genome Res. 2008;121(3-4):149-73
[
18758155.001
]
[Cites]
Genes Chromosomes Cancer. 2002 Sep;35(1):20-9
[
12203786.001
]
[Cites]
Blood. 2002 Dec 15;100(13):4325-36
[
12393746.001
]
[Cites]
Arch Pathol Lab Med. 2003 Jan;127(1):42-8
[
12521365.001
]
[Cites]
Cancer Genet Cytogenet. 1983 Jan;8(1):51-66
[
6572548.001
]
[Cites]
Cancer Res. 1985 Jan;45(1):430-4
[
3855285.001
]
[Cites]
Blood. 1987 Nov;70(5):1400-6
[
3663939.001
]
[Cites]
Cancer Genet Cytogenet. 1988 Jun;32(2):157-68
[
3163258.001
]
[Cites]
Genes Chromosomes Cancer. 1994 Aug;10(4):244-9
[
7522537.001
]
[Cites]
Cancer Genet Cytogenet. 1995 Jul 1;82(1):41-9
[
7627933.001
]
[Cites]
Blood. 1998 Oct 1;92(7):2322-33
[
9746770.001
]
[Cites]
Cancer Genet Cytogenet. 1999 Feb;109(1):76-8
[
9973965.001
]
[Cites]
Hum Genet. 1999 Apr;104(4):315-25
[
10369161.001
]
[Cites]
Hematology Am Soc Hematol Educ Program. 2006;:169-77
[
17124057.001
]
[Cites]
Blood. 2010 Jan 21;115(3):453-74
[
19880497.001
]
[Cites]
Genes Chromosomes Cancer. 2002 Jun;34(2):137-53
[
11979548.001
]
(PMID = 20649984.001).
[ISSN]
1756-8722
[Journal-full-title]
Journal of hematology & oncology
[ISO-abbreviation]
J Hematol Oncol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents
[Other-IDs]
NLM/ PMC2917391
84.
Lee JH, Choi SJ, Lee JH, Lee YS, Seol M, Ryu SG, Jang S, Park CJ, Chi HS, Lee JS, Kim WK, Lee KH:
Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
Leuk Res
; 2006 Feb;30(2):204-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed
acute myelogenous leukemia
.
For refractory and early relapsed
AML
, this prospective phase II clinical trial evaluated a salvage chemotherapy regimen, which was consisted of continuous infusion intermediate-dose cytarabine (1g/m(2)/day, 24h i.v. infusion x 5), mitoxantrone (12 mg/m(2)/day x 3), and etoposide (150 mg/m(2)/day x 3).
Our results suggest that continuous infusion intermediate-dose cytarabine, together with mitoxantrone and etoposide, may induce CR in a significant proportion of patients with refractory or early relapsed
AML
, although
remission
duration was short.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / administration & dosage.
Leukemia
,
Myeloid
,
Acute
/ drug therapy
[MeSH-minor]
Adult
. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Mitoxantrone / administration & dosage. Prognosis. Prospective Studies. Salvage Therapy
Genetic Alliance.
consumer health - Acute Myeloid Leukemia, Adult
.
MedlinePlus Health Information.
consumer health - Acute Myeloid Leukemia
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
NOVANTRONE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Leuk Res. 2009 May;33(5):610-2
[
18990445.001
]
(PMID = 16055185.001).
[ISSN]
0145-2126
[Journal-full-title]
Leukemia research
[ISO-abbreviation]
Leuk. Res.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article
[Publication-country]
England
[Chemical-registry-number]
04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone
85.
Or R, Hadar E, Bitan M, Resnick IB, Aker M, Ackerstein A, Samuel S, Tsirigotis P, Gesundheit B, Slavin S, Shapira MY:
Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.
Biol Blood Marrow Transplant
; 2006 Dec;12(12):1295-301
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The use of a mismatched allograft necessitates T cell depletion for prevention of uncontrolled graft-versus-host disease (GVHD), thus impairing a graft-versus-
leukemia
effect.
In the 6 patients receiving prophylactic DLI, complete
remission
was maintained in 5; however, 2 died from GVHD.
[MeSH-major]
Graft Enhancement, Immunologic.
Leukemia
,
Myeloid
/ surgery. Lymphocyte Transfusion. Peripheral Blood Stem Cell Transplantation
[MeSH-minor]
Acute
Disease. Adolescent.
Adult
. Child, Preschool. Feasibility Studies. Female. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Graft vs
Leukemia
Effect. HLA Antigens / immunology. Histocompatibility. Humans. Kaplan-Meier Estimate.
Leukemia
,
Myelogenous
, Chronic, BCR-ABL Positive / surgery. Leukocyte Reduction Procedures. Lymphoma / surgery. Male. Middle Aged. Myelodysplastic Syndromes / surgery. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / mortality. Precursor Cell
Lymphoblastic
Leukemia
-Lymphoma / surgery.
Remission
Induction. Survival Analysis. Tissue Donors. Transplantation Conditioning. Tumor Burden
Genetic Alliance.
consumer health - Transplantation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17162211.001).
[ISSN]
1083-8791
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / HLA Antigens
86.
Mielcarek M, Storer BE, Flowers ME, Storb R, Sandmaier BM, Martin PJ:
Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation.
Biol Blood Marrow Transplant
; 2007 Oct;13(10):1160-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We retrospectively analyzed outcomes among 307 consecutive patients who had recurrent or persistent
acute leukemia
(n = 244), chronic
myelogenous leukemia
in blast phase (CML; n = 28), or advanced myelodysplastic syndromes (MDS; n = 35) after allogeneic hematopoietic cell transplantation and who received at least 1 relapse-directed intervention: withdrawal of immunosuppression, chemotherapy, or donor lymphocyte infusion (DLI).
The overall
remission
rate was 30%.
Compared to early recurrence, intermediate recurrence and late recurrence were associated with increasing probabilities of
remission
(hazard ratios, 1.89 and 2.16; P = .05 and .02) and decreasing risks of overall mortality (hazard ratios, 0.73 and 0.33; P = .05 and <.0001).
Remission
was associated with a median survival prolongation of 9.5 months.
Individual types or combinations of these nonrandomly assigned relapse-directed interventions were not associated with higher or lower probabilities of
remission
or survival.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Leukemia
.
MedlinePlus Health Information.